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Summary: 
 
Human cardiac ryanodine receptors (hRyR2) are major Ca2+ release channels in the 
heart, which form quaternary complexes with luminal proteins, calsequestrin (CSQ2), 
junctin (JUN) and triadin (TRD1). These proteins facilitate Ca2+ release during 
excitation-contraction coupling, modulating the response of hRyR2 to luminal Ca2+ 
changes. Catecholaminergic Polymorphic Ventricular Tachycardia is an 
arrhythmogenic disorder, caused by mutations in RyR2 and CSQ2 genes. Defective 
sensing of cytosolic/luminal Ca2+ by hRyR2 is a candidate mechanism underlying 
disease pathogenesis, likely caused by defective luminal protein regulation. Using a 
recombinant approach, this study aimed to evaluate if mutant (N4104K and A4556T) 
hRyR2 respond to or interact differently with, these accessory proteins.  
 
Expression constructs corresponding to CSQ2 and JUN were generated and 
expressed stably and transiently with wild-type (WT) or mutant hRyR2 in HEK293 
cells. Immunofluorescent co-localisation confirmed successful co-expression and 
association of these luminal proteins with hRyR2 in situ. Ca2+ activation of wild-
type/mutant hRyR2 in the absence/presence of CSQ2 and/or JUN was assessed by 
[3H]-ryanodine binding, while luminal Ca2+ effects were monitored using single-cell 
Ca2+ imaging - examining spontaneous Ca2+ release events. A4556T-hRyR2 displayed 
similar cytosolic and luminal Ca2+ dependence to wild-type channels, whilst N4104K-
hRyR2 displayed a remarkably different Ca2+ activation profile, demonstrating 
functional heterogeneity between hRyR2 mutants. 
 
Ca2+ imaging revealed an inhibitory effect of CSQ2 on WT and N4104K-hRyR2 
activity, both in the presence and absence of JUN. In line with this, CSQ2 was found to 
bind directly to hRyR2 by co-immunoprecipitation, an observation that has not been 
previously demonstrated in the literature.  Immunofluorescence studies suggested 
reduced CSQ2 and JUN association with A4556T-hRyR2, but this could not be 
confirmed with co-immunoprecipitation. Ca2+ imaging investigations with this mutant 
however, suggested that CSQ2 wasn’t able to regulate these channels in the same 
way as WT, implying a change in functional effect. 
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General Introduction 
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      1.1. Calcium Signalling in the heart: 
 
In cardiac muscle, ionised calcium (Ca2+) acts as a ubiquitous intracellular signalling 
messenger directly regulating a multitude of processes such as the electrical activity of the 
heart, ion channel gating and contractile processes. All of which are central to the 
synchronous systolic-diastolic cycles (ventricular contraction and relaxation, respectively) 
that produce the heartbeat. During the physiological process of Excitation-Contraction 
Coupling (ECC), intracellular Ca2+ homeostasis must be carefully regulated, such that 
cardiac myocytes can distinguish between a series of spatially and temporally discrete 
localised Ca2+ signalling pathways (occurring simultaneously within the cell) which 
combine to produce an overall global Ca2+ transient to generate muscle contraction (Bers, 
2002). Since Ca2+ cannot be metabolised, Ca2+ homeostasis is maintained by a subset of 
critical signalling molecules and protein complexes that function against a background of 
tightly regulated changes in the intracellular free Ca2+ concentration (Scoote and Williams, 
2004, Bers et al., 2008).  
 
1.2. Excitation-Contraction Coupling: 
 
ECC refers to the co-ordinated process that pairs electrical stimulation of the 
cardiomyocytes with the movement of intracellular Ca2+ around the cell to induce muscle 
contraction (Bers, 2008). Ca2+ exerts its major signalling function when elevated in the 
cytosolic compartment of cardiac cells, which is achieved by a specialised intracellular 
architecture that acts in a coordinated manner to regulate Ca2+ handling during each 
heartbeat. Figure 1.1 (A) illustrates major proteins involved in ECC within cardiac muscle.  
 
1.2.1. The systolic phase of the cardiac cycle (muscle contraction): 
 
When the heart is at rest (diastole), intracellular Ca2+ is sequestered into the sarcoplasmic 
reticulum (SR), which is the major internal Ca2+ store of cardiomyocytes. Responsible for 
elevating intracellular Ca2+ within the cytosol, the transverse tubules (or T-tubules) are a 
coalescence of the myocyte cell surface (the sarcolemma), which exist as deep 
invaginations and provide a close apposition between the sarcolemma and the 
intracellular space (the junctional SR membrane (jSR)) of cardiomyocytes (Berridge, 2003, 
Fearnley, 2011). During systole, specific ion fluxes between the extracellular space and 
cytosol initiates electrical excitation of the myocyte sarcolemma, a process known as 
depolarisation. Described further in section 1.2.4, the resultant change in membrane 
potential initiated by depolarisation is known as the action potential (AP), a phenomenon 
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that forms distinct phases which correspond to a specific membrane ion flux, as illustrated 
in Figure 1.1 (B).  
 
When the myocyte becomes depolarised, a small influx of extracellular Ca2+ enters the 
cytosolic compartment of the cell through voltage-gated L-type Ca2+ channels (LTCC) 
present on the sarcolemmal membrane. This inward Ca2+ current initiates Ca2+-induced-
Ca2+ release (CICR), where a much larger Ca2+ efflux from the SR significantly amplifies 
the cytosolic Ca2+ concentration. The amplitude of the resultant Ca2+ transient determines 
the contractile force of the cardiac myocyte (Bers and Guo 2005). A major Ca2+ release 
channel found embedded in the SR membrane facilitates this process, and plays a crucial 
role in CICR. Ryanodine receptors (cardiac isoform known as RyR2) traverse the SR 
membrane and function as regulated Ca2+release channels, allowing Ca2+ to pass from the 
intracellular store into the surrounding cytoplasm, elevating cytosolic [Ca2+] from 
approximately 100 nM during diastole to ~1 !M during the systolic phase of the cardiac 
cycle (Fearnley et al., 2011). The tenfold increase in intracellular Ca2+ induces a 
conformational change in the cardiac muscle myofilaments responsible for cardiomyocyte 
contraction (Bers and Guo, 2005).  
 
 
1.2.2. Calcium sparks and transients: 
 
Clusters of RyR2 channels are localised in discrete areas along the jSR membrane 
(known as calcium release units) and are positioned adjacent to L-type Ca2+ channels 
(Franzini-Armstrong, 2005). The global Ca2+ transient that generates contractile function is 
a summation of many localised intracellular Ca2+ release events known as Ca2+ sparks, 
which were first described as spontaneous elementary Ca2+ signals arising from the SR 
(Cheng et al., 1993, Cheng and Lederer 2008). We now know that Ca2+ sparks reflect the 
concerted opening of a cluster of RyR2 Ca2+ release channels, which were first visualised 
in the cell by fluorescent indicators (Cheng et al., 1993). It has been estimated that up to 
20 RyR2 channels may open during each Ca2+ spark, and that the Ca2+ dependence of 
spark frequency is in line with that of the Ca2+ dependence of RyR2 open probability (Po)  
(Zahradníková et al., 2012).   
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1.2.3 The diastolic phase of the cardiac cycle (relaxation): 
 
Allowing cardiac muscle relaxation (reduced activation of contractile proteins), RyR2 
channel activity declines and the cytosolic Ca2+ concentration is returned to resting levels. 
This is achieved via two primary mechanisms: the Na+/Ca2+ exchangers (NCX), located in 
the sarcolemma, and the sarco/endoplasmic reticulum Ca2+ ATPase pump (SERCA2a), 
located in the SR membrane (Figure 1.1 (A)). In human ventricles, approximately 70% of 
intracellular Ca2+ is removed by SERCA2a (the predominant isoform in the heart), 28% by 
NCX, and the remaining 2% by a mitochondrial Ca2+ uniporter, a pattern also observed in 
other species such as dog, guinea pig and rabbit (Fearnley, 2011, Bassani et al., 1994, 
Bers, 2001). SERCA2a sequesters Ca2+ back into the SR store, which is subsequently 
buffered by the luminal Ca2+ binding protein, CSQ2 (section 1.6). SERCA2a activity is 
regulated by an integral membrane protein, phospholamban (PLB). NCX catalyses the 
electrogenic exchange of Na+ and Ca2+, extruding Ca2+ from the cell and thus restoring the 
intracellular Ca2+ concentration to diastolic levels (Bridge et al., 1990). Given the fact that 
for each Ca2+ ion that is extruded, three Na+ ions enter the cell, it has also been suggested 
that RyR2 Ca2+ sparks stimulate NCX activity and contributes to the generation of a net 
inward Na+ current that is required for action potential initiation (Berridge et al., 2003). 
 
1.2.4. The cardiac action potential: 
 
Generation of an action potential (AP) at the sarcolemma causes the electrical excitation 
required to initiate ECC. The cardiac AP consists of 5 phases as shown in Figure 1.1 (B) 
and is the product of changes in the membrane potential, generated by the activation and 
deactivation of specific ion channels in a time-dependent manner (Scoote & Williams, 
2004). Under diastolic conditions, the resting membrane potential (Em) of a ventricular 
cardiomyocyte is approximately -80 mV (Bers, 2008) and is represented as Phase 4 of the 
AP cycle. Initiating excitation, Phase 0 of the AP represents activation of voltage-
dependent fast inward Na+ currents, responsible for generating rapid depolarisation of the 
sarcolemma to approximately +40 mV. This phase is represented in Figure 1.1 (B) as a 
sharp upstroke.  Once depolarisation is complete, this inward Na+ current becomes 
inactivated and a movement of K+ and Cl- ions from the cell cytosol triggers early 
repolarisation of the membrane potential, represented as a downward deflection in the AP 
cycle (Phase 1).  Phase 2 corresponds to a plateau phase, generated by the manifestation 
of an inward Ca2+ current, primarily through L-type Ca2+ channels, and a K+ efflux through 
slow delayed rectifier channels. In order to return to resting state, rapid (late) 
repolarisation (Phase 3) occurs within the myocyte, whereby the RyR2 channels prevent 
any further Ca2+ influx into the cytosolic compartment by initiating Ca2+ efflux from the SR 
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store, inactivating the L-type Ca2+ channels by the raised [Ca2+] and at the same time, 
rapid and slow delayed rectifying K+ channels remain open and allow the efflux of the 
remaining K+ ions out of the cell. This reduction in positive charge causes the cell to 
repolarise, and the K+ channels close once the membrane potential is restored to -80 mV.  
At the same time, the additional Na+ and Ca2+ that entered the cell during the course of the 
action potential are extruded by NCX, whilst SERCA2a sequesters Ca2+ back into the SR 
store. The Na+/K+ ATPase pump also facilitates the removal of excess Na+ from the cell. 
Following AP repolarisation, cytoplasmic Ca2+ falls and the myocardium relaxes (Bers, 
2008). The action potential lasts approximately 300 milliseconds during which time the cell 
remains refractory to any further activation. 
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Figure 1.1: Cardiac Muscle Excitation Contraction Coupling: Illustrated are 
the major protein components involved in ECC described in sections 1.2-1.2.3 (A) 
Depolarisation of the cardiomyocyte sarcolemma initiates an influx of Ca2+ through 
LTCC that subsequently triggers greater Ca2+ release from the SR store through 
RyR2 Ca2+ release channels. Following contraction, Ca2+ dissociates from the 
contractile proteins and is removed from the cytoplasm primarily by the SERCA2a 
pump that sequesters Ca2+ back into the SR (modulated by PLB) and via NCX, 
which extrudes Ca2+ from the cell. Distinct phases of the cardiac action potential 
are highlighted in (B) and described further in section 1.2.4.  
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1.2.5.  ß-adrenergic stimulation modulates cardiac EC coupling activity: 
 
During times of emotional stress and exercise, a rapid change in the rate (chronotropy), 
force of contraction (inotropy) and relaxation (lusitropy) of the heart is achieved by 
stimulation of the sympathetic nervous system and subsequent activation of a well-
characterised ß-adrenergic signalling cascade within the myocardium (Bers, 2002). This 
process is often known as the “fight-or-flight” response and vitally enhances cardiac 
myocyte activity in situations where there is a higher metabolic demand (Shan et al., 
2010). As summarised in Figure 1.2, neuronally released adrenaline/noradrenaline or 
circulating catecholamines bind to ß-adrenergic receptors present on the cardiomyocyte 
sarcolemma, which initiates a downstream signalling cascade that first activates adenylate 
cyclase and the production of cyclic AMP, which in turn activates phosphorylation 
enzymes such as protein kinase A (PKA). Alterations in the phosphorylation status of 
several proteins central to the regulation of contractility, leads to elevations in the Ca2+ 
mediated responses seen during normal EC coupling (Lakatta, 2004, Bers, 2004, Reiken 
et al., 2003).  
 
The proposed functional consequences of PKA phosphorylation include: (1) positive 
inotropic effects, such as increased activity of LTCC and RyR2 receptors, causing a 
greater influx of extracellular Ca2+ and larger efflux of luminal Ca2+ from the SR, 
respectively (Bers, 2002, Scoote and Williams, 2004); and (2) positive lusitropic effects, 
including phosphorylation of PLB, which relieves SERCA2a inhibition and speeds up Ca2+ 
re-uptake into the SR, increasing the ‘Ca2+ load’. In addition, a reduction in myofilament 
Ca2+ sensitivity occurs via phosphorylation of troponin I, a protein that mediates 
myofilament contraction. This lowered activity is however compensated for by the dramatic 
rise in Ca2+ transient amplitude seen after ß-adrenergic stimulation (Li et al., 2000). Taken 
together, ß-adrenergic activation elicits a cascade of phosphorylation reactions that 
increase Ca2+ levels within the SR and produce larger and faster Ca2+ transients. These 
enhanced processes combine to increase cardiac output and improve overall cardiac 
performance. It is however important to note that whilst catecholamines can improve 
contractile function and increase SR Ca2+ content, Ca2+ load can increase to a level which 
induces spontaneous Ca2+ release from the SR through RyR2 channels, as seen in 
cardiovascular disease (section 1.7-1.7.1).  
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Figure 1.2: Activation of the ß-adrenergic receptor and phosphorylation of protein 
targets: Activation of ß-adrenergic receptors by circulating catecholamines (or 
adrenaline/noradrenaline) triggers downstream signalling cascades that culminate in 
phosphorylation of protein targets. Illustrated here is the G protein (guanosine nucleotide-
binding protein) cascade and activation of PKA. Activation of the G protein complex 
stimulates adenylate cyclase to produce a secondary messenger cAMP (from ATP). This 
in turn stimulates PKA. The effects of phosphorylation of protein targets highlighted here 
with numbers: (1) LTCC, (2) RyR2, (3) PLB and (4) contractile proteins (specifically 
troponin I) is discussed further in section 1.2.5.     
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1.3. Cardiac ryanodine receptors (RyR2): 
 
Ryanodine receptors are the largest known Ca2+ channels in the human body and are 
named after the muscle-paralysing plant alkaloid, ryanodine. Ryanodine exists naturally in 
the roots and stems of the Ryania speciosa and was found in the late 1980s to bind to the 
Ca2+ release channels with very high affinity and specificity (Lai and Meissner, 1989). The 
advantages of using this property to assess RyR2 function will be discussed in Chapter 4. 
RyR channels exist as three mammalian isoforms, each encoded by a distinct gene 
(RyR1, RyR2 and RyR3) and residing on separate chromosomes (Capes et al., 2011). 
Although the regulation and expression of the three known isoforms is tissue specific, all 
three share similar characteristics, functioning as cation-selective ion channels that are 
modulated by Ca2+, Mg2+ and ATP (Lanner et al., 2010).  
 
RyR2 is the predominant isoform found in cardiac muscle (Lai et al., 1988), encoded by 
the RyR2 gene and located on chromosome 1 (1q42-q43), (Otsu et al., 1993, Tunwell et 
al., 1996). Aside from the myocardium, RyR2 is also expressed at lower levels in the 
somata of neurons, the stomach, brain, adrenal glands and ovaries (Lanner et al., 2010, 
Kuwajima et al., 1992, Giannini et al., 1995, Nakai et al., 1990). Biochemical analysis and 
three-dimensional reconstruction studies have revealed that RyR2 Ca2+ release channels 
exists as large homotetramers that traverse the SR membrane, and consist of four 
identical 565 kDa subunits, surrounding a centrally located pore (Lai et al., 1989, Sharma 
et al., 1998). The four protein monomers combine to form a 2.2 MDa complex, with 4967 
amino acids per monomer (Otsu et al., 1993, Tunwell et al., 1996). Channels are 
characterised by their large N-terminal domain which protrudes into the cytosol and is 
recognised in electron micrographs as a “foot-like” structure observed at the junction 
between terminal cisternae of SR and the T-tubule network. A number of associated 
regulatory proteins make the structure a huge macromolecular complex (Franzini-
Armstrong et al., 1999, Yano et al., 2009). Hydropathy plot analysis has revealed that the 
first 4000 amino acids of the RyR2 channel are hydrophilic and correspond to the N-
terminal region of the protein, the smaller C-terminal region is predicted to contain large 
hydrophobic stretches plus highly charged sequence repeats which are thought to be 
important for accessory protein association (Zorzato et al., 1990). The C-terminal section 
of the protein comprises a pore-forming region and approximately 6 transmembrane (TM) 
helices, with one potential TM stretch forming a pore loop from the luminal side of the 
channel, as proposed by Du et al., 2002.  
 
Figure 1.3 illustrates predicted structures of the RyR channel complex. In recent years, 
studies using single-particle cryo-electron microscopy (cryo-EM) have provided us with 
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invaluable structural information regarding the architecture of RyR Ca2+ release channels, 
as well as the identification of binding regions for a multitude of intracellular molecules 
responsible for modulating RyR activity (Hamilton and Serysheva, 2009, Huang et al., 
2012, Efremov et al., 2015, Yan et al., 2015). Numerous allosteric interactions are 
predicted to contribute to the conformational changes necessary within the channel 
domain to allow channel opening, which are largely achieved through extensive van der 
Waals contacts (Samsó et al., 2005, Yan et al., 2015). Furthermore, cryo-EM studies have 
facilitated the mapping of CPVT-associated mutation hotspots within the Ca2+ release 
complex. Closed channel structures of rabbit RyR1 (Yan et al., 2015) have recently been 
achieved at the near-atomic resolution of 3.8 Å (Figure 1.3 (A)), while the open state 
structure has been captured at 8.5 Å (Efremov et al., 2015). Figure 1.3 (A) and (B) (i) 
demonstrate the characteristic mushroom-shaped architecture of the RyR1 channel (that 
is highly conserved between RyR isoforms), which has 4-fold rotational symmetry 
(Hamilton and Serysheva, 2009) and its macromolecular assembly, generated from cryo-
EM imaging and the formation of electron microscopy density maps by Yan et al (2015). 
The distinct domains established by Yan et al (2015) are highlighted in Figure 1.3 (B) (i)-
(iii) and are colour coded for identification (see labelled domains in (B) (ii)). 
Characterisation of RyR2 channels by cryo-EM has been hindered by the difficulty to 
isolate large enough quantities of purified, structurally intact channels from cardiac muscle 
(Liu et al., 2001).  
 
As shown in (B) (i), the large N-terminal cytoplasmic domain of RyR constitutes the bulk of 
the protein (~80% (Huang et al., 2012)), which is adjoined to the C-terminal luminal 
domain via a transmembrane region (TM) that together resembles a stalk-like structure 
(Hamilton and Serysheva, 2009). A structural scaffold for the large N-terminal region is 
formed by a "-solenoid domain, which consists of ~30 "-helices packed into parallel layers 
(Yan et al., 2015). Within the cytoplasmic domain, direct interactions between the central 
and channel domain (marked in Figure 1.3 (B) (ii)) are thought to primarily regulate the 
conformational changes necessary to control RyR opening and closing (Yan et al., 2015). 
Described by Yan et al (2015) the handle and two helical structures (indicated as HD1 and 
HD2 in (B) (ii)) of the cytoplasmic central region (Figure 1.3 (B) (ii)) appear to form a 
discontinuous corona (a protein adsorption layer which surrounds the protein surface, del 
Pino et al., 2014), which is predicted to contain the interaction sites for the ligand binding 
of channel modulators such as FKBPs and CaM.  As highlighted in Figure 1.3 (B) (iii), 
FKBP12 appears to bind within a cleft situated between the N-terminal domain and the 
handle region (residues 1651-2145), and close to the SPRY domains (Yan et al., 2015). 
Earlier studies however, have reported that the binding site for FKBP12 lies between 
amino acids 2458-2468 of rabbit RyR1 (Hamilton and Serysheva, 2009 and Lanner et al., 
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2010), which in the model proposed by Yan et al (2015) locates FKBP12 binding to the 
helical HD1 region (residues 2146-2712). In further studies using cryo-EM analyses, 
Huang at al (2012) established the binding region for the Ca2+ binding protein calmodulin 
(CaM) between RyR1 residues 3614 and 3643. Interestingly, two distinct but overlapping 
areas for CaM binding have been identified, where binding at each site is governed by the 
absence or presence of Ca2+ (Samsó et al., 2005, Huang et al., 2013). When CaM 
switches between Ca2+ free- and bound states, cryo-EM studies revealed that the 
regulatory protein appears to shift approximately 30 Å along the surface of the RyR1 
channel (Huang et al., 2013). As highlighted in (B) (ii) and (iii), three SPRY domains are 
localised within the periphery of the cytoplasmic region, named according to their 
discovery within dual-specificity sp1A kinase and RyR channels (Ponting et al., 1997, 
Efremov et al., 2015). The precise function of these domains remains unclear, yet their 
positioning close to the N-terminal and helical domains (Figure 1.3 (B) (iii) suggests that 
the domains provide a scaffold and maintain structural integrity throughout this channel 
region (Yan et al., 2015, Efremov et al., 2015). As shown in Figure 1.3 (B) (iii), the SPRY 
domains (1-3) are composed primarily of ß-sheets (forming “ß-sandwiches”) and lie close 
to a phosphorylation hotspot labelled P1 (Yan et al., 2015). Another phosphorylation 
hotspot (P2) is highlighted in Figure (B) (ii), which has been predicted to reside within the 
helical domain of RyR1 between residues 2734 and 2940 (Yan et al., 2015). Within this 
region of channel phosphorylation, Zhu et al (2013) reported the presence of eleven 
disease-causing mutations.  
 
The secondary structure of the RyR1 pore formulated by Yan et al (2015) is shown in 
Figure 1.3 (C) (i)-(iii), where six "-helical transmembrane regions (labelled S1-S6) per 
monomer are predicted, which together exhibit a voltage-gated ion channel fold (although 
RyR does not exhibit voltage-dependence) (C) (ii), (Samsó et al., 2005, Yan et al., 2015). 
As highlighted in (B) (ii) and (C) (ii), VSC refers to a cytoplasmic subdomain (named 
according to its location within the voltage-sensor fold region), formed by the intervening 
sequences in between transmembrane regions S2 and S3 (Yan et al., 2015). This 
previously unknown VSC domain appears to link a previously unidentified C-terminal 
subdomain (labelled CTD) close to the S1-S4 regions (shown in (C) (i)) and together with 
the central domain forms the “column-like” structure reported in earlier investigations 
(Samsó et al., 2005, Yan et al., 2015). Finally, as shown in (C) (i)-(iii), the luminal loop is a 
hairpin loop situated between S5 and the pore helix, which projects into the SR lumen and 
sits above the selectivity filter; this structure together with the S6 transmembrane region 
forms the entire ion-conducting pore (as demonstrated in (C) (iii)).   
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The cytoplasmic region of the S6 segment (labelled in (C) and forming part of the 
transmembrane domain) is enriched in aspartic and glutamic acid residues and together 
with the selectivity filter (length ~10 Å, labelled SF in (B) (ii)), forms a long (~90 Å) 
pathway for ion-conduction, allowing rapid Ca2+ transport across the SR membrane (Yan 
et al., 2015). As proposed by Yan et al (2015) opening of the activation gate may simply 
result from twisting within this S6 bundle, this however requires further investigation. 
Interactions between the CTD and the S6 region appear to be stabilised via a zinc-finger 
motif, whereby structural transitions of these domains are predicted to determine allosteric 
regulation of the channel’s activation gate (Yan et al., 2015).  
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Figure 1.3: Illustration of the ultrastructure of RyR channels: Established by cryo-EM 
analysis (A) illustrates an EM density map of the RyR1 channel (in complex with FKBP12) 
which is colour coded to highlight the ranges of resolutions achieved by Yan et al (2015), with 
the highest being at the central region of the structure. (B) (i-iii) depicts the overall RyR1 
structure and the predicted domain organization and their orientation within the Ca2+ release 
channel. These domains are discussed in detail in section 1.3 and are colour coded according 
to the labelling shown in (B) (ii). (C) Illustrates the predicted structure of the channel domain, 
which constitutes the pore-forming region of the channel. Colour coding of structures in (ii) and 
(iii) correlates with those labelled in (C) (i). The labelled transmembrane regions (S1-6), 
luminal loops, pore helix, etc. in one RyR1 protomer are shown in (i) and per tetramer (ii); and 
are discussed in section 1.3. As mapped by cryo-EM, the pore helix and luminal loops (which 
make up the selectivity filter) of the channel are hotspots for CPVT-associated mutations (Yan 
et al., 2015). As shown in (iii) the ion-conducting pathway of the channel is predicted to consist 
of the selectivity filter and the S6 transmembrane segments. Image modified from Yan et al., 
2015.     
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1.4. Modulation of RyR2 channel gating by physiological ligands: 
 
1.4.1. RyR2 regulation by Ca2+: 
 
A variety of physiological ligands, cellular processes, accessory proteins and 
pharmacological agents can modulate RyR2 activity, but Ca2+ is by far the most important 
effector of channel function. There is still however no consensus as to how exactly 
cytoplasmic and luminal Ca2+ regulates channel activity, but at least four Ca2+-sensing 
sites on each RyR2 subunit have been proposed. As shown in Figure 1.4, using all known 
information derived from single channel recordings, Laver et al (2007) developed a model 
of RyR2 Ca2+ sensing sites and their relative contribution to channel activation is 
discussed below.  
 
 
 
 
 
 
 
 
 
 
 
Site Regulatory Effect Ligand Dissociation 
constant 
A-site Cytoplasmic Activation Ca2+ 1-10!M 
L-site Luminal Activation Ca2+ 60!M 
I1-site Cytoplasmic Inhibition Ca2+ and Mg2+ ~10mM 
I2-site Cytoplasmic Inactivation Ca2+ 1!M 
AUTHOR
cytoplasmic Ca2+-inactivation site (I2-site) causes areduction in channel open durations at high levels of Ca2+
feed-through. This review evaluates the evidence for the
principal aspects of the “luminal-triggered Ca2+ feed-
through” model, the properties of the various
Ca2+-dependent gating mechanisms and their likely role in
controlling Ca2+ release from the SR.
Ca
Ca
L-site
I
2
-siteA-site
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1
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Ca
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Figure 2. The process of “luminal-triggered Ca2+ feed-
through” (after Laver, 200724). An illustration of the three
Ca2+ sensing sites that have been linked to regulation of
cardiac RyRs by luminal Ca2+: the luminal activation site
(L-site, 60 µM affinity), the cytoplasmic activation site (A-
s te, 1-10 µM affinity) and the cytoplasmic Ca2+-inactiva-
tion site (I2-site, 1 µM affinity). Ca2+ binding at the L-site
is sufficient to activate channel openings whereupon Ca2+
flow through the channel (Ca2+ feed-through) causes either
additional activation via the A-site or inactivation via the
I2-site. Also shown is the so-called Ca2+/Mg2+ inhibition
site (I1-site, 10 mM affinity, pre viously referred to as the I-
site). This site plays a role in cytoplasmic regulation of
RyRs.
A-site for [Ca2+]C-activation
At an early stage RyRs were found to be activated by
µM [Ca2+] in the cytoplasm.25,26 It is now generally
recognised that this is mediated by a class of cytoplasmic
facing Ca2+ sites referred to as A-sites.27 In the absence of
luminal Ca2+ or cytoplasmic cofactors such as ATP, [Ca2+]Cactivates RyR2 from a basal Po of approximately zero to Po= 0.6 with a half-activating [Ca2+]C (Ka) of !5 µM (Figure3A).28,29 Activation is mediated primarily via a decrease in
"c or an increase in channel opening rate (opening rate =1/"c) whereas "o (!1 ms) showed only a minor dependenceon [Ca2+]C (Figure 3B, C). The A-site gating properties arestrongly affected by cofactors such as ATP, caffeine and
sulmazole.19,30,31 On their own these cofactors do not
trigger channel openings; instead they function to enhance
RyR response to cytoplasmic Ca2+. The result is an increase
in both "o and opening rate which decreases the [Ca2+]Cneeded for activation (this is shown for the case of ATP in
Figure 3). In the presence of ATP, "o acquired a strongdependence on [Ca2+]C (Figure 3B).
Although the precise location of the A-site is still
unknown, mutation experiments carried out on RyR1
provide an indication of its general location. Truncated
RyR1s comprised of only the C-terminal 1030 amino acids
(RyRC; aa4007-aa5037) formed Ca2+ channels with
A-sites32 indicating that the A-site resides somewhere in the
pore forming region of the RyR. Moreover, the aa4032 has
been linked to the A-site gating mechanism because the
E4032A substitution decreased RyR1 sensitivity to
cytoplasmic Ca2+-activation by four orders of magnitude33
(but also see Fessenden et al.34)
I1-site for cytoplasmic Ca2+/Mg2+-inhibition
It has been long known that RyRs can be inhibited by
mM cytoplasmic concentrations of divalent cations
including Ca2+ and Mg2+ (!1 mM for RyR1 and !10 mM
for RyR2.35) This inhibitory action is mediated by low
affinity non-specific divalent cation sites, previously dubbed
I-sites.27 In order to distinguish this process from the other
inactivation process (see next section) the sites are now
called I1-sites and the process is referred to as inhibition
rather than inactivation. The I1-sites, together with the A-sites, produce a bell-shaped dependence of Po on [Ca2+]C
(e.g. Figure 3A). Unlike the A-sites, the divalent cation
affinity of the I1-sites is unaffected by the cytoplasmic
cofactors ATP and caffeine.27,36 The precise location of the
I1-site is unknown. RyRC does not exhibit Ca2+/Mg2+
inhibition32 indicating that the I1-sites reside somewhere inthe N-terminal 4007 amino acids. Several studies have
implicated aa1873-1903, aa1641-2437 and aa615 with the
I1-sites.37 In cardiac muscle, the role of I1-mediatedinhibition is obscure because the affinity of the I1-site is atleast an order of magnitude above the intracellular [Ca2+]
and [Mg2+]. However, the skeletal muscle isoform is much
more sensitive to I1-mediated inhibition and the binding ofcytoplasmic Mg2+ to this site has been proposed to be the
primary restraint on Ca2+ release in resting skeletal
muscle.38
I2-site for [Ca2+]C-inactivation
Early studies of SR Ca2+ release detected a
Ca2+-inactivation mechanism that operates at µM [Ca2+]C.Measurements of global Ca2+ release in skeletal and cardiac
muscle revealed a phenomenon39-41 in which cytoplasmic
Ca2+ causes rapid (< 100 ms) and partial inactivation of SR
Ca2+ release with a half-maximal effect at 0.3 µM. The
kinetics of localised Ca2+ release “Ca2+ sparks” in cardiac
Proceedings of the Australian Physiological Society (2007) 38 61
Figure 1.4: Schematic illustrating the location of predicted RyR2 Ca2+ 
binding sites: The exact locations of these Ca2+ sensing sites remain to 
be identified. Image taken from Laver, 2007.  
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! Cytosolic Ca2+: 
 
Laver (2007) suggests that RyR2 channels are activated by low micromolar 
concentrations (1-10 !M), but inactivated at millimolar concentrations (1-10 mM) of 
cytoplasmic Ca2+.  As shown in Figure 1.4, two cytoplasmic facing Ca2+ binding sites have 
been attributed to this response, termed the A-site (activation, 1 !M affinity) and the I1-site 
(inhibition, 10 mM affinity), which is also known as the Ca2+/Mg2+ inhibition site due to its 
lack of discrimination between these divalent cations (Laver, 2007, Balog et al., 2001). 
Another high affinity inhibitory site is also predicted, termed the I2-site. This site has the 
same affinity as the A-site (1 !M) and causes brief (1 ms) channel closures upon binding 
Ca2+ (Laver, 2007). The bimodal dependence reported by Laver (2007) however has been 
contested, since other research groups including our laboratory have demonstrated that 
the effects of cytoplasmic Ca2+ on channel open probability (Po) exhibits a sigmoidal 
relationship (Li and Chen et al., 2001, Mukherjee et al., 2012). Mukherjee et al (2012) 
demonstrated that the greatest increase in purified recombinant human RyR2 Po was 
evident between 100nM-1 !M cytoplasmic Ca2+, whilst an increase in cytosolic Ca2+ 
concentration >10 !M caused channel Po to reach saturation levels. The sensitivity of 
RyR2 to inactivating Ca2+ has also been reported as heterogeneous, where the levels of 
Ca2+ imparting an inhibitory effect has been shown to vary in single recombinant mouse (Li 
and Chen, 2001) and rabbit RyR2 channels (Copello et al., 1997).  
 
! Luminal Ca2+: 
 
Recognised as early as 1975 (Fabiato and Fabiato, 1975), luminal Ca2+ also modulates 
RyR2 Ca2+ release (Sitsapesan and Williams, 1994, Györke and Györke, 1998). More than 
one model has been proposed for this, though it is likely that there is interplay between 
each of them: 
 
(1) Luminal Ca2+feed through: 
 
Luminal Ca2+ passes though the channel pore and modulates activity by binding to 
regulatory sites (A-, I1- and I2-site – Figure 1.4) on the cytoplasmic domain of RyR2 (Xu et 
al., 2004, Laver, 2007). Single channel recordings identified that activation of RyR2 by 
luminal Ca2+ was governed by the Ca2+ flux in the luminal-to-cytoplasmic direction 
(Tripathy and Meissner, 1996, Xu and Meissner, 1998). Ruling out the possibility of Ca2+-
sensing sites present on the luminal domain, Xu and Meissner (1998) reported that in the 
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absence of cytoplasmic Ca2+ (<0.1 !M) i.e. when the channel is closed, elevating the 
luminal Ca2+ up to as high as 10 mM did not activate channel activity.  
 
(2) Direct luminal Ca2+ activation: 
 
Termed the “true luminal” model by Laver in 2007, evidence also suggests that the effects 
of luminal Ca2+ could involve distinct Ca2+ binding site(s) present on the luminal face of the 
RyR2 channel (Györke and Györke, 1998). In the Laver model, this site is denoted the L-
site (Figure 1.4). Györke and Györke demonstrated that under conditions which favoured a 
net Ca2+ flux in the cytoplasmic-to-luminal direction, raising the luminal Ca2+ concentration 
from 20 !M to 10 mM produced a 10-fold increase in the channel Po, and was attributed to 
unique luminal Ca2+ sensing sites present on the RyR2 channel itself or via an associated 
protein, such as calsequestrin (Györke and Györke, 1998). Ching and co-workers reported 
similar findings, and revealed that tryptic digestion of the luminal side of the RyR channel 
altered channel activity such that an increase in luminal Ca2+ (from 10 !M to 1 mM) no 
longer enhanced RyR2 Po, but instead reduced channel activity. This observation led to 
suggestions that activation sites present on the luminal side of RyR2 channels was 
destroyed with protease digestion, but inactivating sites may also exist on the luminal side 
that remained intact after digestion (not shown on the Laver model), (Ching et al., 2000).  
 
(3) Luminal-triggered Ca2 feed-through mechanism: 
 
RyR2 gating is influenced by Ca2+ sensing mechanisms on both the luminal and 
cytoplasmic sides of the channel, which has led to the development of a unified theory of 
activation termed the “luminal-triggered Ca2+ feed-through” hypothesis. This model 
integrates all of the predicted activation (A- and L-sites) and inactivation sites (I1- and I2-
sites) that can be functionally linked by Ca2+ feed-through (Laver, 2007). During diastole, 
when Ca2+ is loaded back into the SR, channel activation may occur via the luminal, L-site, 
producing brief RyR2 openings that allow luminal Ca2+ to pass through the channel pore 
and initiate further activation at the cytosolic A-site (Laver et al., 2007). Compounds that 
enhance RyR2 activity at the A-site (such as ATP, see section 1.4.3) may therefore 
enhance luminal Ca2+-dependent activation and render the channels more sensitive to 
Ca2+ loading within the SR (Györke and Györke, 1998, Tencerová et al., 2012). This 
observation is important, since under pathological conditions enhanced activation of 
mutant RyR2 by luminal Ca2+ has been proposed as a contributing factor of channel 
dysfunction (Jiang et al., 2005). During systole, the L-site does not appear to influence 
channel activity, since under conditions of high cytosolic Ca2+, raising the luminal Ca2+ 
concentration did not appear to impart any further increase in the duration of channel 
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openings (Laver and Honen, 2008). Aside from the interplay between cytoplasmic and 
luminal Ca2+ microdomains, which are clearly critical determinants of RyR2 activity, other 
intracellular ligands such as Mg2+ and ATP are also thought to play important regulatory 
roles (Zahradníková et al., 2003). 
 
 
1.4.2. RyR2 regulation by Mg2+: 
 
Mg2+ is a physiological inhibitor of RyR2 and plays a role in shaping the cytoplasmic and 
luminal Ca2+ dependencies of channel activity within the cell (Laver and Honen, 2008). 
Mg2+ levels within the millimolar range can inflict an inhibitory effect on channel behaviour 
(reducing channel Po), which has been suggested to occur at the I1- cytoplasmic site 
(Figure 1.4), (Györke and Györke, 1998, Zahradníková et al., 2003). In cardiac muscle at 
rest, the free Mg2+ concentration has been predicted to lie within the 0.5-1.2 mM range, 
and is thought to remain relatively constant throughout the cardiac cycle (Zahradníková et 
al., 2003). It is therefore likely that the free Ca2+ concentration within the cell acts as the 
critical determinant of the degree of channel inhibition seen with Mg2+. It has also been 
proposed that when cytosolic [Ca2+] is at resting levels (during diastole) and the SR store 
is depleted of Ca2+, Mg2+ may also occupy the A- and L- activation sites and render RyR2 
inactive (Laver et al., 2010). Once the SERCA2a Ca2+-ATPase pump sequesters Ca2+ 
back into the SR store and luminal [Ca2+] is increased, Laver et al (2010) proposed that 
Ca2+ displaces Mg2+ at the L-site, relieving inhibition and allowing further RyR2 channel 
activation at the cytoplasmic A-site (Laver et al., 2010). 
 
1.4.3. RyR2 regulation by Adenine Nucleotides (ATP): 
 
Single channel recordings have revealed that the presence of millimolar concentrations of 
ATP enhances the Ca2+ induced activation of RyR2 (Györke and Györke, 1998, Kermode 
et al., 1998). Since this channel effector is unable to activate RyR2 alone, but enhances 
both channel openings and open duration in the presence of both cytosolic and luminal 
Ca2+ (Tencerová et al., 2012), it has been suggested that the primary role of ATP is to 
stabilise the open state of RyR2. Other adenosine nucleotides such as adenosine 
diphosphate (ADP) and adenosine monophosphate (AMP), which are by-products of ATP 
hydrolysis, can also potentiate RyR2 Ca2+ release, but appear less effective (Sitsapesan 
and Williams, 1998). The cytoplasm of resting cardiac muscle contains approximately 3-5 
mM total ATP, which like Mg2+ is thought to remain consistent throughout EC coupling 
(Zahradníková et al., 2003). Since most ATP in cells exists as a complex with Mg2+, under 
normal physiological conditions, it is likely that a complex of MgATP (rather that free ATP 
alone) is responsible for regulating RyR2 Ca2+ release (Lanner et al., 2010).  
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1.5. RyR2 macromolecular signalling complex: 
 
Existing as a huge macromolecular complex, a multitude of regulatory proteins interact 
directly or indirectly with RyR2 channels to modulate their activity (Wehrens, 2005). Whilst 
most regulatory proteins interact with the cytoplasmic side of the Ca2+ release channel, 
others traverse the SR membrane or function as luminal accessory proteins. In this 
chapter, the best characterised of the RyR2 accessory proteins will be discussed.  
 
1.5.1. Regulation of RyR2 by FKBP-binding proteins: 
 
Classed as immunophillins, FKBPs are a family of binding proteins for the 
immunosuppressant drugs FK506 and rapamycin, and display peptidylpropyl-cis-trans-
isomerase (PPIase) activity thought to be important for their roles in protein folding and 
trafficking (Marks, 1996, Kang et al., 2008). This enzymatic activity however, is not thought 
to contribute to their role in modulating RyR2 function (Marks, 1996). 
 
Two isoforms of FKBP are known to interact with RyR2: FKBP12.6 and FKBP12 (Chelu et 
al., 2004, Zissimopoulous et al., 2012). However, since RyR2 exhibits a higher binding 
affinity for FKBP12.6, this is considered the cardiac-specific isoform, associating with a 
stoichiometry of one FKBP12.6 molecule per RyR2 subunit (Timerman et al.,1993). 
FKBP12.6 and FKBP12 share ~85% homology, both consist of 108 amino acids and as 
determined by X-ray crystallography, their structures are nearly identical both alone and 
as a drug complex with rapamycin (Deivanayagam et al., 2000). It is thus unsurprising that 
both are predicted to physically interact with RyR2 channels to regulate their activity 
(Galfré et al., 2012, Zissimopoulous et al., 2012).  
 
It has been hypothesised that the binding of FKBP isoforms to RyR2 channels inhibit Ca2+ 
release activity and act to stabilise the channels closed state (Marx et al., 1998, 2001, 
Ondrias et al., 1998). During ß-adrenergic stimulation it has been suggested that 
FKBP12.6 is partially dissociated from RyR2 channels upon PKA phosphorylation, which 
subsequently enhances intracellular Ca2+ release and improves contractility (Wehrens et 
al., 2003). However, in disease states (discussed in section 1.8.1), defective interaction 
between the two proteins following phosphorylation is consequently proposed as a 
mechanism underlying RyR2 dysfunction. This hypothesis however has been extensively 
challenged, since not all groups have observed the same effects of the RyR2/FKBP12.6 
binding interaction as a channel ‘stabiliser’ (Xiao et al., 2007). Marx et al (2000) 
demonstrated at the single channel level that FKBP12.6-deficient RyR2 channels 
exhibited pronounced subconductance states and enhanced activity recognised by high 
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channel Po. Consistent with this study, mice with gene-targeted knockout of FKBP12.6 
displayed an enhanced predisposition to heart failure (HF) and sudden cardiac death 
(SCD), tested using a pre-designed exercise program (Wehrens et al., 2003). However, 
Xiao et al (2007) reported following single channel, Ca2+ imaging and [3H] ryanodine 
binding investigations that the addition or removal of FKBP12.6 had no observable effects 
on RyR2 channel activity.   
 
Providing a possible explanation for these discrepancies, Galfré et al demonstrated in a 
more recent single channel investigation that FKBP12, which is largely overlooked in 
cardiac cells in terms of function, activated RyR2 channels at very low concentrations, 
whilst FKBP12.6 did not. The FKBP12.6 isoform did however antagonise the effects 
imparted by FKBP12 (lowering channel Po), which led to the idea that dual regulation 
between both isoforms may be important for channel function; and that an alteration in the 
ratio of FKBP12/FKBP12.6 ultimately contributes to the defective Ca2+ handling seen in 
HF (Galfré et al., 2012). 
 
 
1.5.2. Kinase and Phosphatase regulation of RyR2: 
 
Recent studies have revealed that kinases and phosphatases are targeted directly to the 
cytoplasmic domain of RyR isoforms and modulate channel function in response to 
extracellular signals (Marx et al., 2001, Reiken et al., 2003). RyR2 channels have highly 
conserved leucine/isoleucine zipper motifs that associate with adaptor proteins (such as, 
spinophillin and muscle-specific anchoring protein (mAKAP)) that in turn bind 
serine/threonine kinases such as: protein kinase A (PKA) and Ca2+ Calmodulin Kinase II 
(CaMKII), and phosphatases: protein phosphatase 1 (PP1) and 2A (PP2A), that control 
phosphorylation/dephosphorylation in a spatially and temporally regulated manner (Marx 
et al., 2000, Hulme et al., 2004, Blayney et al., 2009).  
 
PKA is a heterodimeric protein kinase activated during the “fight and flight” response to 
enable rapid increases in the heart rate and cardiac contractility in times of stress 
(Wehrens et al., 2006). A secondary messenger, cAMP, the concentrations of which are 
elevated by adrenergic stimulation of the cardiac ß-adrenoreceptors, activates PKA 
(section 1.2.5). An increase in heart rate raises intracellular Ca2+ levels, which in turn 
activates CaMKII. The importance of these interactions in regulating RyR2 activity 
however is still debated. Phosphorylation of RyR2 is predicted to occur at three distinct 
sites: serine-2808 (PKA and CaMKII), serine-2815 (CaMKII) and serine-2030 (PKA) (Xiao 
et al., 2006, Huke et al., 2008). PKA phosphorylation at Ser-2030 has been suggested as 
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the major site that responds to ß-adrenergic stimulation (Xiao et al., 2006). However, other 
groups have reported more recently that phosphorylation of RyR2 at Ser-2030 has no 
functional effect on channel activity (Marx and Marks et al., 2013). Other phosphorylation 
sites have also been detected with mass spectrometry, the significance of which has yet to 
be investigated (Yuchi et al., 2012).  
 
Since kinases directly influence other major Ca2+ handling proteins aside from RyR2 and 
indirectly modify accessory proteins (section 1.2.5), understanding how Ca2+ release is 
regulated by phosphorylation within the cell is difficult to determine (Mackrill, 1999). It has 
therefore proved useful to study the effects of RyR2 phosphorylation using in vitro 
investigations. At the single channel level, phosphorylation with exogenous PKA and 
CaMKII has been reported to increase channel Po, enhance sensitivity to luminal (Xiao et 
al., 2007) and cytosolic Ca2+ (Marx et al., 2000) and reduce cytoplasmic Mg2+ inhibition 
(Uehara et al., 2002). However, an inhibitory component of phosphorylation has also been 
suggested, since some research groups have demonstrated a reduction in RyR2 channel 
activity with kinase association (Hain et al., 1994) and enhanced channel Po following 
RyR2 dephosphorylation (Carter et al., 2011). These differences however could be owed 
to different functional effects of different PKA-phosphorylation sites (Xiao et al., 2006). 
Carter et al proposed that at rest, RyR2 is phosphorylated up to 75% of full stoichiometry 
at S2808 and suggested the stimulatory effects of PKA only occur when channels are 
phosphorylated above this level (Carter et al., 2006). Consistent with this proposal, under 
basal conditions Li et al (2013) reported that S2808 and S2814 (in rats) displayed 
phosphorylation levels of 69% and 15%, respectively. However, these levels increased 
substantially to 83% (S2808) and 60% (S2814) following ß-adrenergic stimulation (Li et 
al., 2013). Phosphorylation of S2030 however was not included in this investigation since 
phosphorylation at this site could not be detected (Li et al., 2013).  
 
With regards to the role of phosphatases, PP1 and PP2A are thought to be responsible for 
both RyR2 (Terentyev et al., 2003a) and PLB dephosphorylation (MacDougall et al., 
1991). Terentyev et al reported that PP1 enhances RyR2 activity, whilst others report that 
channel activity is decreased upon phosphatase association (Terentyev et al., 2003a, Li et 
al., 2013). Although such discrepancies need to be investigated further, it is clear that the 
phosphorylation status of RyR2 has notable effects on Ca2+ release activity.  
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1.5.3. Regulation of RyR2 by Calmodulin and Sorcin: 
 
Sharing common structural and functional features, calmodulin (CaM) and sorcin are EF-
hand-containing Ca2+ binding proteins, proposed to inhibit Ca2+ release activity (Balshaw 
et al., 2001, Farrell et al., 2003). 
 
CaM is a 17 kDa, ubiquitously expressed cytosolic protein that associates directly with 
RyR2 channels, as well as other several other proteins and ion channels (Meissner, 2004, 
Lanner et al., 2010). In terms of structure, CaM consists of four EF-hand Ca2+ binding 
domains (two in the carboxy-terminal and two in the amino-terminal of the protein) and 
binds to one site (1:1 ratio) on each RyR2 monomer (Fruen et al., 2000). Interestingly, 
modulation of RyR2 activity by CaM, over a wide range of Ca2+ concentrations, differs 
from that of other RyR isoforms, suggesting the protein plays a unique role in EC coupling 
regulation (Tripathy et al., 1995, Hamilton et al., 2000). At the single channel level, 
application of CaM can either activate (at low luminal Ca2+ concentrations) or inhibit (at 
high luminal Ca2+) RyR1 and RyR3 channels, thus having a biphasic response, whilst the 
protein appears to only inhibit RyR2 channel function (Tripathy et al., 1995, Hamilton et 
al., 2000). Highlighted by Xu and Meissner, evidence suggests that CaM plays an 
important role in the termination of SR Ca2+ release (Xu and Meissner, 2004). CaM 
application significantly reduced the frequency of RyR2 channel openings, lowering Po, 
and increasing the mean closed times (Xu and Meissner, 2004). CaM is predicted to 
regulate RyR2 gating both in its Ca2+ free (apoCaM) and Ca2+-loaded state, and has been 
suggested to fine-tune the channels sensitivity to intracellular [Ca2+] (Tripathy et al., 1995, 
Van Petegem, 2012).  
 
First discovered in multidrug-resistant cells, sorcin is a 22 kDa Ca2+ binding protein 
identified in cardiomyocytes as directly interacting with RyR2 channels (Meyers et al., 
1998, Bers, 2004). The protein binds Ca2+ with high affinity, with half-maximal binding 
reported to occur at ~1 !M (Zamparelli et al., 2000) Although its precise role remains to be 
established, sorcin is thought to act in a similar way to CaM, causing RyR2 inhibition, as 
demonstrated with [3H]-ryanodine binding and single channel investigations (Lokuta et al., 
1997, Farrell et al., 2003). Farrell et al (2003) demonstrated that sorcin reduces the Po of 
single RyR2 channels, and that inhibition was relieved by PKA-mediated phosphorylation - 
suggesting an indirect role for this protein kinase. Other EF-hand containing proteins have 
also been predicted to regulate RyR2 activity but have not been well studied. S100A1 for 
example has been reported to enhance the opening of RyR2 channels (Prosser et al., 
2011).  
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1.5.4. Regulation of RyR2 by Junctate, Junctophillin and the histidine-rich Ca2+ 
binding protein: 
 
Junctate is a functionally distinct, 33 kDa splice variant of the aspartyl ß-hydroxylase 
(ASPH) gene (Hong et al., 2007, Scriven et al., 2013, Treves et al., 2000). Another splice 
variant of ASPH, junctin, will be discussed in section 1.6.3. Thought to regulate 
intracellular Ca2+ concentration, junctate is an SR located Ca2+ binding protein, composed 
of a single membrane-spanning transmembrane domain, a short N-terminal (cytoplasmic) 
region and a long, highly acidic C-terminal segment that protrudes into the lumen of the 
SR (Hong et al., 2007). Hong et al (2008) used a transgenic mouse model of junctate 
overexpression to assess its effect in cardiac cells, where impairment in SR function was 
reported. This was likely due to a notable downregulation in two major Ca2+ handling 
proteins, SERCA2a and CSQ2 (section 1.6.1), (Hong et al., 2008). Prolonged junctate 
overexpression led to a compensatory enhancement in sarcolemmal protein expression, 
cardiac hypertrophy and consequently a greater susceptibility to cardiac arrhythmias 
(Hong et al., 2008). Although this evidence implies that junctate plays a regulatory role in 
maintaining Ca2+ homeostasis, whether it directly modifies RyR2 activity remains to be 
elucidated.  
 
Junctophillin-2 (JP2), a component of plasma membrane/SR complexes, has a molecular 
weight of approximately 100 kDa and recognised as the primary isoform expressed in the 
heart (Takeshima et al., 2000). Spanning the SR membrane, the cytoplasmic region of the 
protein is reported to interact with the cell membrane/T-tubule network and anchors it 
close to the SR, forming T-tubule-SR junctions (Nishi et al., 2000, Takeshima et al., 2000). 
Since in heart failure, JP2 is significantly downregulated, the protein is hypothesised to be 
critical to the normal operation of CICR between L-type Ca2+ channels and RyR2 (Wu et 
al., 2012). Aside from its role as a structural protein, recent studies have revealed a direct 
interaction between JP2 and RyR2 (using immunoprecipitation, Beavers et al., 2013) and 
its ability to regulate intracellular Ca2+ release (Wang et al., 2014).  
 
Wang et al (2014) suggested that JP2, under normal circumstances, negatively regulates 
RyR2 gating, since cardiac-specific knockdown of the modulatory protein triggered severe 
RyR2-mediated SR Ca2+ leak. In JP2 knockdown mice, two notable molecular 
mechanisms were proposed to explain the arrhythmogenic Ca2+ leak through RyR2 
channels (Wang et al., 2014). Firstly, at the single channel level, the group demonstrated 
that severely low JP2 expression significantly enhanced the Po and mean open time of 
RyR2; whilst the mean closed time was reduced. An earlier single channel study carried 
out by Beavers et al (2013) was consistent with this finding, where a decrease in RyR2 Po 
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was evident when a small synthetic peptide derived from the JP2 primary sequence was 
added back to the reconstituted channel. Furthermore, Ca2+ sparks in JP2-knockdown 
cardiac myocytes showed increased width, duration and frequency, thought to result from 
the enhanced opening of RyR2 clusters (Cheng et al., 1993, Wang et al., 2014). JP2-
deficient cardiomyocytes displayed a ~50% reduction in NCX activity, with no observable 
differences in protein expression, which may also have altered the Ca2+ spark profile 
(Wang et al., 2014).   
 
Proposed to play a prominent role in maintaining Ca2+ homeostasis, the histidine-rich Ca2+ 
binding protein (HRC) is 170 kDa and resides within the SR lumen of cardiac cells 
(Arvanitis et al., 2011). Although it is not thought to interact directly with RyR2 channels, 
HRC associates with both the SERCA2a pump (section 1.2.3) and the transmembrane 
protein triadin (discussed in section 1.6.3), and has thus been implicated both in Ca2+ 
uptake (Gregory et al., 2006) and release (Lee et al., 2001). In mouse hearts with HRC 
overexpression, the rate of Ca2+ re-uptake into the SR was drastically reduced, without 
any notable effects on the SR Ca2+ load. This therefore led to the hypothesis that HRC 
directly suppresses SERCA2a function (Gregory et al., 2006). Binding of HRC to triadin is 
Ca2+-dependent and the interaction between the two proteins has been implicated in 
sensing changes in SR Ca2+ concentration (Arvanitis et al., 2011). This however requires 
further investigation. A recent study by Singh et al (2013) described a genetic variant of 
the HRC protein (Ser96Ala), which generated defective Ca2+ cycling and cardiac 
arrhythmias. The underlying mechanism of this dysfunction was attributed to a reduction in 
the stability of RyR2 channels, imparted by disrupted protein-protein associations of HRC 
with triadin (Singh et al., 2013).  
 
 
1.6. Calsequestrin, Junctin and Triadin: 
 
Existing as a quaternary complex with RyR2 channels at the jSR membrane, calsequestrin 
(CSQ2), junctin (JUN) and triadin (TRD1) are thought to directly regulate the sensitivity of 
RyR2 channels to luminal Ca2+, with CSQ2 in particular hypothesised to act as RyR2s 
luminal Ca2+ sensor (Györke et al., 2004). A key question regarding the role of these 
luminal proteins is whether they can function as direct modifiers of RyR2 channels 
independently, or if to regulate channel function they must assemble as a complex. The 
specific properties of CSQ2, JUN and TRD1, and their importance in regulating RyR2 
channel activity, will be discussed next in sections 1.6.1-1.6.4 (Tables 1.1-1.3). 
 
 
 24 
1.6.1. Properties of cardiac calsequestrin: 
 
First identified in the early 1970s, CSQ2 is the most abundant Ca2+ binding protein present 
within the SR lumen of cardiac myocytes, binding Ca2+ with high capacity (60-80 moles of 
Ca2+ per CSQ molecule) and relatively low affinity (Kd = 1 mM) (MacLennan and Wong, 
1971, Mitchell et al., 1988). Isoform 2 (CSQ2) is the major variant expressed in cardiac 
muscle and is also found in lower quantities in skeletal slow-twitch muscle fibres (Bers et 
al., 2004). Despite dog cardiac CSQ2 being the most extensively studied, sequence 
alignment has estimated approximately 86% homology between dog and human CSQ2 
(Beard et al., 2004).  
 
Contributing to its ability to bind large amounts of Ca2+, CSQ2 is a highly acidic protein 
(Lee et al, 2012). Human CSQ2 is composed of 391 amino acids with an additional 19-
residue signal peptide at the N-terminus (Lahat et al., 2001, Lee et al., 2012), the C-
terminal region of CSQ2 is thought to contain ~60% acidic (in particular aspartate) 
residues (Shin et al., 2000) and provides the sites of interaction for other accessory 
proteins (Shin et al., 2000, Kobayashi et al., 2000). CSQ2 is not embedded in the SR 
membrane, but instead is localised to the junctional face within close proximity to RyR2 
channels by integral SR membrane proteins JUN and TRD1. The two proposed ‘anchoring 
proteins’ facilitate communication between CSQ2 and RyR2, positioning Ca2+ ions 
accumulated by CSQ2 close to the Ca2+ release sites (Györke et al., 2004, Shin et al., 
2000, Rossi and Sorrentino, 2002, Franzini-Armstrong et al., 1987, Bers, 2000). 
Preventing premature Ca2+ release, CSQ2 stores large amounts of releasable Ca2+ within 
the SR lumen, whilst at the same time, maintaining a low level of free Ca2+ that triggers 
Ca2+ re-uptake following muscle contraction (Beard et al., 2004, Novák and Soukup, 
2011). The association of CSQ2 with JUN and/or TRD1 has been suggested to strongly 
affect its disposition (Franzini-Armstrong et al., 2005). In electron micrographs, the protein 
has been reported to exist alone as linear polymers folded randomly within the SR lumen, 
yet when positioned closer to the jSR membrane, the protein appears condensed 
(described as “dense spots”), owing to its association with the two accessory proteins 
(Franzini-Armstrong et al., 2005).  
 
CSQ2 is thought to exist as a mixture of monomers, dimers and polymers, where 
polymerisation and depolymerisation occurs in a [Ca2+]-dependent manner (Beard et al., 
2009, Kim et al., 2007, Lee et al., 2012). Studied using rabbit skeletal CSQ, in the 
absence of Ca2+, the protein is predicted to exist as a random coil monomer with lowered 
alpha-helical content (~11%), which is increased to >20% upon Ca2+ binding and folding of 
CSQ2 monomers into thioredoxin-like domains (Cozens and Reithmeier, 1984, Beard et 
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al., 2009). Investigating the Ca2+-dependent conformational changes of the protein, the 
thioredoxin-like folds are required for protein compaction and subsequent Ca2+ binding at 
intracellular [Ca2+] >10 !M (He et al., 1993, Wang et al., 1998, Beard et al., 2009). Further 
increases in luminal Ca2+ induce conformational changes in CSQ2 monomers, causing 
them to self-associate and assemble into dynamic linear polymers that allow high capacity 
Ca2+ binding (Beard et al., 2004, Kim et al., 2007). CSQ2 polymers are thought to consist 
of two types of dimer termed “back-to-back” (C-terminal) and “front-to-front” (N-terminal) 
interactions, both of which are predicted to form Ca2+ binding pockets essential for storage 
(Park et al, 2003). The conformational state of CSQ2 at luminal [Ca2+] >1mM however has 
been debated in the literature, with both CSQ2 polymers (Wang et al., 1998, Kim et al., 
2007) and monomers (Wei et al., 2009b, Murphy et al., 2011) predicted as responsible for 
the proteins regulatory function.   
 
1.6.2. Physiological role of CSQ2 and functional interaction with RyR2: 
 
For a number of years, the sole purpose of CSQ2 was believed to be the maintenance of 
Ca2+ homeostasis within the SR by acting as a major Ca2+ storage protein. However, in 
recent years, substantial evidence has suggested that CSQ2 also plays a direct role in 
regulating RyR2 activity, coordinating time-dependent Ca2+ release with recovery (Györke 
et al., 2004, Beard et al., 2004, Terentyev et al., 2005). Since the role of CSQ2 in 
regulating RyR2 activity (and the relative contribution of JUN and TRD1 to this regulation) 
will be discussed further in other chapters, some of the experimental systems used to 
study CSQ2 function and their reported findings, will be summarised in Table 1.1. 
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CSQ2 Investigations 
Study Type/species:  Ca
2+
 handling observations: Phenotypic Alterations: Further Details: 
CSQ overexpression (10-
fold) in transgenic mice 
(Jones et al., 1998). 
Whole-cell clamped isolated 
cardiomyocytes displayed a reduced 
frequency in both spontaneous and Ca
2+
-
triggered Ca
2+
 sparks. Reflecting 
increased CSQ2-stored Ca
2+
, caffeine-
induced Ca
2+
 release amplitude was 
enhanced (10-fold). 
Severe cardiac hypertrophy, 
~1.9 fold increase in heart 
mass and cell size, exercise 
intolerance. 
RyR2, JUN and TRD downregulated (~50%).  
 
SERCA and PLB expression unchanged. 
Cardiac –specific 
overexpression of CSQ2 
(20-fold) in transgenic mice 
(Sato et al., 1998). 
Reduced Ca
2+
-induced SR Ca
2+
 release 
amplitude 
Depressed contractility, 
cardiac hypertrophy  
No alterations in RyR2, JUN or TRD 
expression. 
 
Increased protein levels of SERCA and PLB.  
Adenoviral-mediated 
increase or decrease in 
CSQ2 levels in rat 
ventricular myocytes 
(Terentyev et al., 2003). 
In permeabilised myocytes, CSQ2 
overexpression slowed termination of 
Ca
2+
 release from the SR and slowed 
Ca
2+
 spark recovery time. 
Premature activation evident 
in myocytes with lower CSQ2 
expression. Upon electrical 
stimulation, arrythmogenic 
Ca
2+
 transients observed (in 
myocytes with low levels of 
CSQ2).  
Suggests CSQ2 controls Ca
2+
 release by 
prolonging the Ca
2+
 flux duration. 
 
CSQ2 may be involved in the termination of 
RyR2 Ca
2+
 release. 
 
Gene-targeted ablation of 
CSQ2 in mice (Knollmann 
et al., 2006). 
Under basal conditions normal SR Ca
2+
 
release. However, CSQ2-null myocytes 
displayed increased diastolic Ca
2+
 leak 
upon catecholamine stimulation. 
Spontaneous Ca
2+
 oscillations evident 
and an increased propensity for 
arrhythmia. 
 
Increased SR volume (size). 
 
Functional SR Ca
2+
 storage 
unaltered.  
JUN and TRD1 levels undetectable. 
 
No alterations in other Ca
2+
 handling 
proteins. 
Single channel investigation 
utilising purified canine 
CSQ2 (Györke et al., 2004)  
In the presence of JUN and TRD1, CSQ2 
added back to purified RyR2 channels 
inhibited activity (reduced channel 
openings). 
N/A First proposal that CSQ2 (together with 
anchoring proteins JUN and/or TRD1) may 
act as a luminal Ca
2+
 sensor for RyR2 
channel activity. 
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1.6.3. Properties of cardiac junctin and triadin: 
 
Human cardiac muscle JUN is a 26 kDa, 210-amino acid protein that spans the SR 
membrane and exists as a functionally distinct, non-catalytic splice variant of the 
aspartate-!-hydroxylase gene (together with junctate, section 1.5.4), (Lim et al., 2000, Wei 
et al., 2009a). Expressed as a single isoform in cardiac and skeletal muscle (Dulhunty et 
al., 2009), the protein contains a cytoplasmic N-terminal domain (residues 1-22), a single 
transmembrane segment (residues 23-44), and a longer, SR intraluminal C-terminal 
region (residues 45-210) that contains several charged sequence repeats (>13 amino 
acids) of lysine or glutamic acid residues (predicted from the dog cardiac JUN isoform, 
Jones et al., 1995). Known as “KEKE” motifs, these repeats are thought to be important 
for the binding interaction of JUN with the other luminal accessory proteins and RyR2 
(Jones et al., 1995, Shin et al., 2000, Fan et al., 2008). The current accepted model of 
RyR2 regulation by SR luminal proteins suggests JUN has the ability to bind directly to the 
luminal and/or transmembrane regions of RyR2 and acts as an anchoring protein 
(together with TRD1) to position CSQ2 near the channel (Zhang et al., 1997, Györke et al., 
2004). Although the exact physiological role of JUN in regulating the response of RyR2 
channels to luminal Ca2+ is a topic of current research, its function in maintaining normal 
Ca2+ release from the SR lumen has been highlighted in studies of HF, where the protein 
is almost undetectable (Gergs et al., 2007). 
 
JUN may serve as a direct regulator of channel activity or transduce signals from CSQ2 to 
RyR2 in a Ca2+-dependent manner, or both (Beard et al., 2009). In terms of interaction, 
Kobayashi and co-workers demonstrated that JUN does not have a single discrete binding 
domain for CSQ2, since deletions in several “KEKE” motifs along the C-terminal tail all 
reduced CSQ2 binding (Kobayashi et al., 2000). However, binding of JUN to RyR2 
channels has been predicted to occur at two distinct domains (Altschafl et al., 2011). 
Using blot overlay assays, recombinant JUN and RyR2 polypeptides designed to different 
proposed intraluminal binding regions, Altschafl et al (2011) demonstrated that the N-
proximal intraluminal domain of JUN interacted with intraluminal loop I of RyR2, whilst the 
KEKE-motif of JUN interacted with RyR2 at intraluminal loop II; with the latter being 
comparable to the single binding site for TRD1 at intraluminal loop II of the RyR1 protein 
(Goonasekera et al., 2007, Altschafl et al., 2011). The binding of JUN to different sites on 
the RyR2 channel could reflect the ability of the protein to regulate Ca2+ release activity by 
more than one mechanism (Altschafl et al., 2011). 
 
Several isoforms of triadin exist in striated muscle, all of which are splice variants of a 
single TRDN gene (Guo et al., 1996). Whilst sharing a common amino terminus (264 
 28 
residues), each isoform is predicted to differ in their C-terminal regions, which in smaller 
proteins is truncated (Kobayashi and Jones, 1999, Dulhunty et al., 2012). Three cardiac-
specific isoforms have been identified (which are 32, 40 and 75 kDa), with TRD1 (~32 
kDa) being the most abundant, comprising of more than 95% of total TRD found in cardiac 
muscle (Kobayashi and Jones, 1999, Györke and Terentyev, 2007). Like JUN, TRD1 is an 
integral SR membrane protein and is composed of a short cytoplasmic N-terminal tail, a 
hydrophobic segment that spans the SR membrane and a longer, highly charged C-
terminal region located within the SR lumen which comprises the bulk of the protein 
(Györke and Terentyev, 2007, Beard et al., 2009). Interaction sites within TRD1 for its 
molecular partners, i.e. RyR2, CSQ2 and JUN are predicted to reside within the proteins 
C-terminus (Kobayashi et al., 2000). This region of the TRD1 sequence is characterised 
by the frequent occurrence of long stretches of alternating positively and negatively 
charged residues known as KEKE motifs, as previously identified in JUN. Interestingly, the 
CSQ2-binding domain of TRD1 has been localised to a single KEKE motif (amino acids 
210-224) of approximately 15 residues (Kobayashi et al., 2000). The binding regions on 
RyR2 for cardiac TRD1 remain undetermined (Dulhunty et al., 2012). TRD1 and JUN 
binding to CSQ2 was found to be Ca2+-dependent such that the proteins dissociate at high 
Ca2+ (10 mM), whilst TRD binding to RyR2 is thought to occur regardless of changes in 
Ca2+ concentration (Zhang et al., 1997, Kobayashi et al., 2000, Qin et al., 2008).  
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1.6.4.  Physiological roles of JUN and TRD1 and their functional interaction with 
RyR2: 
 
Although the functional role of JUN is still largely undetermined, its experimental 
manipulation, primarily in animal models, has yielded some interesting observations. Table 
1.2 summarises some of the functional studies undertaken to establish the physiological 
importance of JUN in maintaining normal cardiac function. Further investigations where 
the ability of JUN to modulate RyR2 channel activity has been explored will be discussed 
in other chapters of this project.  
 
Given the close structural homology of TRD1 and JUN and the fact that they both 
communicate with RyR2 and CSQ2, it was first anticipated that the two related proteins 
share a similar function of simply anchoring CSQ2 within close proximity to RyR2. In this 
scaffolding capacity, TRD1 is thought to facilitate SR Ca2+ release indirectly, permitting 
CSQ2 to buffer luminal Ca2+ in the vicinity of the Ca2+ release sites (Zhang et al., 1997, 
Kobayashi et al., 2000). Aside from its role as an anchoring protein, unique roles of 
cardiac TRD1 have been reported in recent years, suggesting that TRD1 and JUN may 
serve different functions to regulate EC coupling. Table 1.3 summarises some of the 
functional assays carried out to specifically investigate the role of TRD1 in cardiac muscle. 
  
 
 
 
 
 
 
 
 
 
 30 
 
JU
N 
In
ve
st
ig
at
io
ns
 
St
ud
y 
Ty
pe
/s
pe
ci
es
:  
Ca
2+
 h
an
dl
in
g 
ob
se
rv
at
io
ns
: 
Ph
en
ot
yp
ic
 A
lte
ra
tio
ns
: 
Fu
rth
er
 D
et
ai
ls
: 
24
-2
9-
fo
ld
 o
ve
re
xp
re
ss
io
n 
of
 c
an
in
e 
JU
N
 in
 tr
an
sg
en
ic
 
m
ic
e 
(H
on
g 
et
 a
l.,
 2
00
2)
. 
N
/A
 
At
ria
l f
ib
ril
la
tio
n,
 fi
br
os
is
 a
nd
 
br
ad
yc
ar
di
a 
R
yR
2 
an
d 
TR
D
1 
do
w
nr
eg
ul
at
ed
. 
 L-
ty
pe
 C
a2
+  c
ha
nn
el
 u
pr
eg
ul
at
ed
. 
Ad
en
ov
ira
l-m
ed
ia
te
d 
ov
er
ex
pr
es
si
on
 o
f J
U
N
 in
 
ra
t c
ar
di
om
yo
cy
te
s 
(G
er
gs
 
et
 a
l.,
 2
00
7)
. 
D
ec
re
as
ed
 S
R
 C
a2
+  t
ra
ns
ie
nt
 a
m
pl
itu
de
 
C
el
l s
ho
rte
ni
ng
 (o
bs
er
ve
d 
by
 
th
e 
ce
ll-
ed
ge
 d
et
ec
tio
n 
sy
st
em
), 
re
du
ce
d 
co
nt
ra
ct
ilit
y.
  
 
Im
pa
ire
d 
C
a2
+  h
om
eo
st
as
is
 s
ug
ge
st
ed
.  
  
Ad
en
ov
ira
l-m
ed
ia
te
d,
 4
0%
 
do
w
nr
eg
ul
at
io
n 
in
 J
U
N
 
ex
pr
es
si
on
 (b
y 
an
tis
en
se
 
m
R
N
A)
 in
 a
du
lt 
ra
t 
ca
rd
io
m
yo
cy
te
s 
(F
an
 e
t a
l.,
 
20
07
) 
Im
pr
ov
ed
 C
a2
+  k
in
et
ic
s 
– 
in
cr
ea
se
d 
C
a2
+  
tra
ns
ie
nt
 a
m
pl
itu
de
, i
nc
re
as
ed
 ra
te
 o
f 
C
a2
+  d
ec
ay
 in
 is
ol
at
ed
 c
ar
di
om
yo
cy
te
s 
 
In
cr
ea
se
d 
co
nt
ra
ct
ilit
y 
(in
cr
ea
se
d 
ra
te
 o
f 
co
nt
ra
ct
io
n/
re
la
xa
tio
n)
. 
N
o 
ch
an
ge
s 
in
 th
e 
le
ve
ls
 o
f o
th
er
 C
a2
+  
ha
nd
lin
g 
pr
ot
ei
ns
. 
  
G
en
e-
ta
rg
et
ed
 J
U
N
 a
bl
at
io
n 
in
 m
ic
e 
(Y
ua
n 
et
 a
l.,
 2
00
7)
. 
En
ha
nc
ed
 N
C
X 
cu
rre
nt
, n
o 
di
ffe
re
nc
e 
in
 
th
e 
L-
ty
pe
 C
a2
+  c
ur
re
nt
. I
nc
re
as
ed
 C
a2
+  
tra
ns
ie
nt
 a
m
pl
itu
de
, S
R
 C
a2
+  c
on
te
nt
 a
nd
 
C
a2
+  s
pa
rk
 fr
eq
ue
nc
y 
(is
ol
at
ed
 J
U
N
-n
ul
l 
ca
rd
io
m
yo
cy
te
s)
.  
In
cr
ea
se
d 
ca
rd
ia
c 
fu
nc
tio
n 
re
po
rte
d 
(a
ss
es
se
d 
by
 
ec
ho
ca
rd
io
gr
ap
hy
). 
H
ow
ev
er
, 
st
im
ul
at
io
n-
ev
ok
ed
 
ve
nt
ric
ul
ar
 ta
ch
yc
ar
di
a 
tri
gg
er
ed
 b
y 
D
AD
s.
 
25
%
 o
f m
ic
e 
di
ed
 p
re
m
at
ur
el
y 
(~
3 
m
on
th
s 
of
 
ag
e)
 w
ith
 n
o 
st
ru
ct
ur
al
 a
bn
or
m
al
iti
es
. 
 N
o 
si
gn
ifi
ca
nt
 a
lte
ra
tio
ns
 in
 C
SQ
2,
 T
R
D
1,
 
SE
R
C
A2
a,
 P
LB
,H
R
C
, F
KB
P1
2.
6,
 L
-ty
pe
 
C
a2
+  c
ha
nn
el
, p
ro
te
in
 e
xp
re
ss
io
n.
 H
ow
ev
er
 
70
%
 re
du
ct
io
n 
in
 th
e 
ex
pr
es
si
on
 o
f N
C
X.
 
In
ve
st
ig
at
io
n 
of
 in
tra
ce
llu
la
r 
C
a2
+  h
om
eo
st
as
is
 in
 J
U
N
-
de
fic
ie
nt
 c
ar
di
om
yo
cy
te
s 
(A
lts
ch
al
f e
t a
l.,
 2
01
1)
. 
In
cr
ea
se
d 
C
a2
+  t
ra
ns
ie
nt
 a
m
pl
itu
de
 a
nd
 
in
cr
ea
se
d 
SR
 C
a2
+  c
on
te
nt
 in
 J
U
N
-n
ul
l 
ca
rd
io
m
yo
cy
te
s.
 D
es
pi
te
 S
R
 C
a2
+  
ov
er
lo
ad
, n
o 
di
as
to
lic
 C
a2
+  l
ea
k 
ev
id
en
t. 
 
 Su
gg
es
ts
 a
n 
al
te
re
d 
ab
ilit
y 
of
 R
yR
2 
ch
an
ne
ls
 to
 “s
en
se
” c
ha
ng
es
 in
 in
tra
-S
R
 
C
a2
+  l
oa
d.
 
 
ß-
ad
re
ne
rg
ic
 s
tim
ul
at
io
n 
di
m
in
is
he
d 
R
yR
2 
in
hi
bi
tio
n 
an
d 
in
du
ce
d 
sp
on
ta
ne
ou
s 
C
a2
+  o
sc
illa
tio
ns
 
  
JU
N
 a
ffe
ct
s 
SR
 C
a2
+  r
el
ea
se
 d
ire
ct
ly
, n
o 
al
te
re
d 
ex
pr
es
si
on
 o
f o
th
er
 jS
R
 C
a2
+ -
ha
nd
lin
g 
pr
ot
ei
ns
.  
 D
ua
l r
es
po
ns
e 
of
 J
U
N
 s
ug
ge
st
ed
 a
t t
he
 
si
ng
le
 c
ha
nn
el
 le
ve
l, 
w
he
re
 a
t l
ow
 lu
m
in
al
 
[C
a2
+ ] 
(<
1m
m
ol
) J
U
N
 a
ct
iv
at
es
 R
yR
2 
ac
tiv
ity
, 
bu
t i
nh
ib
its
 it
 a
t h
ig
h 
lu
m
in
al
 [C
a2
+ ].
  
   
24
 
                                    
 
CSQ2 Investigations 
Study Type/species:  Ca
2+
 handling observations: Phenotypic Alterations: Further Details: 
CSQ overexpression (10-
fold) in ransgenic mice 
(Jones et al., 1998). 
Whole-cell clamped isolated 
cardimyocytes displayed a reduced 
frequency in both spontaneous and Ca
2+
-
triggered Ca
2+
 sparks. Reflecting 
increased CSQ2-stored Ca
2+
, caffeine-
induced Ca
2+
 release amplitude was 
enhanced (10-fold). 
Severe cardiac hypertrophy, 
~1.9 fold increase in heart 
mass and cell size, exercise 
intolerance. 
RyR2, JUN and TRD downregulated (~50%).  
 
SERCA and PLB expression unchanged. 
Cardiac –specific 
overexpression of CSQ2 
(20-fold) in transgenic mice 
(Sto et al., 1998). 
Reduced Ca
2+
-induced SR Ca
2+
 release 
amplitude 
Depressed contractility, 
cardiac hypertrophy  
No alterations in RyR2, JUN or TRD 
expression. 
 
Increased protein levels of SERCA and PLB.  
Adenoviral-mediated 
increase or decrease in 
CSQ2 levels in rat 
ventricular myoctes 
(Terentyev et al., 2003). 
In permeabilised myocytes, CSQ2 
overexpression slowed termination of 
Ca
2+
 release from the SR and slowed 
Ca
2+
 sparkrecovery time. 
Premature activation evident 
in myocytes with lower CSQ2 
expression. Upon electrical 
stimulation, arrythmogenic 
Ca
2+
 transients observed (in 
myocytes with low levels of 
CSQ2).  
Suggests CSQ2 controls Ca
2+
 release by 
prolonging the Ca
2+
 flux duration. 
 
CSQ2 may be involved in the termination of 
RyR2 Ca
2+
 release. 
 
Gene-targeted ablation of 
CSQ2 in mice (Knollmann 
et al., 2006). 
Under basal conditions normal SR Ca
2+
 
release. Howver, CSQ2-null myocytes 
displayed increased diastolic Ca
2+
 leak 
upon catecholamine stimulation. 
Spontaneous Ca
2+
 oscillations evident 
and an increased propensity for 
arrhythmia. 
 
Increased SR volume (size). 
 
Functional SR Ca
2+
 storage 
unaltered.  
JUN and TRD1 levels undetectable. 
 
No alterations in other Ca
2+
 handling 
proteins. 
Single channel investigation 
utilising purified canine 
CSQ2 (Györke et al., 2004)  
In the presence of JUN and TRD1, CSQ2 
added back to purified RyR2 channels 
inhibited activity (reduced channel 
openings). 
N/A First proposal that CSQ2 (together with 
anchoring proteins JUN and/or TRD1) may 
act as a luminal Ca
2+
 sensor for RyR2 
channel activity. 
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1.7. RyR2 and CSQ2 mutations cause ventricular tachycardia and sudden cardiac 
death: 
 
Linkage studies and direct sequencing has revealed that inherited mutations mapped to 
chromosome 1q42-q43 (Swan et al., 1999), of the human cardiac ryanodine receptor gene 
(hRyR2), are predominantly associated with two conditions: Catecholaminergic 
Polymorphic Ventricular Tachycardia (CPVT) and Arrhythmogenic Right Ventricular 
Cardiomyopathy/Dysplasia type 2 (ARVC/D2), both of which share the clinical feature of 
exercise- or stress-induced ventricular tachycardia and SCD (Tiso et al., 2001, George et 
al., 2003b, Priori et al., 2001, Lahat et al., 2001, Laitinen et al., 2003, Thomas et al., 
2006).  
 
CPVT is an arrhythmogenic disorder with a high mortality rate in children and young adults 
(Leenhart et al., 1995, Priori et al., 2002). The disease was recently estimated at a 
prevalence of 1:10,000 (Jabbari et al., 2013). Two genetic variants of CPVT have been 
described: an autosomal-dominant form caused by mutations in RyR2 and a recessive 
form associated with mutations in CSQ2. Mutations in the RyR2 gene are much more 
prevalent than those of CSQ2, their autosomal dominant fashion means that the 
inheritance of a single disease-linked allele is sufficient to result in a CPVT phenotype 
(Fisher et al., 1999). The majority of CPVT patients display a family history of symptoms 
associated with the disorder such as VT or SCD, suggesting that it is hereditary (Priori et 
al., 2001, Postma et al., 2005). Conversely, some patients have been found to be the only 
symptomatic family member, with neither parent carrying the mutant allele. This suggests 
that CPVT-linked mutations can also arise in a de novo manner (Postma et al., 2005). The 
phenotypic manifestation of the disorder is also very heterogeneous, even affected 
members of the same family can display symptom variations (Thomas et al., 2007).  
 
Since the majority of arrhythmias in patients affected by CPVT occur during physical 
exercise or emotional distress, ß-adrenergic stimulation (section 1.2.5) is thought to be a 
major trigger of the condition (Priori et al., 2002). Moreover, clinical electrophysiological 
investigations have revealed that exercise testing or catecholamine infusion can induce 
arrhythmias in patients with CPVT (Priori et al., 2002). Affected individuals may display 
adrenergically mediated syncopal events, seizures and arrythmogenic episodes, yet have 
structurally normal hearts and normal resting ECGs (Scheinman and Lam, 2006, 
Leenhardt et al., 1995). Arrhythmias take the form of bi-directional and/or polymorphic VT, 
both of which are capable of degenerating into ventricular fibrillation and SCD, which sadly 
often constitutes the first manifestation of the disorder (Priori et al., 2002, Sumitomo et al., 
2003). 
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Another syndrome associated with missense mutations in RyR2 is ARVC/D2, a condition 
characterised by progressive degeneration of the right ventricular myocardium (Györke et 
al., 2007). Confusion however still surrounds the link between RyR2 and the disease, 
since few RyR2 mutations are known to cause right ventricular dysplasia (Györke et al., 
2009). However, phenotypic heterogeneity in symptomatic families has suggested an 
overlap between the two conditions (Thomas et al., 2007). For example, d’Amati et al 
(2005) reported a male CPVT patient as showing right-ventricle abnormalities 
characteristic of ARVD2, whilst two female members of the same family exhibited stress-
induced polymorphic VT in the absence of any structural alterations of the heart, a 
characteristic phenotype of CPVT (d’Amati et al., 2005, Thomas et al., 2007).  
 
The current preferred treatment of arrhythmia is administration of ß-adrenergic receptor 
antagonists (ß-blockers), which target the effects of adrenergic drive activated during 
stress or exercise. Although often effective in preventing the recurrence of arrhythmia, 
approximately 30% of patients still experience at least one episode of life-threatening 
adrenergically mediated arrhythmia, leading to syncope or cardiac arrest (Priori et al., 
2002, Liu et al., 2011). In patients who display persistent reoccurrence of tachyarrhythmia, 
implantation of an automated cardioverter-defibrillator (ICD) has proved successful. 
However, this treatment is not fully effective, since shocks can cause catecholamine 
release and subsequently generate further arrhythmia (Thomas and Williams, 2012). 
Identifying new therapeutic agents for the treatment of RyR2-linked diseases is therefore 
of primary importance. In patients with RyR2 mutation and using long-term ß-blocker 
therapy, intravenous administration of verapamil (an L-type Ca2+ channel blocker) reduced 
the frequency of isolated and successive premature ventricular complexes during exercise 
stress testing by 76% (Swan et al., 2005). However, the drug has limited success since 
although attenuating VT, its use does not appear to prevent the occurrence of arrhythmias 
(Sumitomo et al., 2003). Although additional studies into the use of Ca2+ channel 
antagonists combined with other therapeutic agents may prove useful in the treatment of 
CPVT.  
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1.7.1. Genetic Basis of CPVT: 
 
There are >150 CPVT-linked RyR2 mutations discovered to date which localise in several 
discrete regions of the polypeptide (Figure 1.5), within which three clusters of mutational 
frequency are evident at the N-terminus, central domain and C-terminus of the Ca2+ 
release channel (Postma et al., 2005, Capes et al., 2011). Highlighting the importance of 
these regions, which appear highly conserved between species and isoform, similar 
clustering patterns of mutation are seen in human RyR1 channels and are implicated in 
the pathogenesis of two neuromuscular disorders, malignant hyperthermia (MH) and 
central core disease (CCD).  
 
 
 
 
 
 
 
Although the molecular mechanisms underlying the pathogenesis of CPVT remain 
unresolved, it is accepted that most mutant RyR2 channels typically display gain-of-
function defects, following ß-adrenergic stimulation (Wehrens et al., 2003, Leenhardt et 
al., 1995). Specifically, it is thought that enhanced SR Ca2+ “leak” through RyR2 channels 
during diastole increases the propensity for triggered arrhythmias (Wehrens et al., 2007, 
Novák and Soukup 2011). Triggered activity is thought be initiated by sub-threshold 
membrane depolarisations, termed afterdepolarisations, which proceed from the previous 
AP. If such membrane depolarisations occur during the repolarisation phase of the 
previous AP, they are known as early afterdepolarisations (EADs), whereas delayed 
afterdepolarisations (DADs) occur after repolarisation and are believed to be the major 
underlying cause of cardiac VT seen in CPVT (Scoote and Williams, 2002). However, 
using induced pluripotent stem cells (iPSCs) derived from a patient carrying a P2328S 
T e p ptide sequences involved in the transmem-
brane domains are known to some extent, although the
exact number of transmembrane sequences (!6) is still
under study. Similarly, the location of the peptide se-
quences in the cytoplasmic domains is only partially
known. The location of the peptide chains in the structure
of the Ca2! channel is still far from complete and even
farther from conclusions regarding control mechanisms
of the Po of the channel, and therefore, a detailed review
of their location (cf. Refs. 332, 334, 350, 466; see also Refs.
35, 191, 333, 334, 465, 467, 629) is beyond the scope of this
iew. Howev r, th proximity of mutations that affect
the channel in skeletal muscle in malignant hyperthermia
and central core disease and arrhythmogenic mutations in
cardiac muscle suggests that the bridge in the rhomboid
structure in the clamp is important to regulation of open-
ing of the channel. The central domain of mutations that
is involved in arrhythmias is again found in the bridge
within the rhomboid structure of the clamp, suggesting
that this structure in the clamp is important in the regu-
lation of the opening probability of the channel.
Similar to what has been hypothesized for RyR1
channel proteins (609), it appears that RyR2 structure
involves a critical interdomain interaction that plays a
role n modulation of the channel’s ability to release Ca2!.
In this hypothesis, specific domains of the NH2 terminus
interact to “zip” shut regions of the central core region.
This zipped conformation has been linked to RyR2 chan-
nels with no Ca2! “leak” (235). In disease and with RyR2
mutations, these regions can become unzipped to “leak”
Ca2! (see sect. IVA1). However, recent data also suggest
that highly reactive free radicals destabilize these inter-
domain interactions and by themselves can cause partial
dissociation of the FKBP12.6 binding protein (616).
FIG. 5. A: ultrastructure of RyR1 at
9.5 A˚ resolution. The receptor is com-
posed of a cytosolic assembly linked to a
transmembrane assembly (TMA) through
a neck region which conveys columns
that form the vestibule of the TMA and
the Ca2! channel in the center of the
TMA to the regulatory elements in the
clamps and handle domain of the cytoso-
lic assembly (see text for further details).
[From Samso et al. (468).] B: schematic
diagram of the reported mutation sites of
RyR1 and RyR2. NH2 terminus, central
domain, and transmembrane (channel)
regions are denoted. For more informa-
tion, see text and http://pc4.fsm.it:81/
cardmoc/. [From Yano et al. (617).]
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Figure 1.5: Schematic demonstrating RyR2 mutation “hot-spots”: RyR2 
mutations tend to cluster within three distinct regions of the protein, the N-terminal 
domain, central domain and C-terminal region (referred to as the channel region 
here). The amino acid residues comprising these regions are indicated. The figure 
highlights only a few of the >150 RyR2 mutations discovered to date. Image modified 
from Yano et al., 2006.  
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mutation in RyR2, Kujala et al (2012) recently implicated the contribution of both EADs 
and DADs in disease pathogenesis. In support of the proposal that DADs occur as a 
consequence of intracellular Ca2+ leak, cell-based assays have demonstrated that 
overexpression of mutant RyR2 channels generate a diastolic Ca2+ leak and spontaneous 
Ca2+ oscillations following catecholamine infusion or caffeine stimulation (which sensitises 
RyR2 to Ca2+), (George et al., 2003a, Jiang et al., 2004). 
 
 
1.8. Mechanisms of mutant RyR2 dysfunction: 
!
Given the dispersion of mutations across the RyR2 sequence and their phenotypic 
variability, it is unlikely that a single universal mechanism is responsible for channel 
dysfunction. Candidate mechanisms hypothesised to underlie CPVT that dominate in the 
field are discussed in sections 1.8.1-1.8.3.  
 
1.8.1 Disruption of the RyR2-FKBP12.6 interaction may be involved in the 
pathogenesis of CPVT: 
 
As aforementioned in section 1.5.1, under normal conditions, ß-adrenergic stimulation and 
subsequent phosphorylation of RyR2 channels by PKA, has been suggested to partially 
dissociate FKBP12.6 from the Ca2+ release channel (Wehrens et al., 2003).  
 
However in failing hearts, Marx et al demonstrated that the stoichiometry of FKBP12.6 to 
RyR2 was reduced significantly and implicated a mechanism of PKA 
“hyperphosphorylation” (enhanced PKA phosphorylation) as a contributing factor of 
triggered arrhythmias in HF (Marx et al., 2000). In recent years, this proposal has also 
emerged as a candidate mechanism of CPVT pathogenesis, where mutant RyR2 
channels are thought to display a reduced binding affinity for FKBP12.6 under basal 
conditions, which is further diminished by PKA phosphorylation of RyR2 (Yano et al., 
2006, Wehrens et al., 2003, 2007). Since this protein is thought to stabilise the closed 
conformational state of RyR2, it has been proposed that “hyperphosphorylation” by PKA 
and subsequent dissociation of FKBP12.6 from the channel complex, contributes to the 
diastolic SR Ca2+ release evident in RyR2 mutants (Wehrens et al., 2007).  
 
The proposed model of FKBP12.6 dissociation outlined by Marx however is not universally 
accepted. The hypothesis has been challenged by other research groups such as George 
et al, who found comparable FKBP12.6 association in WT and mutant RyR2 expressed in 
a murine cardiac cell line (HL-1) both under resting conditions and upon catecholamine 
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stimulation (George et al., 2003a). Furthermore, FKBP12.6 null-mice were not found to 
exhibit enhanced susceptibility to triggered arrhythmias in a study by Xiao et al., 2007. 
Recently, CaMKII-mediated phosphorylation has been implicated in the pathogenesis of 
CPVT whereby Liu et al demonstrated that CaMKII inhibition attenuated the enhancement 
Ca2+ sparks and diastolic Ca2+ leak induced by ß-adrenergic stimulation in the R4496C+/- 
mouse model of CPVT (Liu et al., 2011). In addition, CaMKII inhibition appears to exert its 
antiarrhythmic effect by targeting other regulatory proteins of Ca2+ homeostasis, since a 
reduction in SERCA2a function (lowered Ca2+ re-uptake into the SR) was also reported 
(Liu et al., 2011). Finally, CaMKII inhibition reduced the frequency of DADs in an induced 
pluripotent stem cell (iPSC) derived cardiomyocyte model of CPVT (Di Pasquale et al., 
2013) further suggesting the involvement of CaMKII phosphorylation in regulating mutant 
RyR2 Ca2+ leak.  
 
1.8.2. Defective RyR2 intermolecular domain interactions in CPVT: 
 
Inter-domain interactions between discrete regions of the RyR2 cytoplasmic assembly 
(and notably in mutation “hot-spots”) are thought to participate in the proper folding of the 
protein complex, acting to stabilise the closed state of RyR2 channels (Liu et al., 2010). 
Disruption of such interactions is implicated as a potential mechanism of RyR2 dysfunction 
(Yamamoto & Ikemoto, 2002, George et al, 2004). Ikemoto et al termed this disruption of 
interactions as “domain unzipping” and it is thought to be caused by RyR2 mutation, 
thereby weakening the tight ‘zipping’ of the domains that serve to stabilise the channel 
closed state, enabling the channel to remain open under resting conditions (Yamamoto 
and Ikemoto, 2002). Using a FRET-based approach to assess the distance between the 
domains, Liu et al demonstrated that the N-terminal and central domains are involved in 
inter-subunit interactions (on separate RyR2 subunits) rather than intra-subunit interaction 
(Liu et al., 2010).  
 
In support of Ikemotos’ model, peptide studies have revealed that interacting regions of 
RyR2 can be disrupted by mutation to promote channel instability and SR Ca2+ leak 
(Yamamoto and Ikemoto, 2002, Oda et al., 2005, Yang et al., 2006). In two separate 
studies, a short synthetic peptide homologous to the central domain of RyR2 (DPc10, 
Gly2460-Pro2495) was used to mimic the effect of a cardiac disease mutation found in 
CPVT patients (Yang et al., 2006, Oda et al., 2005, Liu et al., 2010). Oda et al reported 
that the peptide destabilised the interaction between the central and N-terminal domains 
and acted competitively to reversibly enhance channel activity and Ca2+ leak (Oda et al., 
2005). Furthermore, rat cardiomyocytes perfused with the DPc10 peptide displayed an 
enhanced sensitivity to activating Ca2+, increased Ca2+ spark frequency and a sustained 
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increase in resting Ca2+ levels, all indicative of an increased propensity towards diastolic 
Ca2+ leak (Yang et al., 2006). The effects of the peptide were found to be abolished 
following insertion of the CPVT-linked mutation R2474S into the central domain peptide, 
suggesting that the residue mutated is important for maintaining the interaction between 
the two domains (Yamamoto & Ikemoto, 2002, Yang et al., 2006). Other peptides located 
in the N-terminal (DP163-195) and C-terminal (DP4090-4123) regions of RyR2 that mimic 
CPVT mutations R176Q and N4104K, respectively, have also been found to alter inter-
domain interactions and enhance spontaneous Ca2+ release from the SR (Tateishi et al., 
2008, Liu et al., 2010). George et al reported that this C-terminal region, known as the I-
domain, plays an important role in RyR2 autoregulation (George et al., 2006). Mutations in 
the I-domain (including N4104K) of RyR2 were reported to enhance spontaneous Ca2+ 
release following channel activation, which is likely a consequence of channel 
destabilisation between the central domain and C-terminus of the protein (George et al., 
2006).   
 
1.8.3. CPVT mutations alter the cytoplasmic and/or luminal Ca2+ sensitivity of RyR2:  
 
Discussed in greater detail in Chapter 4, section 4.1.3, it has been demonstrated that 
several CPVT-linked RyR2 mutations alter the channels sensitivity to cytoplasmic and/or 
luminal Ca2+ activation, generating aberrant SR Ca2+ release (Jiang et al., 2002, 2004). 
Since almost all CPVT mutations occur in the cytoplasmic domain of the channel, 
however, it still remains to be established precisely how these mutations confer 
hypersensitivity to Ca2+ within the SR lumen.  
 
Yang et al demonstrated that mimicking the effects of a central domain mutation by 
peptide-induced disruption of RyR2, specifically lowered the threshold for cytoplasmic 
Ca2+ activation and generated sustained SR Ca2+ leak (Yang et al., 2006). Furthermore, a 
recent investigation reported that the RyR2 mutation G230C increases sensitivity to both 
luminal and cytosolic Ca2+ activation, as demonstrated at the single channel level (Liu et 
al., 2013). An alternative hypothesis is that RyR2 mutations principally enhance the 
channels sensitivity to luminal Ca2+  (Jiang et al., 2004). Following observations that many 
CPVT-linked mutations exhibit a similar cytoplasmic Ca2+ dependency to WT RyR2 
channels, Chen and colleagues proposed that the major functional consequence of RyR2 
mutation is an enhanced sensitivity to luminal Ca2+ and subsequently, a lowered threshold 
for Ca2+ release from the SR (Jiang et al., 2004, 2005).  This mechanism is termed “Store 
Overload-Induced Ca2+ Release” (SOICR) (Jiang et al., 2004, 2005). Examined in 
heterologous systems, the functional consequences of a number of RyR2-linked mutations 
were investigated and found to display increased spontaneous Ca2+ release, coupled with 
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a decrease in the levels of the ER Ca2+ load (Jiang et al., 2005, Jones et al., 2008). 
Highlighting the functional heterogeneity of RyR2 mutations, a decrease or complete 
ablation of luminal Ca2+ sensitivity has also been observed with some channel mutants 
(Jiang et al., 2007). This model of RyR2 dysfunction is generally favoured since is shows 
some parallels with the mechanism of aberrant Ca2+ release thought to occur in the 
autosomal recessive form of the disease (section 1.8.4). 
 
1.8.4. Autosomal recessive form of CPVT (CPVT2) evoked by mutations in CSQ2: 
 
Among suspected CPVT2 patients, alterations in CSQ2 generally arise from either 
missense mutations, that alter the functional properties of the protein, or nonsense 
mutations that completely abolish protein expression (Lahat et al., 2001, Eldar et al., 2003, 
Postma et al., 2005, Viatchenko-Karpinski et al., 2004). It is reported that CSQ2 mutations 
account for approximately 3% of CPVT patients (Katz et al., 2009).  Different animal and 
cell models of CSQ2-linked CPVT have demonstrated alterations in SR Ca2+ handling via 
different mechanisms, yet all culminate in ventricular arrhythmia and DADs following 
sympathetic stimulation (Györke et al., 2009). 
 
First identified in 7 consanguineous Bedouin families in northern Israel, the CSQ2 
missense mutation D307H converts a negatively charged aspartic acid residue into a 
histidine, in a highly conserved region of the protein identified as a putative Ca2+ binding 
site (Lahat et al., 2001, Elder et al., 2003, Houle et al., 2004). Houle et al reported that the 
D307H mutation blunts the proteins ability to interact with Ca2+, TRD1 and JUN, and thus 
its associations with RyR2 (Houle et al., 2004). Complementing this study, it was later 
proposed that this mutation caused a conformational change in the protein that prevents 
polymerisation and consequently alters the Ca2+ binding capacity of CSQ2 (Kim et al., 
2007). Overexpression studies revealed that this mutation suppressed EC coupling and 
Ca2+ spark frequency, which was consistent with an apparent reduction in Ca2+ storage 
capacity of the SR despite the presence of endogenous WT CSQ2 (Viatchenko-Karpinski 
et al., 2004, Dirksen et al., 2007). Interestingly, a reduction in the expression level of 
CSQ2 was also reported in a D307H knock-in mouse model (Song et al., 2007).  
 
Another CSQ2-linked mutant (R33Q) completely abolishes the ability of CSQ2 to inhibit 
RyR2 channels at low luminal Ca2+ (Terentyev et al., 2006, Qin et al., 2008). Terentyev et 
al also demonstrated that in rat cardiac myocytes overexpressing R33Q, EC coupling and 
Ca2+ spark frequency were enhanced and consequently promoted spontaneous diastolic 
Ca2+ release. Unlike the D307H mutation, Terentyev et al found no alteration in the Ca2+ 
storage capacity with CSQ2-R33Q overexpression (Terentyev et al., 2006). In contrast, 
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Rizzi et al reported that in CSQ2-R33Q knock-in mice, the SR Ca2+ content was 
significantly reduced (Rizzi et al., 2008). In addition, the group reported that the mutant 
caused a 50% reduction in the expression level of CSQ2, TRD1 and JUN, despite the 
presence of normal levels of mRNA (Rizzi et al., 2008). A functional knock-out phenotype 
is generated by the CSQ2 mutation L167H, identified in the first patient known to carry 
heterozygous CSQ2 mutations (di Barletta et al., 2006). Characterisation of the CSQ2-
L167H mutant in vitro has revealed that the mutant does not respond to Ca2+ and prevents 
CSQ2 polymerisation that may be required for Ca2+ binding (Kim et al., 2007, Valle et al., 
2014).  Consistent with these findings, Qin et al demonstrated that at the single channel 
level, the L167H mutant was unable to reduce RyR2 channel openings at low luminal Ca2+ 
concentrations (Qin et al., 2008). 
 
In summary, CPVT-linked mutations in CSQ2 can exert their deleterious effects by at least 
two mechanisms: (1) affecting the protein’s conformation and ability store Ca2+, and (2) 
affecting the ability of CSQ2 to regulate RyR2 function (Györke, 2009). CSQ2 mutations 
that impair the Ca2+ storage capacity of the protein or reduce its expression are suggested 
to accelerate the restitution of Ca2+ release from the RyR2 (Terentyev et al., 2006). 
Following SERCA2a-mediated Ca2+ re-uptake, a lower number of Ca2+ storage sites within 
the SR may result in an overload of free releasable Ca2+ that can no longer be buffered, 
and thus may generate spontaneous Ca2+ release and DADs (Györke et al., 2009, 
Knollmann, 2009). The CSQ2 mutant variants that abolish protein associations between 
CSQ2, other luminal proteins and RyR2, compromise Ca2+ signalling refractoriness 
following systole, by preventing the ability of CSQ2 to inhibit RyR2 activity when the SR 
Ca2+ content is low (Terentyev et al., 2006). 
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1.8.5. Newly identified CPVT-linked mutations in other EC coupling components: 
 
It has been proposed that approximately one-third of symptomatic patients referred for 
genetic screening of CPVT-linked RyR2 and CSQ2 gene mutations remain without an 
identified molecular defect and thus suggests the existence of mutations in other key EC 
coupling proteins (Roux-Buisson et al., 2012). This hypothesis has recently been 
emphasised by Roux-Buisson et al (2012) who screened 97 CPVT-patients without RyR2 
and CSQ2 mutations, and identified three patients with mutations in cardiac triadin TRD1. 
Two of the mutants were found to introduce a premature stop codon, suggesting that TRD 
is degraded in these patients. Interestingly, the identified mutations were mapped to a 
region of the TRD gene common to all isoforms, suggesting that these mutants could also 
lead to an absence of TRD in skeletal muscle (Roux-Buisson et al., 2012). Although this 
discovery of a new gene implicated in CPVT is significant, it is important to note that no 
gene mutations were identifiable in 94 patients, despite being screened for RyR2, CSQ, 
ASPH (within which JUN is a splice variant) and TRD mutants (Roux-Buisson et al., 2012). 
A later investigation by a different research group (Nyegaard et al., 2012) described the 
identification of two CaM mutations detected in screened clinical samples of 64 individuals 
with unspecified arrhythmia, a gene which was not screened by Roux-Buisson (2012) and 
co-workers. A recent investigation published this year by Hwang et al (2014) described the 
functional investigation of two CaM mutants (N54I and N98S), which were found to 
activate RyR2 activity and enhanced the frequencies if spontaneous Ca2+ waves in 
isolated mouse ventricular myocytes. Taken together, these studies not only highlight the 
limitations to a gene candidate approach, but also strongly suggest that other mutations in 
relation to CPVT have yet to be discovered. In a clinical setting these findings highlight the 
importance of assessing mutations in other EC coupling protein genes, the discovery of 
which may lead to advances in the development of patient-specific CPVT therapies.  
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1.9. Research Project Aims: 
 
Taking into consideration the proposed role of the luminal proteins CSQ2, JUN and TRD1 
in regulating the hRyR2 channels response to luminal Ca2+, altered regulation or protein-
protein association of mutant RyR2 with the accessory proteins could be a contributing 
factor in the aberrant Ca2+ release seen in CPVT patients. To investigate this hypothesis, 
this project aims to: 
 
• Co-express recombinant human RyR2 (WT or mutant) with the luminal accessory proteins 
in a heterologous cell system. Evaluate if the protein-protein interactions between the 
luminal proteins and hRyR2 can be re-created in our chosen experimental system.  
 
• Assess if CPVT-linked RyR2 mutation can disrupt protein-protein associations between the 
Ca2+ release channels and the luminal accessory proteins.  
 
• Assess the effects of luminal accessory proteins on WT hRyR2 Ca2+ release. 
 
• Assess the functional consequences of mutant hRyR2 expression on luminal accessory 
protein regulation. Two CPVT-linked mutants will be investigated in this work: N4104K and 
A4556T (Figure 1.6). These two mutants in particular were chosen firstly due to their 
location, since N4104K hRyR2 resides on the cytosolic side of the channel, whilst A4556T 
is located within the luminal region. It will be of interest to establish if an altered response 
to luminal protein regulation or interaction is specific to the location of mutation. 
Furthermore, the consequences of the A4556T hRyR2 mutation are previously 
uncharacterised; whilst N4104K hRyR2 has been studied previously by numerous research 
groups (Jiang et al., 2004, George et al., 2006), allowing the data collected in this work to 
be compared. 
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Figure 1.6: Schematic illustrating the hRyR2 mutations investigated in this 
project: As circled, the N4104K hRyR2 mutation resides on the cytosolic side of the 
channel, whilst a previously uncharacterised mutation A4556T is located on the 
luminal region of hRyR2. Image modified from Thomas et al., 2006. 
Biochemical Society Transactions (2006) 34, 913-918 -  
www.biochemsoctr ns.org 
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Chapter 2 
 
Materials and Methods 
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2.1 Materials: 
 
2.1.1. General laboratory reagents and chemicals:  
 
All chemicals and reagents were of analytical grade and obtained from Sigma-Aldrich or 
Fisher Scientific and all cell culture reagents were from Life Technologies, unless 
otherwise stated. All reagents were dissolved in deionised water (dH2O) and stored at 
room temperature unless an alternative is noted. All reagents and equipment used for 
agarose and polyacrylamide gel electrophoresis were purchased from Bio-Rad, with the 
exception of the iBlot" Gel transfer system, purchased from Life Technologies. 
Centrifugation steps were undertaken using a range of Beckman Coulter centrifuges, 
solution pH was measured using a Mettler Toledo FE20 pH meter (Camlab) and adjusted 
using either 1M HCl or 1M KOH, unless otherwise stated. Solutions were filter sterilised 
where required using a 0.22!M Millex® syringe filter (Millipore). 
 
2.1.2. Molecular Biology Kits and Reagents:  
 
(A) Zero Blunt® PCR Cloning kit (Life Technologies) – stored at -20ºC 
i. pCR!-Blunt II-TOPO® vector: 10ng/!l plasmid DNA in: 50% glycerol, 50mM Tris-HCl 
(pH 7.4), 1M EDTA, 2mM DTT, 0.1% Triton X-100, 100!g/ml BSA and 30!M 
bromophenol blue 
ii. 10x Ligation Buffer: 60mM Tris-HCl (pH 7.5), 60mM MgCl2, 50mM NaCl, 1mg/ml BSA, 
70mM !-mercaptoethanol, 1mM ATP, 20mM dithiothreitol and 10mM spermidine 
iii. T4 DNA ligase: (4U/!l) 
iv. Sterile water: deionised and autoclaved 
v. M13 reverse primer: 0.1 !g/!l in Tris-EDTA buffer. Used in DNA sequencing reactions. 
 
 
(B)  Polymerase chain reaction reagents 
i. Phusion! DNA Polymerase (Finnzymes): (2 U/!l). Also provided with the enzyme: 
DMSO (100%) and 5x Phusion" reaction buffer containing 7.5mM MgCl2. 
ii. dNTP mix, 20mM (Thermo Scientific): dATP, dCTP, dGTP and dTTP neutralised in 
water (pH 7.5). 
iii. Human cardiac muscle cDNA library (BD Biosciences). 
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(C) ABI Prism® BigDye® terminator v3.1 cycle sequencing kit (Applied Biosystems) 
and sequencing reagents 
i. BigDye® Terminator Premix: containing fluorescent BigDye® terminators (ddNTPs: 
ddATP, ddTTP, ddGTP and ddCTP).  
ii. BigDye® Terminator 5x sequencing buffer: 400mM Tris, 10mM MgCl2 optimised for use 
with the BigDye® Terminator premix.  
iii. DyeEx! kit (Qiagen): Used to remove unincorporated dye terminators from sequencing 
reactions. 
 
(D) Agarose gel electrophoresis reagents 
i. TAE, 50x stock (1x diluted stock dissolved with agarose): 2M Tris, 2M glacial acetic 
acid, 50mM EDTA. 
ii. UltraPure! Ethidium Bromide (10 mg/ml stock): Used at 0.1!g/ml. 
iii. DNA loading buffer, 1x stock: 50% 1x TAE buffer, 50% (v/v) glycerol and added orange 
G to achieve the desired detection colour.  
iv. Molecular weight DNA markers: 1 kb plus DNA ladder (Life Technologies). 
 
(E) QIAquick Gel Extraction Kit (Qiagen)                                  
i.  Buffer QG: agarose gel solubilisation and binding buffer containing sodium perchlorate 
and a pH indicator. 
ii. Buffer PE: An ethanol-containing wash buffer. 
 
(F) Rapid DNA ligation kit (Roche)                                  
i. DNA dilution buffer (5x), T4 DNA ligation buffer (2x) and T4 DNA ligase (5U/!l). 
Antarctic phosphatase was used in conjunction with the kit.  
 
(G) Plasmid purification: QIAprep® miniprep spin kit and HiSpeed® maxiprep kit 
(Qiagen)                               
i. Resuspension solution (P1): 50mM Tris-HCl (pH 8), 10mM EDTA, 100 !g/ml RNase A, 
pH adjusted to 7.5 with HCl and filter sterilised. 
ii. Lysis solution (P2): 200mM NaOH, 1% (w/v) sodium dodecyl sulphate (SDS), filter 
sterilised. 
iii. Maxi-prep neutralisation solution (P3): 4.09M Guanidine-HCl, 0.759M potassium 
acetate, pH adjusted to 5.5 with glacial CH3COOH and filter sterilised.  
iv. Mini-prep neutralisation solution (N3): 4.2M Guanidine-HCl, 0.9M potassium acetate, 
and pH 4.8.  
v. Maxi-prep column equilibration buffer (QBT): 750mM NaCl, 50mM MOPS, pH 7.0, 15% 
(v/v) isopropanol, 0.15% Triton® X-100. 
vi. Maxi-prep column wash solution, medium salt (QC): 1M NaCl, 50mM MOPS, 15% (v/v) 
isopropanol, pH 7. 
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vii. Maxi-prep column elution buffer (QF): 1.25M NaCl, 50mM Tris-HCl, 15% (v/v) 
isopropanol, pH 8.5. 
viii. Mini-prep spin column wash buffer (PB): 5 M Guanidine-HCl, 30% isopropanol. 
 
(H) Restriction digest                                  
i. All restriction enzymes and optimised reaction buffers (10x) were purchased from New 
England Biolabs and stored at -20°C.  
 
 
2.1.3. Bacterial Cell Culture: 
 
All glassware and sterile plastics were purchased from Fisher Scientific or Greiner. All 
glassware was washed with dH2O and autoclaved before use. Bacterial growth media was 
also autoclaved in the same manner, before cooling to approximately 50°C prior to the 
addition of antibiotics. 
 
(A) Luria-Bertani (LB) media: 10g/L tryptone, 5g/L yeast extract, 5g/L sodium chloride, 
prepared to 1L with dH2O.  
(B) LB agar plates: Prepared with LB media components and 15g/L agar. Autoclaved 
and antibiotics added before setting within 10cm2 sterile petri dishes. 
(C) Ampicillin 100 mg/ml stock: used at a working concentration of 100!g/ml.  
Stored at -20°C. 
(D) Kanamycin 30 mg/ml stock: used at a working concentration of 30!g/ml.  
Stored at -20°C. 
 
(E) DNA Transformation – chemically competent bacterial cells and reagents    
 
i. One Shot® TOP10 chemically competent cells (Life Technologies). 
ii. XL10-Gold Ultracompetent cells with provided !-mercaptoethanol (Agilent 
Technologies). 
iii. SOC medium: 2% Tryptone, 0.5% Yeast extract, 10mM NaCl, 2.5mM KCl, 10mM 
MgCl2, 10mM MgSO4 and 20mM glucose. 
 
2.1.4. Oligonucleotides: 
 
Oligonucleotide primers (shown in Chapter 3, Figure 3.1) were designed and ordered from 
Sigma Genosys or MWG-Biotech AG and were obtained lyophilised. Following the 
manufacturers guidelines, 100!M and 20!M working stocks were prepared and stored at -
20°C. 
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2.1.5. Plasmid Vectors: 
 
• pCR!-Blunt II TOPO® vector (Life Technologies) 
 
To sequence and confirm that luminal accessory protein constructs were successfully 
amplified, PCR products were inserted into a pCR"-Blunt II TOPO® vector (Figure 2.1, 
(A)) using the Topoisomerase I system. The vector was supplied linearised with Vaccinia 
virus, DNA topoisomerase I, bound covalently to the 3’ end of each DNA strand. To enable 
accurate recombinant selection, the vector is designed to encode a lethal E.coli gene, 
ccdB fused to the C-terminus of the LacZ" fragment. Upon ligation of the blunt ended 
PCR product, LacZ"-ccdB gene fusion expression is disrupted, allowing growth of only 
positive recombinants. Since cleavage sites for restriction enzyme EcoRI are positioned 
either side of the multiple cloning site in the TOPO® vector, restriction digest with this 
enzyme was used to identify vector clones containing the desired insert. Positive clones 
were sequenced from the M13 reverse priming site. The DNA sequencing procedure is 
outlined in section 2.4.1.8.   
 
• Mammalian expression vectors – pcDNA!3 and pcDNA!3.1 Hygro (+) (Life 
Technologies) 
 
Full length WT and CPVT-linked mutant human eGFP-RyR2 constructs were obtained 
from Dr Christopher George (WT and N4104K; George et al., 2003b) and Dr Lowri 
Thomas (A4556T, unpublished), Cardiff University. The hRyR2 constructs were cloned 
into the mammalian expression vector pcDNA"3 (Figure 2.1, B) and tagged at the N-
terminus with an enhanced green fluorescent protein (eGFP), enabling identification of 
protein expression in a mammalian cell line. The coding sequence for human cardiac 
muscle CSQ2 was also obtained from Dr Lowri Thomas and isolated as described in 
Chapter 3, section 3.2.1. Luminal accessory protein constructs were cloned into 
pcDNA"3.1 Hygro(+) (Figure 2.1, C). The decision to use this vector is outlined in Chapter 
3, section 3.3.4. Both pcDNA3" and pcDNA3.1" Hygro(+) vectors contain multiple cloning 
sites in the forward (+) and reverse (-) orientations. To enable plasmid selection in 
bacteria, the vectors encode for !-lactamase allowing selection by ampicillin resistance. In 
mammalian cells, transcription is initiated in both expression vectors by the 
cytomegalovirus (CMV) promoter and terminated by a stop codon inherently encoded by 
the hRyR2 (TAA), CSQ2 (TAG) and JUN (TAA) sequences. Both vectors replicate 
autonomously in mammalian and E.coli cells from the SV40 and ColE1 origin, 
respectively. 
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Figure 2.1: Illustration of plasmid vectors used in this study: (A) pCR-Blunt II TOPO® 
vector: PCR amplified products were inserted into the vector for sequencing. As highlighted, 
EcoRI sites flanking the ligated PCR product enabled easy excision of the insert from the 
vector by restriction digest. To enhance positive selection of cloned DNA, the vector 
contains a ccdB gene, plus a kanamycin resistance gene for selection in E.Coli. Sequencing 
was carried out using the M13 reverse primer site. (B) Mammalian expression vector 
pcDNA3: full-length WT and mutant eGFP-hRyR2 were constructed in this vector (by Dr 
Christopher George), which contains an ampicillin resistance gene for positive selection in 
E.Coli and a gene encoding neomycin (a variant of geneticin/G418) resistance. Expression 
was driven at the CMV promoter. (C) Mammalian expression vector pcDNA3.1hygro(+): 
sequence verified luminal protein cDNA constructs were ligated into this vector. The vector 
enabled positive selection of transformants in mammalian cells via a hygromycin resistance 
gene. Like pcDNA3, the vector also has an ampicillin resistance gene for positive selection 
in E.Coli. All images shown were taken from the Life Technologies website 
(www.lifetechnologies.com) and modified.  
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Appendix 
Map of pcDNA™3.1/Hygro (+) and pcDNA™3.1/Hygro (–) 
Vectors 
 
Map of 
pcDNA™3.1/ 
Hygro (+/–) 
The figure below summarizes the features of the pcDNA™3.1/Hygro (+) and 
pcDNA™3.1/Hygro (–) vectors. The complete sequences for 
pcDNA™3.1/Hygro (+) and pcDNA™3.1/Hygro (–) are available for 
downloading from our web site at www.invitrogen.com or from Technical 
Support (see page 13).  
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Appendix 
Map of pcDNA™3.1/Hygro (+) and pcDNA™3.1/Hygro (–) 
Vectors 
 
Map of 
pcDNA™3.1/ 
Hygro (+/–) 
The figure below summarizes the features of the pcDNA™3.1/Hygro (+) and 
pcDNA™3.1/Hygro (–) vectors. The complete sequences for 
pcDNA™3.1/Hygro (+) and pcDNA™3.1/Hygro (–) are available for 
downloading from our web site at www.invitrogen.com or from Technical 
Support (see page 13).  
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CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTAT TTAGGTGACA CTATAGAATA
GTGTGTCCTT TGTCGATACT GGTACTAATG CGGTTCGATA AATCCACTGT GATATCTTAT
EcoR I
pCR®-Blunt II-
TOPO®
3519 bp
Plac
lacZ! ccdB
pUC
ori
Kanamycin
Z ocin
CTCAAGCTAT GCATCAAGCT TGGTACCGAG CTCGGATCCA CTAGTAACGG CCGCCAGTGT
GCTGGAATTC GCCCTT AAGGGCGAATTCT GCAGATA
TCCATCACAC TGGCGGCCGC TCGAGCATGC ATCTAGAGGG CCCAATTCGC CCTATAGTGA
GTCGTATTAC AATTCACTGG CCGTCGTTTT ACAACGTCGT GACTGGGAAA ACCCTGGCGT
GAGTTCGATA CGTAGTTCGA ACCATGGCTC GAGCCTAGGT GATCATTGCC GGCGGTCACA
CGACCTTAAG CGGGAA TTCCCGCTTAAGA CGTCTAT
AGGTAGTGTG ACCGCCGGCG AGCTCGTACG TAGATCTCCC GGGTTAAGCG GGATATCACT
CAGCATAATG TTAAGTGACC GGCAGCAAAA TGTTGCAGCA CTGACCCTTT TGGGACCGCA
Blunt PCR Product
M13 Reverse priming site
Nsi I Hind III Kpn I Sac I BamH I Spe I
EcoR I EcoR VPst I
Not I Xho I Nsi I Xba I Apa I T7 promoter/priming site
M13 Forward (-20) priming site
201
476
SP6 promoter/priming site
Asp718 I Ecl136 II
Dra II
Comments for pCR®-Blunt II-TOPO®
    3519 nucleotides
lac promoter/operator region: bases 95-2 6
M13 Reverse priming site: bases 205-221
LacZ-alpha ORF: bases 217-576
SP6 promoter priming site: bases 239-256
Multiple Cloning Site: bases 269-399
TOPO®-Cloning site: bases 336-337
T7 promoter priming site: bases 406-425
M13 (-20) Forward priming site: bases 433-448
Fusion joint: bases 577-585
ccdB lethal gene ORF: bases 586-888
kan gene: bases 1099-2031
  kan promoter: bases 1099-1236
  Kanamycin resistance gene ORF: bases 1237-2031
Zeocin resistance ORF: bases 2238-2612
pUC origin: bases 2724-3397
!&#$
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2.1.6. Antibodies: 
 
(A) ab-GFP (B-2): Mouse monoclonal IgG (provided at 200!g/ml). Raised against the 
entire green fluorescent protein of Aequoria Victoria, and cross-reacts with enhanced GFP 
(eGFP). Purchased from Santa Cruz Biotechnology, stored at 4°C. Used at a 1:10,000 
dilution for Western blot analysis. 
 
(B) Anti-Calsequestrin (ab3516, "-CSQ2): Rabbit polyclonal (provided at 0.2mg/ml, 
stored in PBS, preserved with 0.05% sodium azide). Purchased from Abcam®, stored 
at -20°C. Used at a dilution 1:5,000 dilution for Western blot analysis. Used at 1:100 
for immunofluorescence analysis. 
 
(C)  Anti-Aspartate beta hydroxylase (ab72846, "-ASPH): Used for junctin detection (a 
splice variant of ASPH). Mouse polyclonal (provided at 1 mg/ml, stored in 1x PBS, pH 
7.2). Purchased from Abcam®, stored at -20°C. Used at a 1:5,000 dilution for Western blot 
analysis. Used at 1:100 for immunofluorescence analysis. 
 
 
2.1.7. Mammalian Cell Culture Reagents: 
 
(A) Dulbecco’s Modified Eagle Medium (DMEM): containing D-glucose, L-glutamine and pyruvate, 
and supplemented with 10% (v/v) heat inactivated foetal calf serum, 2mM glutamine and 100!g/ml 
penicillin/streptomycin (referred to as complete, cDMEM), and stored at 4°C. 
(B) Trypsin-EDTA 0.05%: 1x, with phenol red. Stored at -20°C. 
(C) Sodium chloride solution (saline): 0.9% (w/v) supplied by Fresenius Kabi. 
(D) Sodium butyrate (NaB (1M stock prepared)): used at 2mM.  
(E) Calcium chloride (CaCl2), 1M stock: purchased from Sigma-Aldrich, stored at -20°C (50ml 
aliquots). 
(F) Hepes Buffered Saline (HBS): 280mM NaCl, 10mM KCl, 1.5mM Na2HPO4, 10mM glucose, 
50mM HEPES, pH 7.05, filter sterilised before storing at -20°C. 
(G) Effectene® Transfection reagent kit (Qiagen): 1mg/ml Effectene® transfection reagent, 1 mg/ml 
enhancer and DNA-condensation buffer (EC). All stored at 4°C. 
(H) Cell freezing medium: 10% (v/v) dimethyl sulphoxide (DMSO) in foetal calf serum, filter 
sterilised and stored at 4°C. 
(I) Hygromycin B antibiotic: 50mg/ml stock in PBS (Life Technologies). 
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2.1.8. Immunofluorescence and calcium imaging reagents: 
 
(A) Alexa Fluor® conjugated secondary antibodies (Molecular Probes): Used at a 1/250 dilution. 
(B) Fluo-3 AM: purchased from Life Technologies, prepared in a solution of 20% Pluronic® acid in 
DMSO. Added to minimal (unsupplemented) DMEM (mDMEM) to generate a working concentration 
of 10!M. 
(C) Phosphate buffered saline (PBS): 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM KH2PO4, 
pH adjusted to 7.4 with HCl, filter sterilised. 
(D) Poly-L-lysine: 0.1% solution, stored at 4°C. Used to coat coverslips/culture dishes.  
(E) Fixing solution: 4% (w/v) paraformaldehyde in PBS. 
(F) Cell permeabilisation solution: 0.1% (v/v) Triton X-100 in PBS. 
(G) Krebs-Ringer-Hepes (KRH) buffer: 120mM NaCl, 5.5mM Glucose, 25mM Hepes, 4.8mM KCl, 
1.2mM KH2PO4, 1.2mM MgSO4, 1.3mM CaCl2, pH 7.4. Filter sterilised. 
(H) Caffeine: 100mM stock prepared in KRH buffer, diluted 1/10 to prepare a 10mM stock.  
 
2.1.9. Protein biochemistry reagents: 
 
(A)  Western blot analysis                                  
i. SDS-PAGE running buffer: 25mM Tris, 250mM Glycine, 0.1% SDS. 
ii. Acrylamide: 40% acrylamide/Bis mix solution, in 37:5:1 ratio (Bio-Rad).  
iii. Ammonium persulphate 10% (w/v): Prepared on the day of use. 
iv. SDS-PAGE loading buffer 2x: 4% (w/v) SDS, 100mM Tris buffer (pH 6.8), 20% (v/v) 
glycerol, 0.2% (w/v) bromophenol blue (with added !-mercaptoethanol 10% (v/v)). 
Stored at -20°C. 
v. Tris-buffered saline (TBS) 1x: 20mM Tris, 137mM NaCl, pH adjusted to 7.6 before 
adding 1 ml/L Tween-20 (v/v) (1x TBS-T). 
vi. Blocking solution: 5% (w/v) non-fat powdered milk in 1x TBS-T.  
vii. Wash buffer/1% blocking solution: 1% (w/v) non-fat powdered milk in 1x TBS-T. 
viii. Molecular weight markers: pre-stained Kaleidoscope marker purchased from Bio-Rad.  
ix. Tris 1.5M (separating buffer): prepared a 1.5M Tris stock, pH adjusted to 8.8.  
x. Tris 0.5M (stacking buffer): prepared a 0.5M Tris stock, pH adjusted to 6.8. 
xi. Transfer buffer (semi-dry): 48mM Tris, 39mM Glycine, 0.01% (w/v) SDS, 20% (v/v) 
methanol.  
xii. Amersham! ECL! Western blotting analysis system: membrane detection reagents 
used with ECL hyperfilm" (GE Healthcare). 
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(B) Mixed membrane preparation                                   
i. Hypo-osmotic HEK cell lysis buffer: 20mM Tris, 5mM EDTA, pH adjusted to 7.4 with 
HCl. 1 protease inhibitor cocktail tablet (Roche), dissolved per 50 ml of buffer. 
ii. Cryopreservant solution (‘Solution C’): 0.4M sucrose, 20mM Hepes and 1x protease 
inhibitor tablet dissolved per 25ml. Used to re-suspend and freeze membrane 
preparations at -80°C. 
 
(C) Protein Assay 
i. Micro BCA" protein assay kit (Pierce). Bovine Serum Albumin (BSA) ampules 
(2mg/ml) were also provided in the kit. 
 
(D) [3H] Ryanodine binding                                  
i. Ryanodine binding buffer: 1M KCl, 25mM PIPES, 100!M CaCl2, pH adjusted to 7.4 
using KOH.  
ii. ‘Cold’ Ryanodine stock (1mg): Stored at -20°C under desiccating conditions, 
purchased from Abcam®, 1 mM working stock prepared in dH2O. 
iii. ‘Hot’ [3H]-Ryanodine stock (9.25 MBq, 250 !Ci): purchased from Perkin Elmer. Stored 
at -20°C in secure conditions. 
iv. Ultima"Gold Scintillation Fluid: purchased from Perkin Elmer. 
 
(E) Immunoprecipitation studies   
i. Solubilisation buffer: 20mM Tris, 150mM NaCl, 0.4% CHAPS (w/v), pH 7.4, 25x 
protease inhibitor solution added (Roche), used at 1x. 
ii. 20mM Tris: solution prepared and used as a final stage wash buffer, pH 7.5. 
 
(F) µ-MACS! GFP Tagged Protein Isolation Kit (Miltenyi Biotec)                                
i. Anti-GFP tagged microbeads: supplied as a solution containing 0.05% sodium azide. 
Stored at 4°C. 
ii. SDS-PAGE elution buffer: 50mM Tris HCl (pH 6.8), 50mM DTT, 1% SDS, 1mM EDTA, 
0.005% bromophenol blue and 10% glycerol. 
iii. Protein A microbeads: solution supplied in 0.05% sodium azide. 
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2.2. Health and Safety: 
 
All experiments were carried out in accordance with COSHH regulations and full general 
health and safety training was received from the WHRI safety manager prior to 
commencing any laboratory work. Use of genetically manipulated organisms was 
registered and all procedures were carried out in accordance with GMAG guidelines. 
Microbiology and cell culture safety training was undertaken with the Wales Heart 
Research Institute (WHRI) biological safety officer. Radioisotope procedures were 
registered and local rules were followed for use and disposal using the IsoStock® 
radioisotope accounting software.  
 
2.3. Computer analysis and software: 
 
Microsoft Excel was used to store and plot most numerical data (expressed as mean ± 
standard error), unless otherwise stated. Statistical analyses and fitting of sigmoidal 
curves were carried out using GraphPad Prism® (GraphPad Software Inc). Co-incident 
pixels were counted using Adobe Photoshop and imaging investigations carried out using 
Leica Microsystems LAS-AF or Zeiss Axiovision software. Quantity-one (Bio-Rad) 
software was used for image processing and densitometric analysis of Western blots. 
DNA sequences were verified using the Basic Local Alignment Search Tool (BLAST, 
http://blast.ncbi.nlm.nih.gov/).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 53 
2.4. Methods: 
 
General molecular biology techniques were performed according to protocols outlined in 
the Molecular Cloning laboratory manual (Sambrook et al., 1989) and procedures 
optimised by the Williams laboratory or other staff members of the WHRI. When applicable 
the manufacturers guidelines were followed.   
 
 
2.4.1. Molecular Biology Methods: 
 
 
2.4.1.1. Polymerase Chain Reaction (PCR): 
 
A series of PCR reactions were carried out using a GeneAmp® PCR system 9700 thermal 
cycler (Applied Biosystems). To generate high-fidelity amplification products, Phusion™ 
DNA polymerase (a pyrococus furiosus (pfu) enzyme (Finnzymes)) was used, which 
possess 5’" 3’ DNA polymerase activity and 3’" 5’ exonuclease (proofreading) activity, 
allowing recognition and excision of any misincorporated bases during polymerisation. 
Furthermore, Phusion™ DNA polymerase generated blunt-ended PCR products, which 
could be ligated directly into a Zero Blunt® TOPO® vector for sequencing. 
 
The complete PCR reactions carried out and the thermal cycling conditions used are 
highlighted in Table 2.1 and 2.2, respectively. To enrich the PCR products generated from 
a first round of amplification (PCR reaction 1), a second round of reactions were 
undertaken using PCR1 products as a template (PCR reaction 2).   
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PCR Reaction 1 PCR Reaction 2 
5!l cDNA library template (20ng) 
1!l forward primer (20!M stock) 
1!l reverse primer (20!M stock) 
10!l reaction buffer (5x) 
0.5!l dNTPs (20mM stock) 
1!l DMSO 
0.5!l DNA polymerase 
(1 unit Phusion™) 
31!l dH2O 
 
TOTAL 50!l 
5!l PCR1 as template (20ng) 
1!l forward primer (20!M stock) 
1!l reverse primer (20!M stock) 
10!l reaction buffer (5x) 
0.5!l dNTPs (20mM stock) 
1!l DMSO 
0.5!l DNA polymerase 
(1 unit Phusion™) 
31!l dH2O 
 
TOTAL 50!l 
Step Temperature (ºC) Time  Number of cycles 
Initial Denaturation 98 30 seconds 1 
Denaturation 
Annealing 
Elongation 
98 
62 
72 
10 seconds 
20 seconds 
1 minute 30 sec 
 
30 
Final Elongation 72 10 minutes 1 
Incubation 4 Indefinite 1 
Table 2.1: PCR reaction components: PCR reaction 1 refers to the first series 
of PCR reactions undertaken, using a cardiac cDNA library as a template and 
primers outlined in Chapter 3, Figure 3.1. PCR reaction 2 refers to a second 
series of PCR reactions carried out to enrich the amplified products. Forward and 
reverse primers were used at a final concentration of 0.4 !M.   
 
Table 2.2: PCR amplification thermal cycling conditions: The annealing temperature 
was chosen according to the primer melting temperature (set 10ºC below this value). 
Elongation time was set according to the length of the expected product. 
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2.4.1.2. Agarose Gel Electrophoresis: 
 
 
Agarose gel electrophoresis was used to verify the size of DNA fragments (such as those 
generated by PCR amplification). A 1% w/v agarose gel was formed by dissolving the 
requisite amount of agarose in 1x TAE buffer before heating in a microwave oven, cooling 
to ~50°C and adding 0.1 !g/ml of ethidium bromide (EtBr). The mixture was set in a gel 
cast with a comb, forming wells for loading, and assembled according to the 
manufacturers guidelines (Bio-Rad). Each prepared gel was placed into a Bio-rad mini-
sub® gel tank and covered with 1x TAE buffer (section 2.1.2 (D) i) before the samples 
were loaded. Loading buffer (section 2.1.2 (D) iii) was added to each sample at 1x (from a 
3x buffer stock) before gel loading, and a 1 kb DNA molecular weight (MW) marker was 
run alongside the samples as a reference of fragment molecular mass. Electrophoresis 
was carried out under constant voltage (typically 90 V) until sufficient DNA fragment 
separation was evident. The Bio-Rad XRS Chemidoc Imaging System® was used to view 
the resolved EtBr stained DNA fragments by UV transillumination.   
 
2.4.1.3. Gel Extraction: 
 
The QIAquick Gel extraction kit (Qiagen), (section 2.1.2 (E)) was used to purify DNA 
fragments separated on agarose gels. The DNA fragments separated by electrophoresis 
were viewed using a U.V transilluminator light box (Syngene), using an appropriate UV 
protective face shield. Fragments were excised from the gel using a scalpel, and weighed 
such that an appropriate volume (3x mass) of a chaotropic salt buffer (QG) could be 
added, leading to solubilisation of agarose polymers and dissociation of proteins 
associated with the DNA complex. Incubating the mix at 50ºC in a water bath, for 10 
minutes, with vortexing every two minutes, encouraged this solubilisation. Once 
solubilised, 1x volume of isopropanol was added to the sample. The QG buffer contains a 
pH indicator, allowing monitoring of pH throughout the reaction, as a pH of <7.5 is 
essential for efficient DNA adsorption to the silica-gel particles lining a QIAquick 
membrane spin column. The sample was applied to a QIAquick spin column, placed into a 
2ml collection tube and centrifuged at >10,000xg for 1 minute. The flow-through was 
discarded, whilst the QIAquick membrane (with captured DNA) was washed with both 500 
!l QG buffer and 750 !l PE buffer to remove any remaining impurities such as agarose 
and salt. DNA was eluted into a 1.5 ml microcentrifuge tube in 50!l dH2O following further 
centrifugation for 1 minute.  The purified DNA was verified by agarose gel electrophoresis 
and stored at -20ºC until required.  
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2.4.1.4. TOPO® cloning of luminal accessory protein cDNA clones: 
 
Zero Blunt® TOPO® (Life Technologies) allowed fast and efficient cloning of PCR 
amplicons such that they could be propagated to sufficient quantities of cDNA for 
automatic sequencing. In contrast to traditional cloning, no restriction digest was 
necessary and only a minimal amount of insert was required for ligation (10:1 molar ratio 
of insert:vector recommended in the manufacturers guidelines for optimal efficiency). All 
reagents used in the ligation reaction were supplied in the Zero Blunt® PCR cloning kit 
(section 2.1.2, (A)). The reaction contained: 1!l pCR-Blunt TOPO® vector (25ng), 5!l blunt 
PCR product (250ng), 1!l 10x ligation reaction buffer ((A) ii), 1!l T4 DNA ligase (4U/!l) 
and 2!l dH2O (Total volume 10!l). The reaction was incubated for 1 hour at 16 ºC before 
transformation. 
 
2.4.1.5. Bacterial Cell Transformation: 
 
Transformation of smaller plasmids (i.e., luminal accessory protein constructs) was carried 
out using chemically competent OneShot®TOP10 E.coli cells. For transformation of 
TOPO® ligations (for example), 2!l (~1ng) of the mix was gently mixed into a chilled 50!l 
aliquot of TOP10® cells, incubated on ice for 30 minutes before a 30 second heat shock 
step at 42°C in a water bath. Following heat shock, vials were immediately transferred 
onto ice for a further 1 minute period, before aseptically adding 1ml SOC medium (section 
2.1.3, (E) iii) and placing the vials into a 37°C incubator with shaking at 225 rpm, for 1 
hour. Cultures were plated at two different densities onto pre-warmed LB agar containing 
100!g/ml of an appropriate antibiotic (kanamycin in the case of TOPO® selection). A cell 
spreader was used to ensure the cells were dispersed throughout the whole plate, 
encouraging growth of colonies in isolation and arising from a single transformed cell. The 
plates were incubated overnight at 37°C (Heraeus Incubator, Thermo Scientific) before 
colony selection. Individual colonies were selected and seeded under aseptic conditions 
into 6ml of pre-warmed LB growth medium (section 2.1.3 (A)) containing an appropriate 
selective antibiotic (100!g/ml), and incubated for 16-18 hours at 37°C with shaking at 225 
rpm.  
 
Due to the fragile nature of the eGFP-hRyR2 plasmid construct (primarily owed to its 
larger size), the amplification technique was executed differently, using a method 
optimised in close collaboration with my colleagues in Professor Williams’ group. 
Alteration of certain conditions aimed to avoid plasmid degradation and ensured sufficient 
quantities of purified hRyR2 DNA was generated. Using the transformation protocol 
aforementioned, the following differences were applied: full-length eGFP-hRyR2 was 
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transformed into 25!l XL-Gold Ultracompetent Epicurian coli cells (in the presence of 1!l 
ß-mercaptoethanol), which are suitable for propagation of larger plasmids. The cells were 
placed on ice for 10 minutes and subjected to gentle agitation every 2 minutes, before 
heat shock and further incubation at 37°C as described previously. After transformation, all 
culture steps were carried out at 30°C.   
 
2.4.1.6. Small-scale DNA propagation (mini-prep): 
 
To identify positive clones, overnight culture (3ml) inoculated with a single colony was 
centrifuged at 13,000xg for 2 minutes and the resultant pellet subjected to alkaline lysis 
using the QIAprep® mini-prep spin kit (section 2.1.2 (G) i-viii). Cells were resuspended in 
P1 buffer (250!l- containing RNAse A) and lysed in an equal volume of P2 containing 
sodium dodecyl sulphate (SDS) which solubilises the phospholipid components of the 
cells and sodium hydroxide which creates an alkaline environment that denatures 
chromosomal DNA and proteins. The lysate was neutralised in a high salt buffer, N3 
(350!l) containing potassium acetate, resulting in precipitation of most of the chromosomal 
DNA, bacterial cell debris and SDS which form insoluble potassium dodecyl sulphate 
complexes. The precipitated matter was removed by centrifugation at 13,000xg for 10 
minutes before adding the cleared lysate to a spin column containing a DNA binding silica 
membrane, which was subjected to further centrifugation at the same speed for 1 minute. 
The plasmid DNA bound to the membrane was washed with two ethanol-containing 
buffers (PB and PE) before elution by centrifugation (13,000xg, 1 minute) in 50!l dH2O. 
Constructs were verified by restriction digest and direct DNA sequencing. 
 
2.4.1.7. Verification of positive transformants by restriction digest:   
 
Restriction endonucleases are widely used in manipulating and analysing DNA, by 
recognising and cleaving specific short sequence elements. Appropriate enzymes were 
chosen after constructing a visual digest via http://tools.neb.com/NEBcutter2/. Restriction 
mapping (prediction of fragment MW) was used to verify all miniprep clones. Restriction 
digest was typically carried out using 1!g of DNA and 5-10 units of endonuclease 
(prepared to a total volume of 20!l with 2!l reaction buffer and dH2O). The plasmid DNA 
was digested for 2 hours in a 37°C water bath and the resultant products separated by 
agarose gel electrophoresis. The digest pattern was visualised using UV transillumination. 
Plasmid preparations that yielded restriction fragments of the expected MW were selected 
for further propagation (large-scale, maxi-prep culturing, section 2.4.1.10). For cloning, the 
desired DNA fragments were excised from the gel and purified using the QIAquick Gel 
Extraction Kit (Section 2.1.2, (E)).  
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2.4.1.8. DNA sequencing:   
 
Luminal accessory protein constructs were sequenced using a BigDye™ Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems), (section 2.1.2 (C)) following the 
manufacturers guidelines. The sequencing PCR reaction was prepared to a total volume 
of 10!l and typically consisted of ~250ng of plasmid DNA, BigDye™di-deoxyterminators, 
BigDye™ reaction buffer (x1) and a suitable sequencing primer (such as the M13 reverse 
primer provided in the TOPO® PCR cloning kit (3.5 pmol used)). The thermal cycling 
conditions are outlined in Table 2.3. Reaction products were purified using a DyeEx™ kit 
(Qiagen), where unincorporated dye terminators were removed by centrifugation of the 
samples in spin columns containing a prehydrated gel-filtration resin. Once collected from 
the columns, the samples were sent for analysis using an ABI 377 automated sequencer 
(Applied Biosystems, carried out by Central Biotechnology Services, Cardiff University). 
During analysis, the fluorescence intensities generated from the labelled di-
deoxyterminators were translated into electropherograms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step Temperature (ºC) Time  Number of cycles 
Initial Denaturation 96 2 minutes 1 
Denaturation 
Annealing 
Elongation 
96 
50 
60 
30 seconds 
30 seconds 
4 minutes 
 
30 
Incubation 4 Indefinite 1 
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endonuclease (prepared to a total volume of 20!l with 2!g reaction buffer and dH2O). 
The plasmid DNA was digested for 2 hours in a 37°C waterbath (unless otherwise 
stated) and the resultant products separated by agarose gel electrophoresis. The 
digest pattern was visualised using UV transillumination (section ?.?). Plasmid 
preparations which yielded restriction fragments of the expected molecular mass were 
selected for further propagation (large-scale, maxi-prep culturing, section ?.?). For 
cloning, the desired DNA fragments were excised from the gel and purified using the 
QIAquick Gel Extraction Kit (section ?.?). The resultant recovery was verified by 
further agarose gel electrophoresis.  
 
 
2.4.1.8. DNA sequencing:   
 
Luminal accessory protein constructs were sequenced utilising a BigDye™ Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems) and following the manufacturer’s 
guidelines. The sequencing PCR reaction was prepared to a total volume of 10!l and 
typically consisted of ~250ng of plasmid DNA, BigDye™di-deoxyterminators, 
BigDye™ reaction buffer (x1) and a suitable sequencing primer (such as the M13 
reverse primer provided in the TOPO® PCR cloning kit (3.5 pmol used)). The thermal 
cycling conditions are outlined in Table 4. Reaction products were purified using a 
DyeEx™ kit (Qiagen), where unincorporated dye terminators were removed by 
centrifugation of the samples in spin columns containing a prehydrated gel-filtration 
resin. Once collected from the columns, the samples were sent for analysis using an 
ABI 377 automated sequencer (Applied Biosystems, carried out by Central 
Biotechnology Services, Cardiff University). During analysis, the fluorescence 
intensities generated from the labell d di-deoxyter inators were translated into 
electropherograms. 
 
Step Temperature (ºC) Time  Number of cycles 
Initial Denaturation 96 2 minutes 1 
Denaturation 
Annealing 
Elongation 
96 
50 
60 
30 seconds 
30 seconds 
4 minutes 
 
30 
Incubation 4 Indefinite 1 
Table 2.3: PCR sequencing thermal cycling conditions: The temperatures were 
chosen according to the BigDye™ Terminator v3.1 Cycle Sequencing Kit guidelines. 
 
 59 
2.4.1.9. Cloning of the luminal accessory protein constructs into a mammalian 
expression vector:   
 
Verified constructs in pCR"-Blunt II-TOPO® were excised from the vector using a double 
restriction digest and subsequent gel extraction (sections 2.4.1.3 and 2.4.1.7), and cloned 
into the mammalian expression vector pcDNA3.1"hygro(+). Prior to preparing the ligation 
reaction, the DNA was treated with Antarctic phosphatase (5 units, 15 minutes at 37°C 
with heat inactivation at 65°C for 5 minutes) to prevent any re-ligation of the plasmid 
vector. Ligations were carried out using the Rapid DNA Ligation Kit (Roche), (section 2.1.2 
(F)) and prepared in a 3:1 (insert:vector) molar ratio, as recommended in the 
manufacturers guidelines (Table 2.4). Reactions were incubated overnight at 4°C before 
being transformed into competent bacteria (OneShot®TOP10, section 2.4.1.5) and 
screened for success, as outlined in section 2.4.1.6-2.4.1.8.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calsequestrin Junctin 
0.5!l pcDNA3.1hygro (+) vector (50ng) 
5!l CSQ2 construct (30ng) 
2!l DNA dilution buffer (x5) 
1.5!l dH2O (5x) 
--------------------------- 
10!l T4 DNA ligation buffer (2x) 
1!l T4 Ligase 
 
TOTAL 20!l 
0.5!l pcDNA3.1hygro (+) vector (50ng) 
2.5!l JUN construct (30ng) 
2!l DNA dilution buffer (x5) 
4!l dH2O (5x) 
--------------------------- 
10!l T4 DNA ligation buffer (2x) 
1!l T4 Ligase 
 
TOTAL 20!l 
Table 2.4: Luminal accessory protein and pcDNA3.1hygro(+) ligation 
reaction: The relative MW of the constructs were used to calculate the molar 
ratio for ligation reactions (pcDNA3.1hygro(+) = 5600bp, CSQ2 = 1216bp and JUN 
= 678bp). Estimates of the luminal protein concentration (per !l) were made from 
the gel recovery (for gel extraction, see section 2.4.1.3), following excision of the 
constructs from pcDNA pCR!-Blunt II-TOPO®. 
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2.4.1.10. Large-scale DNA propagation and maxi-prep purification: 
 
For large-scale plasmid isolation, typically: 2x400ml (luminal protein constructs) or 
4x400ml (full-length eGFP-hRyR2) flasks of LB medium (with ampicillin (100 !g/ml) were 
required to generate one bacterial pellet for DNA purification. Each flask was inoculated at 
a 1/400 dilution with small-scale culture (from the mini-prep process, described in section 
2.4.1.6) and incubated overnight (16-18 hours) at 37°C (luminal protein constructs) or 
30°C (full-length eGFP-hRyR2), with shaking at 225rpm (Innova™ 4300 incubator (New 
Brunswick Scientific)). The bacterial cells were harvested by centrifugation (Avanti J-25, 
Beckman with JLA16.250 fixed-angle rotor) at 7000 xg for 15 minutes at 4°C. Plasmid 
DNA was isolated from the pelleted cells using a HiSpeed® Plasmid Maxiprep Kit (Qiagen, 
section 2.1.2 (G)), which employs an ion-exchange resin method for purification. Bacterial 
cells were treated with the same alkaline lysis reagents used in the mini-prep protocol, 
before decanting the lysed, neutralised cells into the barrel of a QIAfilter cartridge and 
incubating at room temperature for 10 minutes. The precipitated cell debris (containing 
contaminant proteins, detergent and genomic DNA) was removed by filtration and the 
cleared lysate applied to an equilibrated (with QBT) HiSpeed® maxi tip (containing anion-
exchange resin). DNA bound to the resin was washed twice (with buffer QC) before 
elution in 15ml high salt buffer (QF). Plasmid DNA was desalted and concentrated by 
isopropanol precipitation; isopropanol (0.7 volumes) was added to the eluate and 
incubated at room temperature for 30 minutes, before trapping the DNA precipitate in a 
QIA precipitator® filter using a syringe. Ethanol (70% w/v) was passed through the column 
to wash the bound DNA, before elution with 1ml dH2O. Plasmids were quantified and 
verified by restriction digest, before storing at -20°C. 
 
2.4.1.11. DNA Quantification: 
 
DNA concentration (!g/ml) was established by UV spectrophotometric quantification 
(LAMBDA Bio(+) spectrophotometer (Perkin Elmer)) of a 1:50 dilution of sample in a quartz 
cuvette. Absorbance readings were taken at 260 nm (the wavelength at which DNA 
exhibits peak light absorption) and calculated according to an A260 value/optimal density 
of 1 corresponds to 50!g/ml of double stranded DNA. Plasmid purity was also quantified 
by measuring the ratio of A260/A280 (indicative of protein concentration), with values #1.8 
indicating sufficiently pure preparations.  
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2.4.2. Mammalian Cell Culture Methods: 
 
Human embryonic kidney (HEK) 293 cells were developed as an immortal cell line, 
following transformation with sheared adenoviral DNA (Graham et al., 1977) and are used 
extensively as an expression tool for recombinant proteins. Although epithelial in origin, 
the cells’ biochemical machinery is able to reproducibly express large-scale, functional, 
recombinant proteins with high efficiency whilst maintaining any essential post-
translational modifications. Importantly, HEK293 cells have no endogenous RyR2 
expression (Du et al., 1998), ensuring that the isolated proteins were derived from the 
transfected plasmid.  
 
2.4.2.1. Maintenance and sub-culture of HEK293 cells: 
 
All cell culture work was undertaken in a designated laboratory in HEPA filtered class II 
laminar flow containment hoods. Cells were incubated at 37°C, gassed with 5% CO2, 98% 
humidity and typically grown in T75 cm2 culture flasks in the presence of 10ml 
supplemented (section 2.1.7, (A)) Dulbecco’s Modified Eagles Medium (DMEM). To 
maintain a healthy adherent cell population, routine sub-culturing (passage) of the cell 
monolayer (at ~80% confluency) was essential to prevent over confluence and cell death. 
Cells were detached from the culture flasks by trypsinisation (incubated with the cells for 
no longer than 5 minutes), after washing with 10ml 0.9% w/v saline solution. Dissociated 
cells were collected as a cell suspension in cDMEM (10ml) and typically 1-1.5ml was 
subsequently centrifuged at 1000 xg for 5 minutes before the resultant pellet was 
resuspended in 10ml cDMEM and placed into a fresh sterile T75 cm2 culture flask for 
further growth.  
 
2.4.2.2. Calcium phosphate transfection of HEK293 cells: 
 
The eGFP-hRyR2 and luminal accessory protein transfection protocol is described in 
further detail in Chapter 3, section 3.2.3. To generate calcium phosphate-DNA 
precipitates, plasmid DNA (12!g DNA per 8x105 cells) was mixed with 124mM CaCl2 
solution (pH 7) and dH2O to a total volume of 500!l; and subsequently added dropwise to 
500!l of warmed 2x HBS (pH 7.05), (section 2.1.7 (F)) with continuous vortexing. To allow 
precipitate formation, the DNA/CaCl2/HBS mix was incubated for 20 minutes at room 
temperature, before adding dropwise (1000!l/plate) to the cell monolayer. It was essential 
that this process formed a fine precipitate (i.e., not clumpy), such that the DNA could be 
actively introduced into the cells by endocytosis. Cells were incubated at 37°C, 5% CO2 
for 24 hours before upregulation of expression with 2mM NaB, and determination of 
 63 
transfection efficiency (see Chapter 3, section 3.3.5), following a further 24 hour 
incubation. Harvested by trypsinisation, the total cell numbers were established using a 
haemocytometer, before being pelleted by centrifugation (1000 xg, 5 minutes) and stored 
at -80°C.  
 
2.4.2.3. Effectene® transfection of stable cell lines: 
 
Described in Chapter 3, section 3.3.4, stable cell lines were transfected using Effectene® 
reagent (Qiagen). To prepare for Ca2+ imaging (section 2.4.3.9), the stable cells were 
seeded at a density of 1x105 cells into 35mm glass bottom dishes (MatTek" Corporation), 
which were coated with poly-lysine before seeding. The cells were maintained in 200 !l 
menisci of cDMEM for 4-5 hours (to encourage adhesion) before adding 2ml fresh cDMEM 
to each well and incubating overnight at 37°C, 5% CO2 before transfection. Briefly, 
following the manufacturers guidelines, 0.2 !g of recombinant DNA (per micro well) was 
mixed with an enhancer and a DNA-condensing buffer, and incubated for 5 minutes (room 
temperature) before addition of the Effectene® reagent. Following incubation for 10 minutes 
at room temperature, the resultant condensed Effectene®-DNA complexes were mixed with 
cDMEM and added directly to the cells. Addition of the Effectene® reagent to the DNA 
generates micelle structures that are actively taken up by the cells.  
 
2.4.3. Protein Biochemistry Methods: 
 
2.4.3.1. Preparation of mixed membranes from transfected HEK293 cells: 
 
Transfected cell pellets (produced as described in section 2.4.2.2, typically ~100x106 cells 
per pellet) were resuspended in ice-cold hypo-osmotic buffer (1ml for every 1x106 cells) 
before two stages of cell lysis (on ice), (for composition of hypo-osmotic buffer, see 
section 2.1.9 (B) i). Cells were first lysed in a glass homogeniser (x20 strokes) to manually 
disrupt the cells, followed by passing the homogenate 20x through a sterile 23G needle 
(BD Microlance™) aided by the use of an automated cell homogeniser (the 
“montygeniser”, designed and constructed by Richard Montgomery, illustrated in Figure 
2.3, A). The resultant homogenate was centrifuged at 2700 rpm (1200 xg) for 15 minutes, 
at 4°C (using an Allegra™ 6R centrifuge (Beckman Coulter)) and the supernatant 
collected (whilst the pellet consisting of cell debris and nuclear fraction was discarded). 
Microsomal membranes were collected by high-speed centrifugation for 90 minutes at 
28,000 rpm (100,000 xg), 4°C, using an Optima L-90K ultracentrifuge (50.2 Ti fixed angle 
rotor (Beckman Coulter). Membranes were resuspended in ‘solution C’ (section 2.1.9 (B) 
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ii) and homogenised further using a glass homogeniser, before storing as 30!l aliquots at -
80°C, following flash freezing in liquid nitrogen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.3.2. Protein assay and analysis of protein expression: 
 
Total protein in all samples was quantified using the BCA™ system (Thermo Scientific). 
This kit uses bicinchoninic acid (BCA) as the detection reagent for Cu+1 (univalent copper), 
formed when protein reduces Cu2+ in an alkaline environment. The chelation of two BCA 
molecules with one cuprous ion (Cu+1) generates a purple coloured reaction product. The 
absorbance of which at 595 nm can be read using a spectrophotometer. Dilutions (1/50, 
1/100 and 1/200) of membrane samples along with protein standards (0-500!g/ml BSA) 
were mixed with the kit reagents according to the manufacturers guidelines, before 
incubating at 30°C for 20 minutes for chromogenic development. Absorbance readings at 
595nm were taken using a Labsystems Multiscan™ spectrophotometer and Genesis 
software. A standard curve was plotted of absorbance (595nm) vs. protein concentration 
(!g/ml). Sample protein concentration was derived from the values given by the standards, 
using the linear equation y=mx+c. Protein expression levels were ascertained by Western 
blot analysis following separation by SDS-polyacrylamide gel electrophoresis (SDS-
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Figure 2.3: Apparatus used to homogenise transfected HEK293 cell pellets:   
(A) Illustrates the automatic cell homogeniser and (B) is a schematic of a manual 
glass homogeniser.  
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PAGE). Densitometric analysis of Western signals was used to standardise protein 
samples for expression level before use in further investigations.  
 
2.4.3.3. SDS-PAGE gel electrophoresis: 
 
eGFP-hRyR2 protein samples were separated using a 4% acrylamide gel (supplemented 
with 1% agarose to strengthen), whilst luminal proteins were resolved on a 10% gel. Gels 
were cast and run using the Bio-Rad mini-gel apparatus. Separating gels were prepared 
as in Table 2.5 and set (~1 hour) between glass plates, assembled into a gel casting 
system. A stacking gel mixture (4% used for all proteins detected) was layered on top of 
the separating gel (with an inserted comb to form loading wells) and left to set for ~45 
minutes. To prepare the samples for electrophoresis, the proteins were denatured in the 
presence of SDS-containing loading buffer, for 20 minutes at 42°C. The buffer also 
contained 10% ß-merceptoethanol, a reducing agent that prevented the formation of 
protein aggregates. A Kaleidoscope protein MW marker (Bio-Rad) was loaded alongside 
the protein samples. Gel electrophoresis was carried out at a constant current (typically 20 
mA) and run until the appropriate coloured MW markers were resolved. 
 
 
 
                          Separating acrylamide gel composition 
Reagents Typical Volumes (!l) Final concentration 
 4%* 10%**  
 Acrylamide/Bis (37:5:1) 40% 1000 2500 Dependent on % 
acrylamide used 
Tris-HCl 1.5M, pH 8.8 2500 2500 25% (v/v) 
SDS 10% 100 100 1% (v/v) 
Ammonium Persulphate 10% 50 50 0.5% (v/v) 
TEMED 5 5 0.05% (v/v) 
dH2O (supplemented with 1% 
agarose in 4% gels) 
6345 4845 Up to a final volume 
Gel % determined according to the size of the proteins to be separated and is 
indicative of the amount of acrylamide required. 
* Used for running WT and mutant hRyR2 protein. 
** Used for running luminal accessory proteins. 
Table 2.5: Components used to prepare SDS-PAGE gels: The composition of SDS-
PAGE 4% and 10% separating gels are shown. Stacking gels were all 4% and prepared 
as described above (4% separating gel) but the Tris-HCl 1.5M, pH 8.8 was replaced with 
Tris-HCl 0.5M, pH 6.8.  
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2.4.3.3.1. Protein transfer onto a polyvinylidene difluoride (PVDF) membrane: 
 
The separated proteins were transferred onto a PVDF membrane (Immobilon-P, Millipore) 
using either a semi-dry system (Bio-Rad), for CSQ2/JUN transfer or an iBlot" dry blotting 
system (Life Technologies) to transfer eGFP-hRyR2. The iBlot" system was chosen for 
hRyR2 analysis because of the reduced transfer time (14 minutes) required compared to 
using the semi-dry blotting technique (4 hours), but with equivalent transfer efficiency. For 
semi-dry transfer, the PVDF membrane was soaked in methanol for 1 minute, then for a 
further 45 minutes in transfer buffer, along with the SDS-PAGE gel (soaked for 5 minutes) 
and filter paper. The transfer apparatus was assembled as follows: the SDS-PAGE gel 
was placed on top of the PVDF membrane and both were sandwiched between six pieces 
of soaked filter paper. A roller was used to remove air bubbles. ‘Semi-dry’ transfer of 
CSQ2 and JUN was carried out at 400mA (limited to 25V) for 50 minutes at 4°C. Protein 
transfer using the iBlot"system was carried out using specialised iBlot" gel transfer 
stacks (Life Technologies), eliminating the need for any pre-soaked membranes/filter 
paper and transfer buffer. Based on a dry blotting concept, the iBlot" transfer stacks 
consisted of: (1) an anode stack (on top of which the pre-activated PVDF (0.2!M) 
membrane was placed), (2) a cathode stack (with the SDS-PAGE gel placed underneath, 
on top of the membrane) and (3) a disposable sponge with metal contact to associate the 
electrodes of the iBlot" device with the assembled gel stacks. The design of the iBlot" 
system created a shorter distance between electrodes and thus enabled the generation of 
high field strength and currents, and enhanced transfer speed. The program selected for 
hRyR2 transfer consisted of a 13 minute run at 20V.  
 
2.4.3.4. Immunodetection of Western Blotted proteins: 
 
Immediately after transfer, membranes were incubated for 1 hour at room temperature in 
blocking solution (5% non-fat milk in TBS-T, see section 2.1.9 (A) vi) on a rocker. To 
enable immunodetection, the primary antibodies were prepared in 1% blocking buffer 
(section 2.1.9 (A) vii) and applied to the membrane as a 1/5,000 or 1/10,000 dilution, as 
recommended in the manufacturers guidelines (see section 2.1.6 for antibody details), and 
incubated for 2 hours at room temperature or overnight at 4°C. The membrane was 
subsequently washed 3 times (5 minute durations) with wash buffer (section 2.1.9 (A) vii) 
before further incubating the membrane with a horseradish peroxidase (HRP)-linked 
secondary antibody, chosen according the species within which the primary antibody was 
generated. Used as a 1/10,000 dilution in 1% blocking buffer, the secondary antibody was 
incubated with the membrane at room temperature for approximately 90 minutes. Before 
the final stage of detection, the membrane was washed five times (5 minute incubations) 
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with TBS-T buffer (section 2.1.9 (A) v), to remove any remaining traces of unbound 
antibody or milk solution. 
 
To visualise the immunoreactive protein bands, enhanced chemiluminescence detection 
reagents were used (ECL" Western blotting analysis system, Amersham", GE 
Healthcare) according to the manufacturers guidelines. The membrane was then exposed 
to X-ray film (Amersham Hyperfilm", GE Healthcare) for a suitable length of time, 
determined according to the intensity of the chemiluminescence signal detected using a 
Compact x4 x-ray film developer. The obtained immunoblots were subsequently used for 
densitometric analysis, undertaken using a GS-700 imaging densitometer and Quantity 
One® software (Bio-Rad).  
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2.4.3.5. [3H] Ryanodine Binding Protocol: 
 
The details of the [3H] ryanodine binding assays undertaken in this project are discussed 
further in Chapter 4, sections 4.2.1-4.2.1.1. Each reaction contained 100!g of membrane 
proteins, 10nM [3H] ryanodine and was prepared to a final volume of 500!l using 
ryanodine binding buffer (adjusted to a given free Ca2+ concentration). To control 
reactions, the final volume of binding buffer was adjusted to accommodate the addition of 
10!M ‘cold’ (non-radiolabelled) ryanodine. All reactions were prepared in duplicate, 
materials outlined in section 2.1.9 (D) i-iv.   
 
Following thorough mixing, the reactions were incubated in a water bath at 37°C for 90 
minutes, at which equilibrium binding is achieved (Holmberg and Williams, 1990). To 
terminate the reaction, x10 excess (5 ml) ryanodine binding buffer was added. All reactions 
were then filtered through pre-soaked Whatman" glass fibre filters (0.25 !M) under 
vacuum by attaching the filter apparatus to a Heto" masterjet lab suction pump. The full 
apparatus is shown in Figure 2.4. At this stage, unbound [3H]-ryanodine passed through 
the filter with washing, whilst eGFP-hRyR2 (and any bound [3H]-ryanodine) was retained 
on the filter. Each filter was placed into a 10 ml scintillation vial (Fisher Scientific) and fully 
submerged in 5 ml Ultima" Gold Scintillation Fluid (Packard Bioscience). All samples were 
mixed and incubated at room temperature for 24 hours before reading in a Packard 
(2100TR) liquid scintillation counter. Decontamination of used plasticware was carried out 
according to local rules.  
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Figure 2.4: [3H] Ryanodine binding filter apparatus. 
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2.4.3.6. Co-immunoprecipitation (Co-IP) of hRyR2 with luminal proteins: 
 
Co-IP studies are described in Chapter 5 and were carried out using a !MACS™ GFP 
protein isolation kit (Miltenyi Biotec), (section 2.1.9 (F) i-iii), whereby WT and mutant eGFP-
hRyR2 proteins and their interacting partners were isolated from solubilised membrane 
preparations using super-paramagnetic !MACS" microbeads, conjugated to an anti-GFP 
monoclonal antibody. Using the same protocol described below, luminal protein 
associations were investigated using !MACS™ Protein A microbeads (Miltenyi Biotec).  
 
All samples used for co-IP studies were first analysed by Western blot and densitometry to 
ensure that equal amounts of both WT and mutant eGFP-hRyR2 used. Using a 
solubilisation buffer, 1-1.5 mg of ER membranes were solubilised overnight at 4°C, before 
removal of any unsolubilised, unbound material using centrifugation (10 minutes, 11500 
rpm (16,000 xg) in an Allegra 6R Beckman Coulter, at 4°C). All samples were made up to 
a total volume of 1 ml with solubilisation buffer and the appropriate volume of protease 
inhibitor. Anti-GFP paramagnetic microbeads (50!l, 50 nm in diameter) were mixed and 
incubated with the solubilised WT/mutant eGFP-tagged hRyR2 protein for at least 30 
minutes, on ice.  
 
To isolate the proteins bound to the anti-GFP-microbeads, the samples were applied to 
!MACS" columns, which were equilibrated (with solubilisation buffer, section 2.1.9 (E) i) 
and placed into a !MACS" separator (a magnetic stand, Miltenyi Biotec). !MACS" 
columns are packed with steel spheres that enhance the magnetic field necessary to 
capture the !MACS" microbeads and bound target protein/s. Assembly of the set-up is 
shown in Figure 2.5. The immunoprecipitates were applied to the !MACS" columns where 
the magnetically labelled proteins were retained. The columns were washed four times with 
200 !l solubilisation buffer, before a final wash step with 20 mM Tris, pH 7.4 (100 !l), 
ensuring removal of any non-interacting material (such as detergent and salt) that would 
interfere with analysis. The samples of interest were eluted in 50!l of an SDS-containing 
elution buffer (composition detailed in section 2.1.9), which was heated to 95°C in a hot 
block before use. Eluted proteins were analysed by SDS-PAGE and Western blotting.  
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2.4.3.7. Immunofluorescent co-localisation investigations: 
 
Transfected HEK293 cells were collected and plated as a 200!l meniscus onto poly-lysine 
coated glass coverslips (22 x 22 mm) at a density of 8x104 cells/coverslip, and left to 
adhere overnight at 37°C with 5% CO2. The cells were washed three times in 1x 
phosphate buffered saline solution (PBS, section 2.1.8 (C)) before fixing with a 4% 
paraformaldehyde/PBS solution (pH 7.4) for 10 minutes in the dark. The fixed cells were 
washed and re-hydrated with PBS solution for 60-90 minutes before permeabilisation at 
room temperature in 0.1% v/v Triton X-100 in PBS for 30 minutes. The cells were further 
washed in PBS before blocking in 10% FCS (in PBS) for 30 minutes at room temperature. 
Primary antibody (used at 1/100) was then added as a 150!l meniscus in PBS, for 90 
minutes at room temperature. Coverslips were then washed and incubated with a 
fluorescent secondary antibody (used at 1/250), again at room temperature for 90 minutes. 
Following three final wash steps in PBS and dH2O, the coverslips were dried and mounted 
onto ethanol washed glass slides using Fluorsave" (Millipore). The slides were left to dry 
for 30 minutes before storing at 4°C until required. The slides were visualised using a 
confocal Leica SP5 microscope (Leica, Heidelberg, Germany), with an oil immersion, 63x 
objective lens. Co-incident eGFP- and Alexa® Fluor- labelled cells were identified using the 
Leica LAS-AF software.  
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Figure 2.5: Co-immunoprecipitation investigations: (A) Schematic of the labelling 
of eGFP-hRyR2 with !MACS™ anti-GFP microbeads, prepared within a 
microcentrifuge tube and incubated for at least 30 minutes (B) image of the !MACS™ 
column and separator apparatus used for immunoprecipitate isolation.  
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2.4.3.8. Loading of transfected HEK293 cells for Ca2+ imaging studies: 
 
Cells for Ca2+ imaging investigations were prepared as described in section 2.4.2.3. Fluo-3 
AM (50!g) was dissolved in 15!l DMSO containing 20% w/v Pluronic® F-127, making a 
3mM stock. This was added to mDMEM at a concentration of 10!M and incubated with 
the cells at 30°C with 5% CO2 for 45 minutes. Cells were then de-esterified in mDMEM for 
10 minutes prior to Ca2+ imaging.   
 
 
2.4.3.9. Ca2+ imaging protocol:  
 
Fluo-3 loaded cells were imaged using a laser scanning confocal microscope (Leica SP5, 
Leica, Heidelberg, Germany), with an oil immersion, x63 objective lens and Argon laser, 
controlled with Leica software. To visualise Ca2+ dependent Fluo-3 fluorescence, excitation 
was initiated at a wavelength of 488 nm and fluorescence detected by a photomultiplier 
tube (PMT) at 520±28. To view, the cells were immersed in a 200!l meniscus of Krebs-
Ringer-Hepes (KRH) buffer containing 1.3 mM CaCl2 (section 2.1.8 (G)) and spontaneous 
Ca2+ release events were imaged (5 frames/second) for 2 minutes at 512 x 512 pixel 
resolution. To estimate cell ER load, the transient amplitude following 10 mM caffeine 
addition was assessed. A caffeine response also verified the presence of functional RyR2 
channels.  
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Generation of recombinant 
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constructs and co-expression 
with wild type and mutant 
hRyR2 
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3.1 Introduction: 
 
It is now well accepted that in addition to the diverse range of interacting proteins reported 
to regulate hRyR2 activity from the cytosolic side of the channel, luminal accessory 
proteins also play a prominent role in Ca2+ release regulation. In particular, a quaternary 
complex located at the junctional SR membrane, comprising: RyR2, the Ca2+ buffering 
protein CSQ2 and two SR transmembrane proteins JUN and TRD1, are thought modulate 
the ability of RyR2 channels to sense changes in SR luminal [Ca2+]  (Zhang et al., 1997, 
Dulhunty et al., 2012). While defective Ca2+ sensing by RyR2 is a candidate mechanism in 
CPVT, it is unknown if mutant channels respond to or interact differently with luminal 
accessory proteins; a concept investigated in this project. 
 
 
3.1.1 Regulation of ryanodine receptor Ca2+ release by luminal accessory proteins at 
the junctional domain of the sarcoplasmic reticulum membrane: 
 
A detailed understanding of precisely how CSQ2, JUN and TRD1 modulate normal SR 
Ca2+ cycling (and specifically RyR2 function) as a complex or individually, is an active area 
of research (Beard et al., 2009, Lee et al., 2012, Rossi et al., 2014). Investigations using 
overexpression/knockout CSQ2/JUN/TRD1 animal models or in vitro techniques have 
provided us with an insight into how the luminal proteins may control normal SR Ca2+ 
cycling, however some functional differences have been reported (as highlighted in 
Chapter 1 (Tables 1.1-1.3)) which likely reflect species variability or inconsistencies 
between experimental conditions.   
 
To exemplify this, single channel investigations carried out by Györke et al (2004) with dog 
isoforms of the luminal accessory proteins demonstrated that CSQ2, when added back to 
the RyR2/JUN/TRD complex inhibited channel activity (decreased RyR2 Po); whilst Wei et 
al (2009b) with cardiac isoforms isolated from sheep, reported that CSQ2 activated RyR2 
channels (increased Po) when associated with RyR2/JUN/TRD1 in a lipid bilayer system 
(Wei et al., 2009b). Discrepancies in studies of protein-protein interaction have also been 
attributed to differences between species (Qin et al., 2009), whereby at physiological 
concentrations of luminal Ca2+, Zhang et al (1997) demonstrated an interaction between 
dog JUN and CSQ2, whilst using similar conditions no binding between rabbit JUN and 
CSQ2 was evident (Qin et al., 2009). Across species, CSQ2 shares ~75% homology 
(Prins and Michalak, 2011, Beard et al., 2004), whilst both JUN and TRD1 display their 
greatest divergence in C-terminal regions (Lim et al., 2000, Marty et al., 2009). Human, 
rabbit and dog JUN sequences for example, demonstrate ~97% homology in N-terminal 
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and putative transmembrane domains among species, but <72% similarity in C-terminal 
sequence (Wetzel et al., 2000), which could explain disparities in functionality. Thus, in 
order to reliably investigate the physiological roles of CSQ2, JUN and TRD1 in the human 
heart, human isoforms of the luminal accessory proteins should be used. In vitro 
techniques however have proved more useful for closely investigating the molecular 
mechanisms and protein-protein interactions that mediate RyR2 luminal Ca2+ sensitivity 
(Zhang et al., 1997, Lee et al., 2012). In transgenic animal models with gene-targeted 
over-expression, down regulation or complete ablation of CSQ2, JUN or TRD1  (Jones et 
al., 1998, Fan et al., 2008, Chopra et al., 2009, Altschafl et al., 2011), compensatory 
mechanisms are often reported, such as down regulation of other critical EC coupling 
proteins or structural remodelling (as in Chopra et al., 2009). As a consequence, the 
observed alterations in cellular Ca2+ homeostasis cannot be confidently attributed to one 
particular luminal component or their role as a complex confidently established (Dulhunty 
et al., 2012).  
 
Taking the aforementioned into consideration, a recombinant approach has been 
employed in this project, firstly to explore how the sensitivity of RyR2 channels to cytosolic 
and/or luminal Ca2+ may be modulated by luminal accessory protein co-expression and to 
assess the protein-protein interactions between them. To provide a simplified model by 
which luminal accessory protein regulation of RyR2 channels could be investigated 
(without the presence of other specialised SR proteins complicating findings), the 
recombinant proteins were expressed a mammalian HEK293 cell system, which does not 
endogenously express RyR2 or any associated proteins. Allowing the proteins to 
assemble in situ, without the need for purification, the combination of luminal accessory 
protein(s) co-expressed with RyR2 channels (for example, CSQ2 alone with hRyR2 or in 
the presence of JUN) could be manipulated. Furthermore, expression of recombinant 
RyR2 in HEK293 cells enabled the functional effects of CPVT-linked RyR2 mutations 
found in cardiac disease to be examined (Thomas et al., 2010). Although defective 
cytosolic/luminal Ca2+ sensing has been reported as a common mechanism in CPVT 
pathogenesis (Terentyev et al., 2006, Jiang et al., 2005), it is unknown if mutated RyR2 
channels respond differently to luminal accessory protein regulation or if their association 
is altered. Thus, the response and interaction of mutant hRyR2 channels (N4104K and 
A4556T) with the luminal proteins has also been explored in this investigation, and directly 
compared with data obtained using WT hRyR2.  
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3.1.2 Chapter Objectives:  
 
HEK293 cells are currently the most widely used RyR2-deficient cell line (Du et al., 1998) 
for studies of recombinant RyR2; and have been used extensively by Professor Wayne 
Chen (University of Calgary, Canada) to study the molecular mechanisms underlying Ca2+ 
release through RyR2 channels and spontaneous Ca2+ release events seen with channel 
mutation (Jiang et al., 2002, 2004, 2005; Li and Chen, 2001). This expression system has 
also been used previously by the Williams laboratory to investigate the Ca2+ handling 
dynamics of both WT and mutant RyR2 channels (Euden et al., 2013, Thomas et al., 
2005, 2004) and as a vehicle for RyR2 expression prior to purification and use in single-
channel investigations (Mukherjee et al., 2012, Mason et al., 2012). The benefits of using 
a mammalian cell system for human recombinant protein expression are significant, since 
any post-translational modifications such as glycosylation, which is important for junctional 
SR trafficking (Kiarash et al., 2004) are likely to be native or near-native (Hopkins et al., 
2012); and the expressed proteins are able to associate within a mammalian cell 
environment (section 3.3.5). This chapter will focus exclusively on generating the luminal 
accessory protein constructs and optimising recombinant protein co-expression in a 
heterologous HEK293 cell system. Specifically, the following strategies will be discussed: 
 
(1) Amplification of cDNA encoding CSQ2, JUN and TRD1 from a human cardiac muscle 
library with a view to clone and express each protein alone and in combination with 
WT and mutant eGFP-hRyR2.  
 
(2) Selection of an appropriate vector system for luminal accessory protein stable cell line 
generation in HEK293 cells for Ca2+ imaging studies (Chapter 4) and optimisation of 
expression conditions such that sufficient hRyR2/CSQ2/JUN expression levels are 
obtained for [3H] ryanodine binding (Chapter 4) and immunoprecipitation studies 
(Chapter 5). 
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3.2 Methods: 
 
3.2.1. Strategies used for cloning and expression of luminal accessory protein 
constructs: 
 
• Junctin and Triadin (isoform 1, TRD1) 
 
PCR amplification (section 2.4.1.1, Tables 2.1 and 2.2) was used to isolate the open 
reading frames (ORFs) of human cardiac muscle JUN and TRD1 in vitro, from a human 
cardiac muscle complementary DNA (cDNA) library (BD biosciences). PCR primers 
designed to the desired luminal accessory protein cDNAs (NCBI accession numbers: 
AF184241 (cardiac JUN), U18985 (TRD1 skeletal), U31540 (TRD1 rabbit) and AF165915 
(TRD1 dog) are shown in Figure 3.1 (also see results, section 3.3.1). The components of 
each PCR reaction are outlined in Table 2.1. Several different primers were used in 
attempts to amplify human cardiac muscle TRD1 (Figure 3.1, B), however this was 
unsuccessful (see section 3.3.1.). 
 
• Calsequestrin (isoform 2, CSQ2) 
 
The coding sequence for human cardiac muscle CSQ2 (accession number: NG_008802) 
was obtained by direct cloning from an existing expression construct (obtained from Dr N.L 
Thomas, cloned into the pECFP-N1 vector and inserted at the XhoI/SacII sites). The full 
open reading frame including kozak sequence and a TAG stop codon was digested from 
pECFP-N1-CSQ2 using restriction enzymes XhoI/ApaI and ligated directly into 
pcDNA3.1"hygro(+) (ligation reaction outlined in section 2.4.1.9, Table 2.4).  
 
All constructs were verified at each cloning stage by restriction mapping (using NEB cutter) 
and digest, followed by automated sequencing (sections 2.4.1.7-2.4.1.8). To sequence 
JUN and TRD1 amplicons, cDNAs were cloned into the Zero Blunt® II TOPO® vector (Life 
Technologies), transformed into bacterial cells and propagated to sufficient quantities, as 
outlined in Chapter 2, sections 2.4.1.4-2.4.1.6 and 2.4.1.10-2.4.1.11. Clones containing the 
desired insert were sequenced using the protocol described in section 2.4.1.8. Those 
successfully verified were subsequently cloned into the mammalian expression vector 
pcDNA3.1"hygro(+) (section 2.4.1.9), following PCR amplification using primers containing 
restriction sites for BamHI and NotI endonucleases (Figure 3.1, shown in bold). The 
resultant amplified fragment was cut with BamHI and NotI to enable ligation into the 
multiple cloning site of the similarly digested pcDNA3.1"hygro(+) vector. Restriction digest 
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and further automated sequencing was used to confirm ligation of the luminal proteins 
(CSQ2 and JUN) into pcDNA3.1"hygro(+).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1:  
 
(A) Luminal accessory protein forward (5’) and reverse (3’) primers used in 
PCR isolation of junctin from a human cardiac muscle cDNA library. The 
primers were designed to contain restriction sites for BamHI (forward primer) and 
Not I (reverse primer), found in the multiple cloning site of the mammalian 
expression vector pcDNA3.1hygro(+). Human cardiac muscle JUN exists as a splice 
variant of the ASPH gene, encoding aspartyl ß-hydroxylase (AspH) (Jones et al., 
1995).  
 
(B) Primer combinations used in the attempt to isolate cDNAs encoding 
human cardiac muscle triadin. Initial PCR reactions were carried out using 
primers designed to contain BamHI and NotI restriction sites. The sequence for 
human cardiac muscle TRD, isoform 1 (TRD1) was unknown at the time of this work 
and thus the human sequence for the skeletal isoform and rabbit and dog cardiac 
sequences were consulted for primer design. The forward primer (5’) was designed 
to a conserved region found in all known TRD isoforms, established using BLAST. 
However, since the C-terminal regions of each isoform differed in sequence (and 
each protein differed in size between species), the reverse (3’) primer was designed 
to the C-terminal end of human skeletal TRD (i). Due to unsuccessful PCR 
amplification of TRD1, alternative reserve primers were used in additional reactions 
as shown in (ii) and (iii), with the intention that the resultant product could 
subsequently be used as a template for further amplification using the reserve 
primer containing the Not I site. This will be discussed further in section 3.3.1.  
 
!
 
     pcDNA3.1hygro(+)-JUN Forward:  5’CCGCAGGGATCCACCATGGCTGAAGATAAAGAG3’ 
                                                              clamp      BamHI          hJUN sequence 
 
     pcDNA3.1hygro(+)-JUN Reverse:  3’CCATCGCGGCCGCTTAGCCGTTTCTTTTCTGGGT5’ 
                                                              clamp      Not I             hJUN sequence 
 
 
 
     pcDNA3.1hygro(+)-TRD Forward:  5’CCGCAGGGATCCACCATGACTGAGATCACTGCTG3’ 
                                                              clamp      BamHI          cTRD sequence 
 
(i)  pcDNA3.1hygro(+)-TRD Reverse:  3’CCATCGCGGCCGCTTACTGTCCTTGTTGCTTCTG5’ 
                                                              clamp      Not I             cTRD sequence 
 
(ii) Matchmaker AD pACT2 Reverse: 3’GTGAACTTGCGGGGTTTTTCAGTATCTACGA5’ 
 
(iii) Non-specific-TRD Reverse: 3’CCAYTGNATYTGYTTYTTNCCNAGNGT5’  
 
 
!"#$
!%#$
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3.2.2. Comparison of G418 and hygromycin mediated selection of luminal accessory 
protein expressing stable cell lines: 
 
Hygromycin and G418 (Geneticin Sulphate) are often used as positive selection markers 
for stable protein expression, where only cells expressing the gene of interest display 
antibiotic resistance (Massignan et al., 2010). As a consequence, transfected cells lacking 
permanent integration of the recombinant DNA are subsequently eliminated upon 
antibiotic treatment. Prior to producing the stable cell lines, comparisons were made 
between the effectiveness of the two antibiotics on HEK293 cells, and an optimal selection 
concentration established.   
 
To determine a working concentration of G418 or hygromycin treatment that would enable 
long-term selection of HEK293 cells stably expressing the luminal proteins, a series of kill 
curves were constructed (n=3 curves formulated for each antibiotic dose range). 
Untransfected HEK293 cells were plated into 6 well culture dishes, seeded at a density of 
1 x 106 cells/well and once at ~80% confluency (~24 hours later), exposed to increasing 
concentrations of G418 or hygromycin (100!g/ml-1000!g/ml). The cells were incubated in 
the presence of the given antibiotic for 48 hours before analysis. 
 
To generate each stable cell line, HEK293 cells transfected with CSQ2, JUN or 
CSQ2+JUN were cultured in the presence of the chosen antibiotic (400!g/ml hygromycin). 
To achieve a clonal population, the cells were subjected to a limiting serial dilution, 
achieved by diluting a harvested stable cell population in excess cDMEM containing 
hygromycin and plating out the generated cell suspension in a series of 1/10 dilutions 
across a 96 well plate, until only ~1 cell/well was evident. Isolated cells were grown to 
confluency in 96 well plates before seeding the cell populations into T75 cm2 culture flasks 
for further growth, and positive selection with hygromycin treatment (approximately 28 
days to obtain a confluent (70-80%) flask).   
 
 
3.2.3 Optimisation of eGFP-hRyR2 expression in HEK293 cells using calcium 
phosphate mediated transfection: 
 
To establish an effective, reproducible method of achieving high levels of recombinant 
gene expression, it was imperative that the transfection protocol was first optimised. eGFP 
tagged full-length WT and mutant (N4104K and A4556T) hRyR2 mammalian expression 
constructs (obtained from Dr Chris George and Dr N. Lowri Thomas (Cardiff University), 
respectively) allowed the transfection efficiency, established from using two different 
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calcium phosphate (CaPO4) protocols, to be effectively estimated (section 3.3.5). To 
optimise WT hRyR2 expression, the following protocols were compared:  
 
(1) Protocol A was designed by Dr N.L Thomas (modified from Sambrook et al, 1989) and 
used previously to express eGFP-hRyR2 for Ca2+ imaging investigations (as used in 
Thomas et al, 2005).   
 
(2) Protocol B was designed by Professor.W.Chen (modified from Chen and Okayama, 
1987) and used to express high levels of mouse RyR2 for single channel analysis (Li and 
Chen, 2001, Jiang et al., 2002).  
 
To establish optimum conditions that would consistently generate high protein expression, 
the transfection variables most likely to affect transfection efficiency were considered:  
 
(i) Cell density: HEK293 cells were transfected at either ~75% (Thomas et al., 2005) or 
~30% (Jiang et al., 2002) confluency, achieved by plating the cells at higher (8.5x104 
cells/cm2, plated into a 6 well culture dish with a growth area of 9.6cm2 (8x105/well)) or 
lower (1.5x104 cells/cm2, plated into a 10cm2 petri-dish with a growth area of 55cm2 
(8x105/dish)) starting cell densities respectively. Sparse distribution of cell populations will 
increase the surface area over which the condensed DNA/Ca2+ precipitates can be 
endocytosed likely leading to higher transfection efficiencies. However, a high DNA/cell 
ratio can result in a cytotoxic effect suggesting the cells need to be at a sufficient 
confluency before transfection, without being too confluent to result in too low a 
transfection efficiency or detachment of fully confluent sheets of cells. 
 
(ii) DNA concentration: Expressed as the quantity of DNA/cell (estimated according to the 
starting cell number), comparisons were made between the use of 5 pg DNA/cell (4!g DNA 
per 8x105 cells), (Thomas et al., 2005) and 15 pg DNA/cell (12!g DNA per 8x105 cells), 
(Jiang et al., 2002). Higher DNA concentrations can reduce cell growth and may become 
cytotoxic, especially if the cell density is too low. In addition overexpression could promote 
protein malfunction. However, use of lower DNA concentrations may limit CaPO4 
precipitate formation and uptake and as a consequence, produce lower transfection 
efficiencies.   
 
All transfection reactions were formed by adding the DNA and CaCl2 to 2x HBS with 
vigorous vortexing, followed by incubation of the transfection mix at room temperature (20 
minutes), to allow precipitates to form before adding to the cell monolayer. The cells were 
incubated for 24 hours, before the addition of 2mM sodium butyrate (NaB) to culture 
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medium, which upregulates transcription (Gorman et al., 1983, George et al., 1998). The 
cells were incubated for a further 24 hours (in the presence of NaB), before the 
transfection efficiency was established. Chapter 2, sections 2.4.2-2.4.2.1 and 2.4.3.1 
further describes culturing and harvesting of transfected HEK293 cell populations. 
Transfection efficiencies were calculated as outlined in section 3.3.5.   
 
3.2.4. Co-expression of luminal accessory protein constructs with wild type and 
mutant eGFP-hRyR2 in HEK293 cells: 
 
Using an optimised CaPO4 precipitation protocol (sections 3.2.3 and 3.3.5), the luminal 
accessory protein constructs were co-transfected in an equimolar ratio with WT or mutant 
eGFP-hRyR2. Typical DNA concentrations used per reaction (12 !g total) are summarised 
below (Table 3.1). Each cell population was harvested 48 hours post-transfection and 
microsomal membrane vesicles subsequently isolated from these cells, as described in 
section 2.4.3.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transcript 
Length: 
hRyR2+CSQ2+JUN hRyR2+CSQ2 hRyR2+JUN 
hRyR2  
15,219 bp 
10.7 !g (89%) 11 !g (92%) 11.5 !g (95.6%) 
CSQ2 
1216 bp 
 0.80 !g (6.7%) 1 !g (8%) - 
JUN 
678 bp 
0.5 !g (4.3%) - 0.5 !g (4.4%) 
Total DNA 12 !g 12 !g 12 !g 
Table 3.1: Co-expression of hRyR2 and luminal accessory proteins was 
achieved by transfection of cDNA constructs in an equimolar ratio: WT/mutant 
hRyR2 were transfected in equimolar quantities with each of the luminal proteins, 
individually (CSQ2/JUN) or in combination (CSQ2+JUN). The DNA transfection ratio 
was calculated according to the relative length of the transcripts.  
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3.3 Results: 
 
3.3.1 PCR amplification of cDNA sequences encoding the luminal accessory 
proteins JUN and TRD1 from a human cardiac muscle cDNA library: 
 
• Isolation of JUN cDNA 
 
Using the primers detailed in Figure 3.1 (A), initial PCR amplification from the human 
cardiac muscle cDNA library yielded a band of the expected molecular weight for human 
cardiac muscle junctin (~700bp, Table 3.2).  However, the target DNA amplified in the 
initial PCR reaction (PCR1) was not of sufficient quantity for gel extraction and needed 
further enrichment (as described in section 2.4.1.1). As demonstrated in Figure 3.2 (A) 
sufficient quantities of the target JUN cDNA were generated by a second PCR reaction 
(PCR2), achieved using the PCR1 recovered cDNA as a template (Table 2.1, section 
2.4.1.1). The desired fragment was subsequently gel extracted to eliminate non-specific 
amplification products and purified using a QIAEX® II kit (Qiagen), the recovery of which is 
shown in Figure 3.2 (D).  
 
 
• Isolation of TRD1 cDNA 
 
Using primers designed to try and target the cardiac protein (Figure 3.1, B), PCR isolation 
of human TRD1 generated four distinct cDNA fragments (Figure 3.2, B (i)), but did not 
yield any products with the predicted molecular weights of ~950-1000bp, expected of 
TRD1 (Table 3.2). The bands closest to this predicted molecular weight were evident at 
~600bp or ~1600bp (indicated with an asterisks in Figure 3.2, B (i)), which were 
subsequently sequenced. In further attempts to isolate TRD1, the variant known to be the 
predominant isoform expressed in the myocardium (Kobayashi and Jones 1999, Roux-
Buisson et al., 2012) and thus the target in this project, the amplification strategy was 
consequently re-designed. Since TRD isoforms seem to be well conserved in their N-
terminal sequences, showing great variability in their C-terminal tail (due to differential 
splicing, Feng et al., 2009), the original 5’ primer was used with less specific 3’ ones. A 
series of additional PCR reactions were carried out using the primers outlined in Figure 
3.1 B, (ii) and (iii), with the idea that the generated amplicons could be subsequently used 
as templates for additional amplification using the pcDNA3.1hygro(+)-TRD specific primers.  
 
In an attempt to amplify TRD1, repeat PCR reactions were carried out using the forward 5’ 
pcDNA3.1hygro (+)-TRD primer and the following alternative 3’ reverse primers:  
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(1) Matchmaker (pACT-2 specific) 3’ AD, targeting the human cardiac muscle cDNA 
library cloned into the pACT2 vector (Clontech). 
 
(2) A “non-specific” 3’ TRD primer designed to the 3’ end of the known TRD sequences 
and targeted towards conserved regions within the sequence (established using BLAST). 
 
The two PCR reactions yielded some prospective clones, with fragments at ~1000bp 
Figure 3.2, B, (ii) and ~1500bp, Figure 3.2, B, (iii) being of particular interest, since they 
appeared at the expected molecular weight of TRD1.  
 
3.3.1.1 Isolation of cDNA encoding CSQ2 from a pECFP-N1 expression vector: 
 
A double digest with restriction enzymes XhoI and Apal was used to excise the coding 
sequence for human cardiac muscle CSQ2 from a pECFP-N1 expression vector (section 
3.2.1). As highlighted in Figure 3.2 (C), the digest yielded two fragments at ~4486, 
corresponding to cut pECFP-N1 vector, and ~1200bp, which was at the correct molecular 
weight of the desired CSQ2 target (Table 3.2). Gel extraction and purification of this band 
generated a sufficient cDNA recovery as shown in Figure 3.2 (D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accessory protein: Base Pairs: Protein size in kDa 
CSQ2 ~1200 bp  ~45 kDa   
(Scott et al., 1988) 
JUN  ~700 bp ~26 kDa 
(Jones et al., 1995) 
 
TRD1 ~950-1000 bp ~35 kDa-40kDa   
(Kobayashi and Jones, 
1999), or 
~37 kDa  
(Roux-Buisson et al., 
2012) 
Table 3.2: Predicted molecular weights of CSQ2, JUN and TRD1. Highlighted are the 
molecular sizes of each luminal accessory protein cDNA in base pairs (bp), and 
estimates of their protein size in kilodaltons (kDa). TRD1 is thought to exist in two forms, 
glycosylated and deglycosylated, reported by Kobayashi and Jones to be appear as 40 
and 35 kDa, respectively with Western anaylsis. However, Roux-Buisson et al., 2012, 
reported that TRD1 appears as a double band at 37kDa (with no 5 kDa difference 
evident). Although CSQ2 has been predicted to exist in numerous glycosylated and 
phosphorylated states (12 structural forms in native heart tissue), all are predicted to run 
as a single band in SDS-PAGE analysis (Scott et al., 1988, O’Brian et al., 2002). 
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Figure 3.2: Agarose (1%) gel electrophoresis to visualise PCR and gel extraction 
products: A fragment corresponding to amplified JUN cDNA appeared at the expected 
molecular weight (MW) of ~700 bp (A). Initial attempts at PCR amplification of cardiac TRD1 
generated four distinct fragments, which were not at the MW expected for the cardiac isoform 
(B),(i). The amplification strategy was designed as discussed in section 3.3.1. Using a 3’ 
reverse primer designed to target the pACT2 vector (into which the human cardiac muscle 
cDNA library was cloned), a fragment at ~1000bp evident in the PCR reaction was of 
particular interest as it appeared at the expected MW of TRD1 (B),(ii). An additional PCR 
reaction carried out using a “non-specific” 3’ reverse primer, designed to target conserved 
regions within the C-terminus of the known TRD sequences, generated distinct fragments at 
~1500bp and ~550bp (B),(iii). CSQ2 cDNA was excised from an existing pECFP-N1-CSQ2 
expression construct (section 3.2.1) by a double digest with XhoI/ApaI, the desired fragment 
at ~1200bp was subsequently gel extracted and purified (C). Isolation of CSQ2 and JUN 
cDNA appeared successful, where fragments indicative of the two luminal proteins (~1200bp 
and ~700bp, respectively) was evident in the gel extraction recovery (D). The expected 
product sizes corresponding to luminal accessory protein cDNA, compared with those 
obtained, are summarised in (E). All bands highlighted by asterisks were isolated and 
sequenced as outlined in section 3.3.2. A 1 kb DNA ladder was used in all gels shown. 
Where cropped for presentation purposes, the original photos will be shown in the Appendix, 
Figure 1.   
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Figure 8: Agarose (1%) gel electrophoresis to visualise PCR recovery and gel 
extraction products: A fragment corresponding to amplified JUN cDNA appeared at the 
expected molecular weight of ~700 bp (A). Initial attempts at PCR amplification of cardiac 
TRD1 generated four distinct fragments, which were not at the molecular weight 
expected for the cardiac isoform (B),(i) and summarised in (E). The amplification strategy 
was designed as discussed in section ?.?. Utilising a 3’ reverse primer de igned to target 
the pACT2 vector (into which th  human cardiac cDNA library was cloned), two 
fragments at ~2100bp a d ~1000bp were evident in the PCR recovery (B),(ii). An 
additional PCR reaction carried out utili ing a “non-specific” 3’ reverse primer, designed 
to target conserved regions within th  C-terminus of the known TRD sequences, 
g nerated distinct fragments at ~1500bp and ~550bp (B),(iii). CSQ2 cDNA was excised 
from an exi ting pECFP-N1-CSQ2 expression con truct (section 3.2.1) by a double 
digest with XhoI/ApaI, t  desired fragment at ~1200bp was subsequently gel extracted 
and purifi d (C). Isol tion of CSQ2 and JUN cDNA appeared successful, where 
fragments indicative of the two luminal proteins (~1200bp and ~700bp, respectively) was 
evident in the gel extraction recovery (D). The expected product sizes corresponding to 
luminal accessory protein cDNA, compared with those obtained, are summarised in (E). 
A 1kb DNA ladder was used in all gels shown. Where cropped for presentation purposes, 
the original photos will be shown in Appendix ?.   
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3.3.2 Sequence verification of luminal accessory protein constructs: 
 
Sequences were identified and verified using the Basic Local Alignment Search Tool 
(BLAST, http://blast.ncbi.nlm.nih.gov), where an alignment report was generated against 
known, related sequences currently present within the NCBI database. The generated 
cDNA construct corresponding to JUN (in TOPO® vector) displayed exact sequence 
homology (100% identification, including start, kozak and TAG stop sequences) to the 
known human cardiac muscle JUN sequence (current accession number: AF224468 (Lim 
et al., 2000)). As discussed in section 3.2.1, the CSQ2 construct was sequenced once 
inserted into the pcDNA3.1 hygro(+) vector and was also found to display 100% sequence 
identity to the known cardiac CSQ2 sequence (current accession number: NM_001232 
(Kawamura et al., 2013)). Conversely, sequence analysis of the prospective TRD1 clones 
did not display any sequence homologies to the known TRD isoforms following a BLAST 
search. In addition, the isolated fragments were also manually aligned against the known 
TRD1 sequences of other species to assess the degree of homology, yet no significant 
similarities were found. Table 3.3 lists the outcomes of the BLAST search following 
sequencing of all prospective TRD amplicons.  As further considered in the discussion 
section of this chapter (section 3.4.1), when this section of the project was carried out, the 
human cardiac muscle TRD1 sequence was unknown, thus designing PCR primers with 
significant specificity to TRD1 proved problematic, and reliable verification of the obtained 
PCR products difficult. In light of this, and considerable evidence in the literature 
suggesting that TRD1 and JUN have functionally distinct roles in regulating RyR2 activity 
(Altschafl et al., 2011, Chopra et al., 2013), I decided to focus my investigations on the 
interaction and functional regulation of hRyR2 by luminal proteins CSQ2 and JUN. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR isolated Fragment: BLAST homologous 
sequence: 
Accession Number: 
~600 bp (Figure 3.2, B (i)) 
~550 bp (Figure 3.2, B (iii)) 
Homo sapiens chromosome 
14, alternate assembly 
NC_018925.2 
~1000 bp (Figure 3.2, B (ii)) Homo sapiens chromosome 
11, alternate assembly  
NC_018922.2 
~1600 bp (Figure 3.2, B (i)) 
~1500 bp (Figure 3.2, B (iii)) 
Homo sapiens chromosome 
1, alternate assembly 
AC_000133.1 
Table 3.3: Identification of prospective TRD amplicons using BLAST. 
The obtained sequences of each isolated fragment were assessed using BLAST, 
but did not display any sequence homologies to human cardiac muscle triadin 1 
(TRD1). The human TRDN gene is located on chromosome 6 (Thevenon et al., 
2003).  
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3.3.3 Cloning CSQ2 and JUN constructs into mammalian expression vector 
pcDNA3.1hygro (+): 
 
• pcDNA3.1hygro (+)-JUN 
 
Sequence verified JUN cDNA was excised from TOPO® vector using an overnight double 
digest with BamHI and NotI restriction enzymes at 37°C and subsequently cloned into the 
pcDNA3.1 hygro(+) expression vector (Life Technologies) following the ligation protocol 
described in section 2.4.1.9.  
 
• pcDNA3.1hygro (+)-CSQ2 
 
Following an overnight digest of pcDNA3.1hygro (+) with XhoI and ApaI (section 3.2.1), a 
ligation reaction was undertaken (Table 2.4) to directly clone the isolated CSQ2 cDNA into 
the new expression vector.  
 
 
To confirm successful generation of full-length luminal protein-pcDNA3.1hygro(+) 
expression constructs, restriction enzymes Psi I (JUN-pcDNA3.1hygro(+)) and Bpu10I 
(CSQ2-pcDNA3.1hygro(+)) were used for restriction mapping (using NEB cutter, 
http://tools.neb.com) and subsequent digest, chosen on the basis that recognition sites for 
the given enzymes were present in both the pcDNA3.1hygro(+) vector and the luminal 
protein insert. Restriction fragments were resolved according to their molecular weight 
using 1% agarose gels (section 2.4.1.2) and further automated sequencing confirmed that 
the luminal protein inserts were successfully cloned into the mammalian expression vector 
before using the constructs in further investigations.    
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3.3.4 Hygromycin is a better selection antibiotic than G418 for making stable cell 
lines in HEK293 cells: 
 
Optimal concentrations of selection antibiotic were determined by plotting dose-response 
(or kill-) curves for hygromycin and G418 (Figure 3.3) carried out on untransfected 
HEK293 cells, as outlined in section 3.2.2. In contrast to hygromycin treatment, HEK293 
cells displayed a high level of resistance to G418, which resulted in very little cell death 
(Figure 3.3). In light of this, hygromycin selection was chosen as the most efficient 
treatment. As shown in Figure 3.3, a concentration of 400 !g/ml was chosen, since 
treatment of cells with this dose eliminated ~65% of cells and increases in concentration 
from here did not cause an appreciable increase in cell death.  Shown in Figure 3.4 are 
representative images of HEK293 cell death when treated with increasing doses of 
hygromycin. Three HEK293 cell lines stably expressing CSQ2, JUN or CSQ2+JUN were 
generated as described in section 3.2.2, cultured in the presence of 400 !g/ml 
hygromycin. Western Blotting was used to establish the expression levels of each protein 
(section 3.3.6).  
 
Illustrated as a bar graph in Figure 3.5 (A), the growth rate of stable cell lines was 
significantly slower than that of untransfected HEK293 cells, which consequently reduced 
transient CaPO4-mediated expression of hRyR2 (generating lower transfection 
efficiencies, examples of which are shown in Figure 3.5, (B)).  This hindered original plans 
to use luminal accessory protein-expressing stable cells for large-scale hRyR2 co-
expression. Since it was necessary for sufficient [3H] ryanodine binding and co-
immunoprecipitation investigations (discussed in Chapter 4 and 5, respectively) to produce 
large amounts of hRyR2, recombinant material was generated from transient transfection 
of hRyR2 (alone or in the presence of luminal accessory proteins) in normal HEK293 cells, 
achieved using the CaPO4 precipitation method (outlined in section 3.2.4 and Table 3.1).  
 
Since the luminal accessory proteins were not tagged with fluorescent proteins, it was 
essential to ensure that all cells imaged expressed the luminal accessory proteins of 
interest. WT or mutant hRyR2 could then be transiently expressed on top, as these cells 
would be able to be identified by their caffeine response (Thomas et al, 2004). Thus, 
stable cells were transfected with hRyR2 using the lipid-based Effectene® reagent (Life 
Technologies), (section 2.4.2.3), which requires less DNA than the CaPO4 method and is 
therefore less cytotoxic, ensuring cell viability is maintained (which is of the utmost 
importance for single-cell Ca2+ imaging studies, since damaged cells will not show agonist 
response). In addition, Effectene® does not form a precipitate and its efficacy is not 
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dependent on cell doubling rate. As illustrated in Figure 3.6 (A), sufficient transfection 
efficiencies of hRyR2 for Ca2+ imaging was achieved in stable cells using this method.  
 
However, [3H] ryanodine binding and immunoprecipitation experiments require large-scale 
transfection and high hRyR2 expression levels.  For these purposes Effectene®-mediated 
hRyR2 transfection of stables was not deemed adequate because: 1) The growth rate of 
the stable cell lines was prohibitively slow for large-scale transfection to be achieved, 2) 
the volume of Effectene® required was prohibitive, and 3) the overall expression level of 
hRyR2 was lower that that achieved using transient co-transfection of all constructs using 
CaPO4. As highlighted in Figure 3.6 (B), although Effectene® and CaPO4-mediated 
transfection of hRyR2 in HEK293 cells displayed similar transfection efficiencies (i.e. the 
percentage of cells that were green), higher protein levels per cell were achieved using 
CaPO4 precipitation, as indicated by the appearance of brighter green cells. However, due 
to higher protein expression, the cells did not appear as healthy as those transfected with 
Effectene® (which is essential for Ca2+ imaging), but this was not a concern for 
investigations which required the cells to be harvested and lysed.   
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Figure 3.3: Hygromycin and G418 Kill-Curves: HEK293 cells were seeded at a density of 1 
x 106 cells/well and exposed to increasing concentrations of hygromycin and G418. Following 
2 days culture in the presence of the antibiotic, the surviving cells were counted using 
haemocytometry. The kill-response curves were constructed using an average of the surviving 
cell number/dose determined from an n=3 experiments. HEK293 cells displayed high levels of 
resistance to G418 treatment, resulting in very little cell death. Hygromycin proved more 
effective, yielding an LD50 (the dose of antibiotic which killed 50% of cells) of 164 !g/ml 
(asterisks).  A treatment of 400 !g/ml, that killed 65% of cells (indicated with a dashed line) 
was chosen as the optimum dose to select for stable expression, since treatment at this 
concentration appeared to eliminate a significant proportion of cells without causing 
detrimental cell loss (plateau phase). 
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Figure 3.4: Representative images of HEK293 cell populations following 
treatment with hygromycin. To find an optimal dose of hygromycin treatment 
that would allow selection of transfected HEK293 cells stably expressing the 
luminal proteins, a hygromycin dose-dependence curve was constructed. Shown 
here are representative images of HEK293 cells treated with increased 
concentrations (!g/ml) of hygromycin.  Once cultured for 48 hours in the presence 
of the antibiotic, the number of surviving cells was counted. As illustrated, cell 
death increased in a dose-dependent manner.  
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Figure 14: Assessment of transient hRyR2 expression in stable HEK293 
cells: Utilising the CaPO4 precipitation method, transient transfection of WT 
hRyR2 into CSQ2 (A),(i) and JUN (A),(ii)-expressing stable cell lines, generated 
low transfection efficiencies (established by counting the percentage of green 
cells, as described in section 3.3.4). This was likely due to the slower growth rate 
of the cells compared to normal (WT) HEK293 cells, as illustrated in (B). Thus, the 
stables were not considered suitable for large-scale hRyR2 expression.  
!"#$
Figure 3.5: Assessment of transient hRyR2 expression in stable HEK293 
cells: (A) As illustrated using CSQ2 stables as an example, stable cells displayed 
a much slower growth rate than untransfected HEK293 cells and likely explains 
why using the CaPO4 precipitation method, transient transfection of WT hRyR2 
into CSQ2 (B) i and JUN (B) ii-expressing stable cell lines, generated low 
transfection efficiencies (established by counting the percentage of green cells 
from 4 fields of view). Thus, the stables were not considered suitable for large-
scale hRyR2 expression. 
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Figure 3.6: Assessment of the Effectene®-mediated transfection protocol: 
Transfection of WT hRyR2 into stable CSQ2-expressing cells (used here as an example) 
with Effectene® reagent, generated sufficient transfection efficiencies for Ca2+ imaging 
studies (A). Use of the reagent to transfect hRyR2 into wild-type HEK293 cells was also 
compared with the optimised CaPO4 precipitation protocol (for large-scale transfections) 
outlined in section 3.3.5 (Fig. 3.7 and 3.8). As shown in (B), whilst both methods 
generated similar transfection efficiencies, hRyR2 expression in cells transfected with 
CaPO4 appeared brighter (brighter green, bottom panels left and centre), indicative of 
higher protein expression per cell. Cells transfected using the Effectene® protocol 
appeared healthier (top left panel vs bottom left panel), likely due to lower protein 
expression. However, although more cytotoxic, in cells which were ultimately going to be 
harvested and lysed to produce microsomal mixed membranes necessary for further 
investigations, the CaPO4 precipitation method produced higher quantities of recombinant 
hRyR2 protein.    
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3.3.5. Assessment of HEK293 cells transiently transfected with eGFP-hRyR2: 
 
Prior to large-scale transfections of WT/mutant hRyR2 alone or in the presence of CSQ2 
and/or JUN, it was important to determine the optimal conditions required to generate 
high-levels of recombinant protein expression. Optimisation focused on the use of different 
starting cell confluency at the point of transfection and incubation with different 
concentrations of DNA. Each experiment was replicated 4 times and the results expressed 
as the mean transfection efficiency±S.E.M. Fluorescence microscopy was used to 
visualise WT eGFP-hRyR2 expression in cell populations 48 hours post-transfection, and 
images were taken of 3 fields of view (bright field and the corresponding fluorescence of 
the same field of view). To assess transfection efficiency, bright field and corresponding 
fluorescent fields of view were selected at random, cells were counted and the efficiency 
calculated as the percentage of green cells of the total number of cells in a mutual field of 
view.  
 
Figure 3.7 (A) illustrates typical fields of view of transiently transfected HEK293 cells, 
corresponding to each set of variables tested. Transfection of cells with a low DNA: cell 
ratio of 5 pg/cell (determined according to starting cell numbers) yielded transfection 
efficiencies of ~41±2% and ~30±1.5%, when at lower or higher cell densities, respectively 
(Figure 3.7, A (iii), (iv) and B). In comparison, the use of higher concentrations of DNA per 
cell (~15 pg/cell) appeared to increase the transfection efficiency to  ~51±3%, at lower cell 
densities (Figure 3.7, A (i) and B), and ~39±1% at higher cell densities (Figure 3.7, A (ii) 
and B), respectively. Taken together, optimal eGFP-hRyR2 expression was achieved 
using lower starting cell densities and a higher DNA: cell ratio, as illustrated in a bar graph, 
Figure 3.7 (B).    
 
Expression levels of WT hRyR2 achieved using the different transfection variables, were 
also assessed by Western Blot analysis (Figure 3.8 A). Consistent with calculations of 
transfection efficiency, cell populations transfected at a lower starting cell density and 
higher DNA: cell ratio (Figure 3.8, A), expressed WT hRyR2 to a significantly higher level 
than in other variable combinations tested, as measured by densitometric analysis (Figure 
3.8, B).  
 
Once optimised, all CaPO4 transfections were carried out using lower starting cell 
densities i.e. 30-40% confluency and transfected using a DNA concentration of 15 pg/cell. 
Since CSQ2 and JUN constructs were untagged, transfection efficiencies of the luminal 
proteins co-expressed with WT/mutant hRyR2 could not be assessed (48 hours post-
transfection) in the same manner as eGFP-hRyR2. Therefore, in addition to Western Blot 
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analysis (section 3.3.6), luminal protein expression was visualised by confocal microscopy 
and immunofluorescent co-localisation (the investigations of protein-protein interactions 
using this method are outlined in Chapter 5, section 5.3.3). As illustrated in Figure 3.9, the 
localisation of hRyR2 (A, (ii) and B (ii)), CSQ2 (A, (iii)) and JUN (B, (iii)) to the ER in 
transfected HEK293 cells could be assessed using this technique. Determination of the 
transfection efficiencies of CSQ2 and JUN  (together with eGFP-hRyR2) detected by 
immunofluorescent labelling is shown in Figures 5.2 and 5.3 in Chapter 5 (described in 
results section 5.3.1).     
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Figure 3.8: Comparison of transfection variables by protein expression, assessed 
by Western Blot analysis. (A) Resolved by SDS-PAGE (50!g of each mixed membrane 
preparation), transient expression of WT hRyR2 was examined by Western blotting, using 
an eGFP-specific mouse-monoclonal anybody. As indicated with an arrow, Western 
signals corresponding to hRyR2 were detected at 565 kDa, which appeared above the 
highest Kaleidoscope™ prestained marker at 250kDa (as shown in the Appendix, Figure 3 
(D)). Protein expression were much higher in cell populations transfected at a lower cell 
confluency and a high DNA:cell ratio, compared to expression detected in other 
preparations, and was in accordance with the higher transfection efficiencies calculated in 
Figure 3.7. Densitometric analyses were carried out on two experiments (following the 
generation of 1 preparation per variable, 4 in total), the results of which are presented in 
(B). Data are presented as the mean±S.E.M. Asterisked data indicates a significant 
difference in the relative densities measured in all other transfected cell populations 
compared with densitometric analysis of Western signals achieved from membrane 
preparations where higher DNA:cell ratios and low starting cell densities were used for 
transfection (one-way ANOVA, ** = p<0.01 and ***=p<0.001 (Tukey-Kramer post test)). 
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Figure 3.9. Immunofluorescent detection of hRyR2, CSQ2 and JUN expression 
confirms ER trafficking. Cells co-expressing eGFP-hRyR2 and CSQ2 or JUN were 
imaged by confocal microscopy (at x63 magnification). WT hRyR2 was visualised using 
eGFP fluorescence (A (ii) and B (ii)) whereas accessory proteins were immunolocalised 
using anti-CSQ2 or anti-JUN antibodies with "-rabbit (CSQ2) or "-mouse (JUN) Alexa-594 
conjugated secondary antibodies, A (iii) and B (iii), repectively. Corresponding phase 
images are shown in A (i) and B (i).  Both eGFP and Alexa 594 signals displayed a reticular 
pattern of fluorescence, indicating trafficking of all membrane proteins to the ER in situ.   
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3.3.6 Successful expression of recombinant hRyR2, CSQ2 and JUN in HEK293 cells 
confirmed by Western Blot analysis: 
 
Prior to investigating the functional regulation and interaction of the luminal proteins with 
hRyR2, it was essential to determine the relative expression levels of each recombinant 
protein in the microsomal membranes, and confirm that full-length eGFP-hRyR2, CSQ2 
and JUN were being expressed. Western analysis confirmed successful co-expression of 
CSQ2 and/or JUN with WT/mutant hRyR2 in HEK293 cells. Figure 3.10 (A) illustrates 
typical bands detected by Western blotting, where sufficient protein expression was 
evident in all the microsomal membrane preparations generated. High levels of transient 
protein expression of (A) WT/mutant hRyR2 (~565kDa), (B) CSQ2 (~45kDa) and/or (C) 
JUN (~26kDa) was evident in all preparations assessed (n=4 blots were generated for 
each recombinant protein). Comparable levels of luminal accessory protein expression 
were seen in all microsomal membrane preparations (Figure 3.10, B). Furthermore, 
transient (co-expressed hRyR2 with CSQ2 and/or JUN) and stable expression of CSQ2 
and JUN were compared (50!g mixed membranes loaded into each lane, Figure 3.11 A, 
(i-iii)). In addition, membrane proteins from untransfected HEK293 cells were loaded 
alongside samples to verify the lack of any endogenous CSQ2 or JUN in HEK293 cells. All 
three stable cell lines appeared to sufficiently express the desired luminal proteins: (i) 
CSQ2 only, (ii) JUN only and (iii) double stables co-expressing CSQ2+JUN. However, 
levels of expression were lower than those achieved by transient expression (expression 
in CSQ2 stables was 23±2.5% less than in mixed membranes transiently expressing 
CSQ2 with WT hRyR2, whilst expression in JUN stables was 24±3% less than in 
membranes transiently expressing JUN with WT hRyR2). As discussed in section 3.3.4, 
the relative expression levels of hRyR2 achieved by transient expression in stable 
HEK293 cells was not sufficient for reliable detection by SDS-PAGE and Western blot 
analysis, and thus were deemed unsuitable for use in [3H] ryanodine binding experiments. 
Therefore, transiently transfected cell populations (Figure 3.10) were used for [3H] 
ryanodine binding experiments (Chapter 4, section 4.3.1), which required prior 
standardisation of hRyR2 expression in all mixed membrane preparations by 
densitometric analysis (described in Chapter 4, Figure 4.4).   
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Figure 3.10: Western Blotting confirms transient expression of hRyR2, CSQ2 and 
JUN in co-transfected HEK293 cells: (A) Representative bands achieved from Western 
blot analysis of (i) hRyR2 (~565kDa), (ii) CSQ2 (~45kDa), and (iii) JUN (~26kDa) 
expression (n=4), detected in the various microsomal membrane preparations generated 
(4 per recombinant protein combination). Original and additional Western blots are shown 
in the Appendix, Figures 3 and 4. (B) Expression levels of CSQ2 and JUN in mutant 
hRyR2 mixed membrane preparations were comparable to WT. Densitometric analysis 
shown here was carried out on Western signals of CSQ2 and JUN expression obtained 
from membranes expressing hRyR2+CSQ2 (i) and hRyR2+JUN (ii), respectively.     
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Figure 3.11: Stable expression of luminal proteins in HEK293 cells confirmed by Western 
Blot analysis: (A) Detected using 50!g of isolated microsomal membranes, Western blotting 
revealed significant protein levels in stable cell lines expressing: (i) CSQ2 only (~45kDa), (ii) JUN 
only (~26kDa) and (iii) CSQ2 (top bands) and JUN (bottom bands) double stables. Representative 
bands were selected from an n=3 blots. It is possible that untransfected HEK293 cells may express 
a small amount of endogenous CSQ2, suggested by the presence of bands at ~45kDa shown in A 
(i). In comparison to transient expression however, the Western signals detected were very low (as 
highlighted in A (iii)). (B) Assessed by densitometric analysis, expression levels of CSQ2 only (i) 
and JUN only (ii) in stable cell lines were less than those achieved with transient expression. 
Nevertheless, the expression levels obtained in stable cell lines were sufficient for use in further 
investigations. *=p<0.05 compared with expression in membranes expressing WT hRyR2+CSQ2 or 
JUN, respectively (one-way ANOVA, Tukey-Kramer post test). It is important to note that these 
differences could reflect the fact that Western signals for transient expression are slightly over-
exposed, leaving room for error with densitometry. However, the blots needed to be left for a longer 
exposure time in order to detect the Western signals for stable expression, thus suggesting 
transient expression is higher.    
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3.4 Discussion:   
 
• In order to assess the response and interaction of WT and mutant hRyR2 channels to 
luminal accessory protein co-expression, pcDNA3.1 hygro(+)-CSQ2 and pcDNA3.1 
hygro(+)-JUN expression constructs were generated and sequence verified. The TRD1 
sequence could not be isolated from the human cardiac library used. 
 
• High-levels of WT/mutant hRyR2 expression and subsequent luminal protein co-
expression in HEK293 cells was achieved by optimising the transfection protocols, 
using transient and stable HEK293 cell lines.  
 
• Successful expression of all recombinant proteins in HEK293 cells was confirmed by 
Western blotting, trafficking to the ER was confirmed by immunofluorescence.    
 
 
3.4.1. Successful generation of human cardiac muscle CSQ2 and JUN mammalian 
expression constructs 
 
Cloning of full-length cDNA encoding CSQ2 (~1200bp) and JUN (~700bp) into the 
mammalian expression vector pcDNA3.1hygro(+) was verified by restriction digest and 
automated sequencing (ABI 3700, Applied Biosystems). Generated constructs displayed 
100% sequence homologies with the known cDNA sequences of human cardiac muscle 
CSQ2 and JUN, respectively (NCBI, Genbank). 
 
Isolation of the open reading frame of human cardiac muscle TRD1 however, proved 
problematic and was hindered by the absence of the published human cardiac muscle 
sequence within the NCBI database at the time this work was carried out. Described in 
section 3.3.1, a series of PCR reactions were carried out using several primer 
combinations designed to target the luminal protein (Figures 3.1, B). Specifically, different 
PCR reverse 3’ primers were used (section 3.3.1), taking into consideration that: (1) the C-
terminus of TRD1 is known to contain numerous positively and negatively charged 
sequence repeats (“KEKE” motifs) which may limit primer specificity and (2) suggestions 
in the literature that each TRD isoform displays a unique C-terminal sequence, which also 
varies between species. As reported by Kobayashi and Jones (1999) the C-terminal 
regions of rabbit (Guo et al., 1996) and dog TRD1 share only ~77% homology, and it is 
likely that the human isoform also diverges from these species with its own unique C-
terminal sequence. In support of this concept, Kobayashi and colleagues (1999) described 
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that poor cross-reactivity was evident when probing human cardiac muscle microsomes 
with an antibody designed to the distinct C-terminal region of dog TRD1, and detection of 
TRD1 in the human preparation was only achieved following the use of five times more 
concentrated antiserum and much longer exposure times (Kobayashi and Jones, 1999). 
 
As shown in Figure 3.2 (B), (i)-(iii), several prospective amplicons were generated and 
subsequently sequenced, but none of which were found to show any homology to cardiac 
TRD1 using a BLAST search (Table 3.3), and manual alignment against the known TRD 
sequences (human skeletal, rabbit and dog cardiac) that were currently published. 
Kobayashi and Jones (1999), also encountered difficulties in isolating full-length cardiac 
TRD isoforms from dog cDNA libraries, where screening identified numerous partial or 
corrupt clones with unrelated sequences ligated adjacent to the correct coding sequence 
of the protein. The group carried out reverse transcription-PCR of dog left ventricle total 
RNA using dog-specific primers to predict the correct size of TRD1 and TRD3. These data 
were subsequently used to eliminate false clones and to confirm the generation of full-
length isolated cDNA of both TRD isoforms, which were assembled from overlapping 
partial clones (Kobayashi and Jones, 1999). 
 
Although released towards the end of the tenure of this project (and thus it was too late to 
obtain the clone), it is important to note here that a sequence corresponding to human 
TRD1 (also known as Trisk 32) is now accessible via the NCBI database (accession 
number: NM_006073.3), published by Roux-Buisson et al in 2012. To formulate this 
sequence, the group identified a sequence in the human TRDN gene that displayed 
significant homologies with the specific cardiac TRD1 sequence in rats. Total RNA was 
extracted from a human cardiac muscle sample obtained from the “Myobank-AFM” tissue 
bank (Paris, France) and the full-length coding sequence amplified by RT-PCR, using a 3’ 
reverse primer designed to the homologous genomic sequence identified in both the rat 
and human TRDN gene, and a 5’ forward primer designed to the first exon of the human 
TRDN gene. Using the same primers, the amplified transcript was bidirectionally 
sequenced and although differing in the specific C-terminal region (as also reported by 
Kobayashi and Jones, 1999), displayed significant homologies to rat, rabbit and dog 
protein sequences (Roux-Buisson et al., 2012). The potential TRD1 sequences obtained 
in this investigation were subsequently aligned against this new sequence, but no 
significant homologies were identified. 
 
Due to the difficulties encountered isolating human TRD1 from the cardiac cDNA library, 
the remainder of this project focussed solely on the functional effects and interactions of 
WT and mutant hRyR2 with luminal accessory proteins CSQ2 and JUN. The use of 
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cardiac TRD1 isolated from a different species was not favoured, since some 
investigations of luminal accessory protein function have reported species variability (Wei 
et al., 2009b, Qin et al., 2008). 
 
 
3.4.2 Optimised co-expression of hRyR2 channels with CSQ2 and JUN in transient 
and stable HEK293 cell lines 
 
By comparison of two calcium phosphate precipitation methods (section 3.2.3), a modified 
transfection protocol was established, and subsequently used to routinely achieve high 
transfection efficiencies. Representative images taken 48 hours post-transfection are 
shown in Figure 3.7 (A), following transfection of WT hRyR2 into HEK293 cells using 
different starting cell densities and DNA: cell ratio (section 3.3.5). As used in Jiang et al., 
2002, the use of lower starting cell densities was found to prevent over-confluence and 
provided a greater surface area over which DNA precipitates could be endocytosed. 
Furthermore, although using higher concentrations of DNA can enhance cytotoxicity, 
transfecting with 15 pg DNA/cell (providing the cells with a greater concentration of DNA 
for uptake) was found to yield significantly higher transfection efficiencies of 51±3%, 
achieved in combination with a low starting cell density. In agreement with the higher 
transfection efficiencies calculated, WT hRyR2 protein expression was found to be 
significantly higher in these cell populations as assessed by densitometric analysis of 
Western blot signals (Figure 3.8, A and B).  
 
Using the optimised transfection protocol, different combinations of the luminal accessory 
proteins CSQ2 and JUN, were transiently co-expressed with WT or mutant hRyR2 in an 
equimolar ratio (Table 3.1). Using this approach, CSQ2 and JUN constructs were 
expressed both individually and in combination (CSQ2+JUN) with hRyR2 channels. 
Transfection efficiency 48 hours post-transfection could only be monitored via eGFP 
expression (detection of hRyR2), since the luminal accessory proteins were untagged, 
however the efficiencies achieved were comparable to those obtained when hRyR2 
channels were expressed alone, suggesting that co-expression of all recombinant proteins 
did not cause any cytotoxic effects. In addition, WT and mutant hRyR2 expression yielded 
similar transfection efficiencies  (see Appendix, Figure 2).  
 
HEK293 cells stably expressing CSQ2, JUN and CSQ2+JUN (double stables) were also 
generated. Attributed to constitutive expression of the target genes and the pressures of 
antibiotic selection, cell proliferation was found to be much slower in stable cell lines 
compared to untransfected HEK293 cells (Figure 3.5, A). Consequently, using CaPO4 
 102 
mediated transfection, hRyR2 expression was found to be much lower in the stable cell 
lines (Figure 3.5, B) and expression could not be clearly visualised by SDS-PAGE and 
Western Blotting. These cells were therefore considered unsuitable for applications where 
high levels of recombinant hRyR2 were required (e.g., for [3H] ryanodine binding, where 
sufficient counts can only be achieved using large quantities of RyR2 channels, see 
section 4.2.1). However, the stable cell lines were essential for single-cell Ca2+ imaging, 
where experiments require that all cells express both hRyR2 and the luminal protein of 
interest. As described in Chapter 5, stable cells expressing the luminal proteins which 
were also transfected with hRyR2 could be identified by the occurrence of spontaneous 
Ca2+ release events, (Jiang et al., 2004, MacLennan and Chen, 2009), which do not occur 
in the absence of hRyR2 channels.  
 
Therefore, to eliminate the potentially cytotoxic effects of the CaPO4 precipitation method 
which could diminish cell viability (Jordan and Wurm, 2004), a commercially available 
Effectene® (lipid-mediated) transfection reagent was used to introduce WT and mutant 
hRyR2 into HEK293 cells stably expressing the luminal proteins (section 2.4.2.3). Using 
this transfection reagent proved more suitable to maximise hRyR2 expression in stable 
cell lines (as demonstrated in Figure 3.6, A). This method however was not used for large-
scale transfections, since the overall protein expression generated was lower than that 
achieved when hRyR2 was transfected into normal HEK293 cells by the optimised CaPO4 
precipitation method (Figure 3.6, B). There are however limitations of using HEK cells with 
transient expression of the luminal proteins with hRyR2, since the existence of mixed 
populations of complexes are possible. For example, in cells transiently expressing 
hRyR2+JUN, there may be cells within the preparation that only express hRyR2 (though 
these will be few due to the overwhelmingly higher transfection efficiency of the accessory 
proteins, see section 5.3.1) and a larger population of cells that just express JUN. This will 
thus need to be considered when assessing the response of WT/mutant hRyR2 to luminal 
protein co-expression. Shown later in Chapter 5, Figures 5.2 and 5.3, immunofluorescent 
co-localisation studies suggest that high levels of hRyR2 and luminal protein expression 
were achieved and the given proteins of interest were predominantly expressed within the 
same cells of a population.   
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3.4.3 Western blot analysis of recombinant protein expression in HEK293 cells 
 
Western blot analysis of mixed membrane preparations from transfected HEK293 cell 
populations (section 2.4.3.3-2.4.3.4), confirmed that full-length recombinant proteins were 
being expressed (hRyR2 detected at ~565kDa, CSQ2 at ~45kDa and JUN at ~26kDa). As 
highlighted in Figure 3.10 (A), high levels of transient WT and mutant hRyR2 expression in 
the absence or presence of CSQ2 and JUN was achieved. Furthermore, mutant hRyR2 
expression did not affect the expression levels of the luminal proteins (Figure 3.10, B).  
The luminal proteins were also expressed in sufficient quantities in stable HEK293 cell 
populations (CSQ2, JUN and CSQ2+JUN), as demonstrated in Figure 3.11. Described in 
Chapter 4, densitometric analysis of Western signals was used to standardise hRyR2 
expression in all test samples before further investigation.  
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Chapter 4 
 
Influence of cardiac CSQ2 and 
JUN on the intracellular Ca2+ 
regulation of WT and mutant 
hRyR2 
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4.1 Introduction: 
 
4.1.1. Regulation of RyR2-mediated Ca2+ release by luminal accessory proteins at 
the junctional domain of the SR membrane: 
 
Intracellular Ca2+ release from the SR store through RyR2 channels is a crucial event 
during EC coupling, which must be carefully regulated for normal contraction and 
subsequent relaxation of the mammalian heart (Bers, 2004; Thomas et al., 2004; Györke 
and Terentyev 2007). As discussed in previous chapters, it is well known that RyR2 
activation is governed not only by cytosolic Ca2+, but also by Ca2+ accumulated within the 
SR lumen, where small increases in luminal Ca2+ load generate large elevations in Ca2+ 
release (Györke and Györke, 1998; Ching et al., 2000, Shannon et al., 2005; Radwanski 
et al., 2013). Situated within the SR membrane, the SERCA2a pump (Figure 1.1, A) is 
responsible for raising the free intra-SR luminal Ca2+ concentration close to 1 mM (Beard 
et al., 2005, Györke et al., 2008, Stevens et al., 2009) and acts in tandem with the luminal 
accessory protein CSQ2. This Ca2+ storage molecule acts as a major luminal Ca2+ buffer, 
which indirectly regulates RyR2 function by altering the releasable (free) Ca2+ 
concentration within the SR (Györke and Terentyev 2007; Gaburjakova et al., 2013).  
 
Independent of its role in global SR Ca2+ buffering, a growing number of investigations 
have suggested that CSQ2 also has the ability to directly regulate channel activity 
(Shannon et al., 2005, Györke, 2009, Terentyev et al., 2006). First proposed by Györke et 
al (2004), it is now believed that a quaternary complex assembles at the jSR membrane 
between RyR2, CSQ2 and two SR transmembrane proteins JUN and TRD1, and forms a 
putative luminal Ca2+ sensor which responds to changes in SR Ca2+ load and modulates 
RyR2 activity accordingly (Zhang et al., 1997; Györke et al., 2004; Terentyev et al., 2003b; 
Beard et al., 2005). Györke et al (2004) used recombinant dog cardiac CSQ2 (Kobayashi 
et al., 2000), JUN (Zhang et al., 1997) and TRD1 (Kobayashi and Jones, 1999) to 
examine the potential role of the luminal proteins in conferring RyR2 luminal [Ca2+] 
sensitivity. Purified RyR2 channels reconstituted in a lipid bilayer system were reported by 
Györke et al (2004) to be unresponsive to changes in luminal Ca2+ (ranging from 20 !M-5 
mM), and luminal Ca2+ sensing was only restored in the presence of the accessory 
proteins. Upon adding CSQ2 back to the luminal side of the channel, it was reported that 
RyR2 activity was inhibited, but only at low luminal [Ca2+] <20 !M, and in the presence of 
JUN and TRD1. This inhibition is important, since in CPVT2, CSQ2 mutation cause RyR2 
channels to display a short refractory period before release (Terentyev et al., 2006). 
Furthermore, JUN and TRD1 added back to the purified channels alone (in the absence of 
CSQ2) enhanced channel open probability, suggesting an additional activatory role of the 
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two proteins (Györke et al., 2004). Taking into account that CSQ2-RyR2 regulation 
appeared luminal Ca2+ dependent, the group concluded that the intracellular Ca2+ binding 
protein (via its associations with JUN and TRD1) acts to mediate the ability of RyR2 
channels to respond to luminal Ca2+(Györke et al., 2004). However, the individual 
contributions of JUN or TRD1 to the CSQ2-RyR2 functional interaction (since both were 
added back to the channel complex together) was not addressed in this work, or the 
potential of each protein as direct modulators of RyR2 activity established (Altschafl et al., 
2011; Dulhunty et al., 2012; Gaburjakova et al., 2013). Interestingly, a later single channel 
investigation using skeletal CSQ1, demonstrated that the inhibitory action of the accessory 
protein on RyR1 activity was only seen when expressed in the presence of JUN, leading 
to suggestions that JUN acts distinctively from TRD1, which was also investigated (Beard 
et al., 2009, Dulhunty et al., 2009).   
 
Although evidence is limited with regards to the role that JUN plays in mediating the 
effects of luminal Ca2+ on RyR2 function (Radwañski et al., 2013), the physiological 
importance of the luminal protein to Ca2+ release activity has been highlighted in animal 
models. For example, in adult rat cardiomyocytes with acute downregulation of JUN 
(~40%), (Fan et al., 2008) and in a mouse model with JUN ablation (Yuan et al., 2007), 
the frequency and amplitude of Ca2+ sparks and contractility within isolated 
cardiomyocytes were enhanced, which consequently increased the propensity for 
triggered arrhythmias and SCD. In both models, there were no notable alterations in the 
expression of other Ca2+ handling proteins (e.g., CSQ2 or RyR2), which led to the 
assumption that the effects seen were exclusively due to downregulation/ablation of 
cardiac JUN (Fan et al., 2008, Yuan et al., 2007). This may suggest that JUN has an 
inhibitory effect on RyR2 function or that it enhances the inhibitory effects of CSQ2, as 
discussed previously (Györke et al., 2004, Miller et al., 2005). This however requires 
further investigation, and will be explored in this project using single cell Ca2+ imaging.  
 
Mutations in RyR2 and CSQ2 are both implicated in the development of CPVT and 
defective luminal Ca2+ sensing is a candidate mechanism of disease pathogenesis (Priori 
and Chen 2011; Jiang et al., 2005). Since the RyR2 channels response to changes in 
luminal [Ca2+] appears to be modified by the luminal accessory proteins, a better 
understanding of how each luminal protein contributes to Ca2+ release function could also 
reveal alterations that might occur as a result of mutation. For example, although no 
CPVT-linked mutations in JUN have currently been identified, changes in the levels of 
JUN expression led to an increased incidence of arrhythmia, a symptom that defines 
CPVT (Altschafl et al., 2011; Yuan et al., 2007). In addition, CSQ2 mutations have been 
proposed to alter the proteins ability to modulate RyR2 luminal Ca2+ sensitivity (for 
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example, the R33Q mutant studied by Houle et al., 2004, Terentyev et al., 2006) or reduce 
the luminal Ca2+ buffering capacity within the SR (D307H mutant, examined by 
Viatchenko-Karpinski et al., 2004). It however remains to be elucidated whether RyR2 
mutation can alter the way in which the channels respond to luminal accessory proteins or 
whether association of the complex with RyR2 is disrupted by the mutation.  
 
4.1.2. Spontaneous Ca2+ release events in CPVT: 
 
Arrhythmogenic episodes in CPVT occur during times of physical or emotional stress, i.e., 
when the levels of circulating catecholamines are high and the ß-AR signalling cascade is 
activated (Priori et al., 2002). Known as the “fight or flight” response, increased cardiac 
output is required to meet the higher metabolic demands of the heart during periods of 
stress, and subsequently improves contractile force (Marx and Marks, 2013). Discussed 
further in Chapter 1 (section 1.2.5) stimulation of the ß-AR pathway causes dissociation of 
PLB from the SERCA2a pump, which relieves inhibition and speeds up Ca2+ re-uptake into 
the SR. As a consequence, the SR Ca2+ load is increased and thus the amount of 
releasable Ca2+ available during subsequent action potentials is enhanced. If however, SR 
Ca2+ content reaches a particular level, spontaneous Ca2+ release through RyR2 channels 
can occur in the form of Ca2+ oscillations, a phenomenon now known as “Store-Overload 
Induced Calcium Release” or SOICR (Jiang et al., 2004, Venetucci et al., 2008). In view of 
the association between Ca2+ overload, DADs and CPVT, disease-causing mutations have 
been suggested to reduced the threshold for SOICR occurrence, which in turn increases 
the susceptibility for arrhythmogenesis (Priori and Chen 2011).  
 
4.1.3. CPVT-associated mutations enhance the sensitivity of ryanodine receptors to 
Ca2+ activation: 
 
A co-ordinated change in Ca2+ concentration on both the cytosolic and luminal side of the 
jSR membrane is responsible for regulating Ca2+ release through RyR2 channels. As 
illustrated in Figure 4.1, Jiang et al (2004, 2005) proposed that in disease states such as 
CPVT, mutation causes an enhanced sensitivity of RyR2 channels to luminal Ca2+, which 
as a consequence, lowers the threshold SR Ca2+ load at which SOICR occurs. The group 
examined a number of RyR2 (recombinant mouse) mutations spanning the length of the 
protein, expressed in HEK293 cells, including the mutation studied in this project, N4104K 
(located in the C-terminal region), (Jiang et al., 2004, 2005). Using single-cell Ca2+ 
imaging, all mutations were found to enhance the frequency of spontaneous Ca2+ 
oscillations, resulting in a decrease in the ER Ca2+ store (measured by caffeine-induced 
Ca2+ release). Compared with WT RyR2 at the single channel level, mutant RyR2 
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channels displayed an increased open probability in response to luminal Ca2+, (Jiang et 
al., 2004, 2005). Consistent with this observation, Ca2+ oscillations were evident at lower 
extracellular Ca2+ concentrations in mutant expressing cells, leading to suggestions that 
spontaneous Ca2+ release manifests at a reduced ER load in CPVT. This may also explain 
how enhanced SOICR occurs with mutant RyR2 expression, despite an observed 
reduction in the SR Ca2+ content (Jiang et al., 2005). Measured using [3H]-ryanodine 
binding, mutant and WT RyR2 channels responded equivalently to activating Ca2+, which 
predominantly reflects the channel’s sensitivity to cytosolic Ca2+ (Jiang et al., 2005). A 
recent publication by Chen et al (2014) reported the discovery of a key residue (E4872) 
which may comprise the inherent luminal Ca2+ sensor of RyR2, located within the region of 
the proposed Ca2+ sensing gate (helix bundle crossing region). HEK293 cells expressing a 
mutation of this residue, E4872Q, displayed no SOICR activity, highlighting its involvement 
in sensing SR Ca2+ content. In addition, knock-in of the E4872Q mutation into a mouse 
model expressing the CPVT-mutant R4496C protected the animals against stress-induced 
arrhythmia (Chen et al., 2014). To distinguish this mechanism from that of the CSQ2-
based luminal Ca2+ sensor, the effects of RyR2 E4872Q were also examined in CSQ2-
knockout mice (Zhang et al., 2014), where comparable to the aforementioned findings, the 
mutant eliminated spontaneous Ca2+ release and triggered arrhythmia. Currently, the 
interplay between the luminal Ca2+ sensor formed by the luminal accessory proteins and 
the RyR2-resident sites remains unexplored (Chen et al., 2014).   
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The heterogeneous nature of RyR2 mutant dysfunction, first proposed by Thomas et al., 
2004, was highlighted in a more recent investigation by Loaiza et al (2013), where it was 
demonstrated that a CPVT-linked mutant, V2475F, displayed enhanced sensitivity to both 
cytosolic and luminal Ca2+ regulation. Compared with WT channels, the RyR2 mutant 
exhibited sensitised activation by increasing concentrations of cytosolic Ca2+, established 
using a [3H]-ryanodine binding assay. Interestingly, as found by Jiang et al (2005), the 
V2475F mutation also displayed a pronounced responsiveness to changes in luminal Ca2+ 
(measured by single channel recordings). However, when WT and mutant channels were 
expressed in HEK293 cells (as in Jiang et al., 2004, 2005) no differences in the SOICR 
threshold were evident. An earlier investigation by Meli et al (2011) reported that luminal 
Ca2+ sensing is not defective in CPVT and demonstrated that the RyR2 mutation G230C 
exclusively displays enhanced sensitivity to cytosolic Ca2+. However, characterising the 
same mutation, Liu et al (2013) provided evidence of an enhanced propensity for SOICR 
occurrence. This thus highlights the need to assess the functional alterations of RyR2 
mutants in more than one experimental system and further demonstrates the complexity in 
Figure 4.1: Schematic of the store-overload induced Ca2+ release (SOICR) 
mechanism hypothesised for CPVT mutants: When normal RyR2 are 
expressed in cardiomyocytes, the levels of free SR luminal Ca2+ (blue shading), 
largely regulated by CSQ2, is below the normal threshold for spontaneous Ca2+ 
release (solid red line, panel A), thus there is no SOICR activity (panel A). Upon 
ß-AR stimulation under conditions such as stress or exercise, when the levels of 
free luminal Ca2+ are elevated (orange shading) by enhanced SERCA2a actvity, 
the SR Ca2+ level under normal conditions still remains below the SOICR 
threshold (Panel A, right). It is however hypothesised that as a consequence of 
RyR2 mutation, the threshold for SOICR occurrence is reduced (panel B, reduced 
threshold indicated by solid red line, normal SOICR threshold dashed red line). 
Therefore, under stimulated conditions the raised free luminal Ca2+ exceeds the 
SOICR threshold (orange shading, panel B, right) and spontaneous Ca2+ release 
is generated, greatly increasing the propensity for DADs and triggered 
arrhythmias. Image modified from Jiang et al., 2004.   
 
 
RyR2 mutations, by reducing the threshold for SOICR as a result
of enhancing luminal Ca2! activation, increase the susceptibility to
VT and sudden death under conditions of Ca2! overload. Our
findings link defective luminal Ca2! activation of RyR2 to VT and
sudden death and suggest RyR2 luminal Ca2! activation as an
alternative target for antiarrhythmic treatment.
Recapitulation of Cardiac SOICR in HEK293 Cells. Investigation of the
causative mechanisms of CPVT has been hampered by the lack
of animal models for CPVT and methods for introducing large
DNA such as the RyR2 cDNA ("15 kb long) into cardiac
myocytes. The present study demonstrates that HEK293 cells
expressing RyR2 could be used as an alternative means to
investigate the behavior of RyR2 under conditions of Ca2!
overload and the molecular basis of CPVT RyR2 mutations. We
have shown that, despite the lack of a number of cardiac-specific
Ca2! handling proteins, HEK293 cells expressing RyR2 produce
SOICR at elevated [Ca2!]o in a manner virtually identical to that
observed in cardiac cells (Fig. 1). We have also shown that
HEK293 cells not expressing RyR2 do not display SOICR at
elevated [Ca2!]o (Fig. 1). These observations indicate that RyR2
is essential for SOICR, and that SOICR is not unique to cardiac
cells; rather, it reflects the intrinsic properties of RyR2. Hence,
HEK293 cells expressing RyR2 provide a readily accessible cell
model for molecular analysis of the impact of various CPVT
RyR2 mutations on SOICR.
RyR2, a Critical Determinant of the SOICR Threshold. It is well
documented that elevated [Ca2!]o produces SR Ca2! overload,
and that once a threshold level of SR Ca2! content is reached,
SOICR occurs. Interestingly, further Ca2! loading has no effect
on SR Ca2! content. SR Ca2! content increases only when there
is no SOICR (24). Essentially the same relationship between
store Ca2! content and SOICR was observed in HEK293 cells
expressing RyR2 (Fig. 1). It is also known that the activity of
RyR2 influences the threshold for SOICR in cardiac myocytes.
For instance, modest activation of RyR2 by caffeine reduced the
threshold for SOICR and SR Ca2! content, although moderate
inhibition of RyR2 by tetracaine increased both the threshold for
SOICR and SR Ca2! content (26, 27). Consistent with this view,
we have shown that mutations in RyR2, N4104K, R4496C, and
N4895D increased the occurrence of SOICR and the frequency
of Ca2! oscillations and reduced the store Ca2! content (Fig. 2).
Taken together, these observations suggest that RyR2 is a critical
determinant of the threshold for SOICR and consequently for
the SR Ca2! content.
Molecular Mechanisms Underlying the Action of CPVT RyR2Mutations.
How do CPVT RyR2 mutations alter the threshold for SOICR?
Given that SOICR is triggered by SR Ca2! overload, and that
elevated SR luminal Ca2! activates RyR2 (28, 29), it is likely that
CPVT RyR2 mutations alter the channel sensitivity to activation
by luminal Ca2!. In support of this view, we obtained direct
evidence that the RyR2 mutations N4104K, R4496C, and
N4895D substantially increased the channel sensitivity to acti-
vation by luminal Ca2! (Fig. 3). However, it remains to be
determined how these CPVT mutations exert their effects on
RyR2 luminal Ca2! activation. One possibility is that CPVT
RyR2 mutations affect domain–domain interactions in RyR2
that mediate luminal Ca2! activation. CPVT mutations are
largely clustered in three domains of RyR2 (21). It has been
proposed that interactions among these domains are involved in
conformational changes associated with channel gating (30). It
is possible that mutations in these domains may weaken the
interactions among them and destabilize the closed state of the
channel, rendering the channel more sensitive to activation by
stimuli. Consistent with this, we found that CPVT RyR2 muta-
tions enhanced basal channel activity (Fig. 4). Another possi-
bility is that CPVT RyR2 mutations affect protein–protein
interactions among RyR2 and its associated proteins such as
FKBP12.6, CASQ2, triadi , and junctin, which may regulate
luminal Ca2! activat on. Wehrens et al. (31) have shown that
CPVT RyR2 mutations reduced the affinity of FKBP12.6 bind-
ing. On the contrary, however, George et al. (32) have recently
demonstrated that CPVT RyR2 mutations augmented SR Ca2!
release in a manner independent of FKBP12.6. Thus, whether
CPVT RyR2 mutations alter FKBP12.6 binding requires addi-
tional investigations. Regardless of what the exact molecular
mechanisms might be, abnormal RyR2 luminal Ca2! activation
may underlie the ultimate outcome of CPVT RyR2 mutations.
A detailed understanding of the molecular basis and regulatory
mechanism of RyR2 luminal Ca2! activation will be necessary to
appreciate the precise impact of CPVT RyR2 mutations.
A Proposed Model of CPVT. Based on the results of the present
study and those of previous investigations, we propose a simple
model to account for CPVT (Fig. 5). In this model, we hypoth-
esize that the threshold for SOICR is primarily determined by
RyR2. In normal SR, the threshold for SOICR is higher than the
SR free Ca2! level under both resting and stimulated conditions
(catecholamines or stresses). Therefore, there is little or no Ca2!
spillover from the normal SR in either the resting or stimulated
states (Fig. 5A). On the other hand, in the CPVT SR, the
threshold for SOICR is reduced by mutations in the RyR2
channel. Under resting conditions, the reduced threshold for
SOICR is still higher than the resting SR free Ca2! level, so that
there is little or no Ca2! spillover. However, under stimulated
conditions, the CPVT SR is abruptly overloaded with Ca2!.
Becaus of the reduced threshold, SOICR will be more likely to
Fig. 5. Aproposedmechanism for CPVTassociatedwithRyR2mutations. The
relationship between the threshold for SOICR and the SR-free Ca2! level in
normal (A) andCPVT SR (B) in the resting and stimulated states is schematically
shown. The threshold for SOICR, which is primarily determined by RyR2, is
depictedby a redbar. Note that the threshold for SOICR is reduced in theCPVT
SR as a consequence of the RyR2 mutations. The SR free Ca2! level, which is
predominantly determined by CASQ2, is represented by the blue area. Note
that the resting level of SR-free Ca2! in the CPVT SR might have adapted to a
reduced level due to the existence of SR autoregulation (33). An abrupt
increase of SR-free Ca2! as a result of stimulations by catecholamines or
stresses is depictedby the yellowarea.When the SR-freeCa2! level reaches the
SOICR threshold, SOICR occurs, leading to a large SR Ca2! spillover, which in
turn can generate DAD and triggered arrhythmia.
13066 ! www.pnas.org"cgi"doi"10.1073"pnas.0402388101 Jiang et al.
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deciphering the mechanism behind channel dysfunction. Since the studies by Jiang et al 
(2004) and Loaiza et al (2013) used purified mouse RyR2 channels and expression in 
HEK293 cells, which are devoid of accessory proteins, the altered sensitivity of RyR2 
mutants to luminal/cytosolic Ca2+ could not be attributed to changes in channel modulation 
by the CSQ2-mediated luminal Ca2+ sensor. However, given the proposed role of the 
proteins in regulating RyR2 channel activity and the fact that CSQ2 mutations can also 
cause the CPVT phenotype (Houle et al., 2004), alterations in the function of these 
proteins may also contribute to defective RyR2 luminal Ca2+ sensing and thus needs to be 
investigated.    
 
4.1.4. Chapter Aims  
 
Luminal regulation of Ca2+ release through RyR2 channels is thought to be influenced both 
by the sensitivity of RyR2 channels themselves to activating luminal [Ca2+] (Laver et al., 
2007) and it’s ensuing effect on cytosolic Ca2+ sensitivity; and via interaction with the 
luminal accessory proteins CSQ2, JUN and/or TRD1 (Györke and Györke, 1998). It is 
possible that two luminal Ca2+ sensing mechanisms exist to regulate RyR2 function, one of 
which forms part of the RyR2 channel itself (Chen et al., 2014) and the other composed of 
the luminal accessory proteins interacting with the Ca2+ release channels (Györke and 
Györke, 1998, Wei et al., 2009b).  
 
Since it is unknown how RyR2 mutation could affect luminal accessory protein regulation, 
the behaviour of mutant channels with CSQ2 and/or JUN co-expression has been 
evaluated, and directly compared with findings using WT hRyR2. Cytosolic and luminal 
Ca2+ regulation of WT and mutant (A4556T and N4104K) channels will be examined in this 
chapter, since the two are ultimately linked.  
 
In the absence and presence of luminal accessory proteins CSQ2 and JUN, WT and 
mutant hRyR2 channel regulation by Ca2+ has been assessed as follows:  
 
• Quantitative [3H]-ryanodine binding experiments were used to evaluate the cytosolic 
Ca2+ activation profile of WT and CPVT-linked mutant RyR2 channels in the 
presence/absence of CSQ2 and/or JUN. Used extensively as an effective agent to 
examine RyR2 function, [3H] ryanodine will only bind RyR channels in their open 
conformation and thus acts as a surrogate marker of channel activity (Meissner et al., 
1988, Li and Chen, 2001, Jiang et al., 2005).  
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• Since the term SOICR, is somewhat of a misnomer, as it refers to a lowered threshold 
for spontaneous Ca2+ release as opposed to actual store overload, the Ca2+ oscillations 
analysed in this investigation will be referred to as spontaneous Ca2+ release (SCR) 
events. Using single cell Ca2+ imaging, the parameters of SCR events (such as 
amplitude, duration and frequency) were monitored to establish luminal Ca2+ effects, 
where a direct comparison was made between HEK293 cells expressing WT/mutant 
RyR2 channels alone or in the presence of accessory proteins (achieved using stable 
cell lines expressing CSQ2, JUN or CSQ2+JUN). This technique was first used to 
establish if WT and mutant RyR2 are activated differently by luminal Ca2+. The 
responses of WT and mutant channels to luminal accessory protein co-expression were 
then compared.  
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4.2 Methods: 
 
4.2.1. Optimisation of the quantitative [3H]-ryanodine binding assay: 
 
A series of [3H] ryanodine binding reactions (further details described in Chapter 2, section 
2.4.3.5, Figure 2.4) were used to test a range of different protein concentrations (50-
200!g), where each binding assay included 10nM [3H] ryanodine, prepared to a final 
volume of 500!l with a binding buffer designed to optimise the open probability of RyR2 
channels (containing 1M KCl, 100!M Ca2+ and 25mM PIPES (pH 7.4)). To distinguish any 
non-specific binding, 1000-fold excess ‘cold’, unlabelled ryanodine (10!M) was added to 
control samples. Liquid scintillation counting was used to quantify [3H]-ryanodine binding 
data, where the counts achieved were measured in decays (or disintegrations) per minute 
(dpm). Subtraction of the non-specific counts achieved in control samples (in the presence 
of excess unlabelled ryanodine) from the total counts obtained in the test samples (using 
the same protein concentration) was used to calculate specific [3H] ryanodine binding (for 
example, if a control sample yielded 2000dpm and a test sample 8000dpm, specific [3H] 
ryanodine binding was calculated as 6000dpm). In preliminary investigations, the same 
assay was also carried out using two native sources (rabbit skeletal and rat cardiac heavy 
SR membranes) where it could be guaranteed that RyR was being expressed to a very 
high level. The data established using the native material was subsequently used to gauge 
the expression levels achieved using recombinant protein, by measurement of the specific 
[3H] ryanodine bound, in pmol/mg of protein.   
 
4.2.1.1. [3H] ryanodine binding as a measurement of hRyR2 Ca2+ activation: 
 
A suitable range of Ca2+ concentrations for hRyR2 activation (0-500!M (Mukherjee et al., 
2012)) was achieved by accurately buffering stock binding solutions with three Ca2+ 
chelators: EGTA, HEDTA and NTA (see abbreviations table, Patton, 2004). To achieve a 
given free Ca2+ concentration, the appropriate amounts of CaCl2 to add to stock binding 
buffer (in the presence of 1mM of each Ca2+ chelator) were calculated using the 
Maxchelator software (http://www.standford.edu/~cpatton/maxc.html). Prior to using 
recombinant protein, the Ca2+ activation assay was tested using a native sample, as with 
previous optimisation (section 4.3.1). 
 
To establish enough material for further investigations, 48 microsomal membrane 
preparations were generated in total (n=4 per protein combination). The following eGFP-
hRyR2 and luminal protein combinations were produced: (1) WT hRyR2 alone or in the 
presence of CSQ2 and/or JUN, (2) A4556T hRyR2 alone or in the presence of CSQ2 
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and/or JUN and (3) N4104K hRyR2 alone or in the presence of CSQ2 and/or JUN. 
Harvest of  ~100x106 transfected HEK293 cells was required to generate each mixed 
membrane sample, which typically yielded a protein concentration of 4-6 mg/ml 
(established using a BCA protein assay). To undertake each [3H] ryanodine binding Ca2+ 
activation assay in duplicate, approximately 4.4 mg of protein was necessary (calculated 
based on the use of 100 !g per reaction). 
 
Densitometric analysis of Western blot signals was used to standardise expression levels 
of WT/mutant hRyR2 from each mixed membrane preparation, i.e., a representative 
WThRyR2 sample was used as a densitometric control, ensuring all test samples were 
standardised for hRyR2 expression prior to use in Ca2+ activation experiments. Each [3H] 
ryanodine binding Ca2+ activation curve was fitted using non-linear regression (variable 
slope) and statistically compared using the extra-sum of squares F-test (GraphPad Prism).   
 
 
4.2.2. Examination of spontaneous Ca2+ release properties using single cell Ca2+ 
imaging: 
 
Generation of stable HEK293 cell lines, Effectene®-mediated transfection and loading of 
cells with Fluo3-AM are described in Chapter 2 (sections 2.4.2.3 and 2.4.3.8-2.4.3.9). Prior 
to confocal imaging, mDMEM was removed from the loaded cells and replaced with a 
200!l meniscus of Krebs-Ringer-Hepes (KRH) buffer, supplemented with 1.3 mM Ca2+. As 
demonstrated by Jiang et al., 2004, raising the external Ca2+ around HEK293 cells is an 
effective way to induce SOICR-events. This is an intrinsic property of RyR2 channels 
(Jiang et al., 2004), since untransfected HEK cells loaded with Fluo3-AM did not display 
any SOICR-like events (as shown in the Appendix, Figure 5). 
 
The transfected cells were imaged using a laser scanning confocal microscope (Leica 
SP5, Leica, Heidelberg, Germany), with an oil immersion, 63x magnification objective lens 
and an argon laser, controlled with Leica software. Ca2+ dependent Fluo3-AM 
fluorescence was visualised by excitation at 488 nm and fluorescence emission detected 
over a range of 520±28 nm. Using Leica LAS AF confocal software (Leica Microsystems), 
data were collected over 2 minute recordings (5 frames/second) at 512 x 512 pixel 
resolution. Acquired as regions of interest (ROIs), all cells displaying SCR-activity 
(visualised as cell oscillations) representing global Ca2+ environments, or caffeine-
dependent Ca2+ release, were selected. All collated data were exported to Microsoft Excel 
for further analysis and statistical differences calculated using one-way ANOVA and a 
Tukey-Kramer post-test (GraphPad prism). Outliers in the collected data were identified 
using the GraphPad prism Grubbs’ test (column scatter plots of all collected data are 
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shown in the Appendix, Figure 6). Illustrated in Figure 4.2, all properties of the Ca2+ SCR 
events were examined as follows:  
 
1. Basal Signal Intensity: The basal signal intensity (F0) was measured by taking a 
mean of the fluorescence values between each SCR event (inter-SCR). F0 is 
highlighted by a dashed line in Figure 4.2 (A).  
 
2. Amplitude: Subtraction of the average inter-SCR basal signal intensity (F0) from 
peak signal intensity (F) of each event was used to determine SCR amplitude (F-
F0). F is indicated with a green arrow in Figure 4.2 (A) and (B). The amplitude was 
expressed as a proportion of the basal signal intensity (F-F0/F0, denoted as !F/F0). 
 
3. Duration: Measured in seconds (s), the duration of each SCR event was 
established by obtaining the difference between the time at which the SCR-event 
was initiated and the time when the signal intensity returns to basal levels (F0). The 
SCR event start  (red arrow) and end (brown arrow) are highlighted in Figure 4.2 
(A).  
 
4. Rate of Ca2+ Release: The rate of Ca2+ release is expressed as a change in the 
signal intensity over time (("F/F0)sec-1). Firstly, the time taken to reach peak Ca2+ 
levels was established by subtracting the time at which the SCR-event was 
initiated from the time taken to reach peak signal intensity. To calculate the rate at 
which spontaneous Ca2+ release occurred, the amplitude of the SCR event (F-
F0/F0) was divided by the time taken to reach peak Ca2+ levels.  
 
5. Rate of Ca2+ Decay: The rate of Ca2+ decay is also expressed as a change in the 
signal intensity over time (("F/F0)sec-1). The time taken for the Ca2+ peak to return 
to F0 was first established by subtracting the time at peak signal intensity from the 
time taken for the SCR-event to return to baseline levels (SCR end, indicated with 
a brown arrow in Figure 4.2 (A)). To calculate the rate at which spontaneous Ca2+ 
release decayed (indicative of it’s removal from the cytosol), the amplitude of the 
SCR event (F-F0/F0) was divided by the time taken for the signal intensity to return 
back to basal levels.   
 
6. Inter-SCR Duration: Measured in seconds (s), the inter-SCR duration 
(representing the time period in between each SCR-event) was established by 
taking the time at which a new SCR-event occurred and subtracting from it the time 
at which the previous event ended and returned to baseline.  
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7. Frequency of events: Measured as SCR-events per minute, the frequency was 
determined by first adding together the SCR event duration and the inter-SCR 
duration, which established in seconds is the duration of a full SCR-event, and 
subsequently calculating the occurrence of these events per minute.  
 
8. Estimation of ER Ca2+ load: Demonstrated in Figure 4.2 (B), ER Ca2+ load was 
estimated by calculating the Ca2+ release amplitude induced by caffeine application 
(10mM, dissolved in KRH).  Subtraction of the average basal signal intensity (F0) 
from peak signal intensity (F) was used to determine the SCR event amplitude (F-
F0). F is indicated in (B) with a green arrow. The amplitude was subsequently 
expressed as a proportion of the basal signal intensity. 
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Figure 4.2: Illustration of the SCR kinetic parameters measured in transfected 
HEK293 cells: A representative trace of SCR events obtained from Fluo-3 loaded 
HEK293 cells (in the presence of 1.3mM external Ca2+) are shown in (A), where the 
parameters assessed are indicated with blue arrows.  The start, end and peak of a 
SCR-event are highlighted with red, brown and green arrows, respectively. F0 
represents the basal Fluo-3 signal intensity. The ER Ca2+ store load, was estimated 
by measuring the amplitude of caffeine-induced Ca2 release, as demonstrated in (B).  
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4.3 Results: 
 
4.3.1. Optimisation of [3H] ryanodine binding assays using native and recombinant 
material:  
 
Demonstrated in Figure 4.3 (A), establishing a suitable protein concentration of 
recombinant hRyR2 for use in future experiments was achieved by plotting an average of 
the specific [3H] ryanodine binding counts (in dpm) generated when using the recombinant 
material, against the chosen protein concentration range (0-200!g) used in the assay. 
100!g was chosen as the optimal protein quantity for use in subsequent investigations 
since this concentration appeared to be the minimal protein amount which yielded the 
least [3H] ryanodine binding variability, and at which sufficient liquid scintillation counts 
were achieved.  
 
Since the [3H]-ryanodine binding assay requires the use of functional RyR2 channels 
expressed to a high level, it seemed rational to also carry out the same optimisation 
experiments using native sources, such that a comparison could be made between the 
data collected using the recombinant material. Illustrated in Figure 4.3 (B) as a bar graph, 
despite being lower, the specific [3H] ryanodine bound in 100!g of recombinant protein 
could be directly compared to native material, a WT hRyR2 mixed membrane preparation 
bound to 0.3 ± 0.02 pmol/mg [3H] ryanodine, compared with 1.0 ± 0.18 and 16.8 ± 1.30 
pmol/mg for native rat cardiac and rabbit skeletal membranes, respectively. Furthermore, 
native rat cardiac membranes were also used to test the Ca2+ activation assay before 
proceeding with recombinant material. As shown in Figure 4.3 (C), the resultant [3H] 
ryanodine binding Ca2+ activation curve displayed a sigmoidal relationship (EC50 = 
0.35±0.02!M), indicating that the range of Ca2+ concentrations chosen were buffered 
efficiently (section 4.2.1.1).  
 
As described previously in section 4.2.1.1, before use in [3H] ryanodine binding Ca2+ 
activation assays, all eGFP-hRyR2 mixed membranes (expressed alone/in the presence 
of CSQ2, JUN or CSQ2+JUN) were standardised for hRyR2 expression by Western 
blotting and densitometric analysis.  Highlighted in Figure 4.4 (A), the same representative 
WT hRyR2 mixed membrane preparation was loaded alongside all additional mixed 
membrane preparations during hRyR2 detection and using 100!g of recombinant protein 
as a benchmark, the concentration of a given mixed membrane sample was adjusted for 
use in Ca2+ activation assays accordingly, ensuring equivalent amounts of hRyR2 protein 
were used in each experiment (Figure 4.4,B).   
 
 118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Determination of an optimal recombinant protein amount for use in [3H] ryanodine 
binding assays and a preliminary Ca2+ activation assay using native material: To establish an 
optimal recombinant protein concentration for use in Ca2+ activation assays, the [3H] ryanodine binding 
counts (in dpm) achieved using increased amounts of recombinant WT RyR2 protein (n=3 
experiments) were determined by liquid scintillation counting and the averages plotted as shown in 
(A). To gauge the success of acquiring sufficient [3H] ryanodine binding counts using the recombinant 
material generated, two native preparations: rat cardiac and rabbit skeletal membranes were included 
as controls in optimisation investigations (n=3 experiments for each), (B). The concentration of specific 
[3H] ryanodine bound to 100!g of recombinant material was calculated as:  0.3 ± 0.02 pmol/mg of 
protein, compared with 1.0 ± 0.18 and 16.8 ± 1.30 pmol/mg of rat cardiac and rabbit skeletal 
membranes, respectively. Prior to commencing Ca2+ activation experiments, a preliminary experiment 
(n=4) was carried out using rat cardiac muscle membranes. The [3H] ryanodine binding Ca2+ curve 
obtained is shown in (C), which yielded an EC50 of 0.35±0.02!M. 
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Figure 4.4: Standardisation of mixed membrane preparations for hRyR2 expression 
by densitometry before use in [3H] ryanodine binding Ca2+ activation assays: As an 
example, standardisation of hRyR2 in mixed membrane preparations generated from 
HEK293 cells expressing mutant A4556ThRyR2+CSQ2 are shown as a Western blot 
(signal detection: 1.30 minutes) in (A), with a corresponding table of results in (B). The 
same process was carried out for all other test samples. Following SDS-PAGE and 
Western blotting, each mixed membrane sample intended for future use was checked for 
sufficient hRyR2 expression by densitometric analysis of Western signals. Using the levels 
of hRyR2 expression detected in a WT sample as a standard, 100!g (established as 
optimal to achieve sufficient [3H] ryanodine binding) of this sample was used as benchmark 
to adjust the protein concentration of other mixed membrane preparations accordingly, 
such that equivalent amounts of hRyR2 protein were used in each Ca2+ activation 
experiment.  
 
 
 
!"#$
CSQ2 
stable HEK 
cell line 
Untransfected 
HEK293 
30 kDa 
Transient 
expression 
of CSQ2 
565 kDa 
WT hRyR2 
A4556T hRyR2+CSQ2 
1 2 3 4 
!%#$
Mixed membrane 
Sample 
Density 
(ODu/mm2) 
Normalisation Protein amount 
required for [3H] 
ryanodine binding (!g) 
WT hRyR2 21.13749136 1 100 
A4556T hRyR2+CSQ2 
(Preparation 1) 
13.70498893 0.648373577 154.2319711 
A4556T hRyR2+CSQ2 
(Preparation 2) 
12.08151488 0.571567863 174.9573104 
A4556T hRyR2+CSQ2 
(Preparation 3) 
10.61617886 0.502244117 199.1064104 
A4556T hRyR2+CSQ2 
(Preparation 4) 
33.78306817 1.598253624 62.56827763 !
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4.3.2. Measurement of the Ca2+ dependence of [3H]-ryanodine binding for WT, 
A4556T and N4104K hRyR2 channels in the absence of luminal accessory proteins:  
 
[3H]-ryanodine binding was used to assess the cytosolic Ca2+ sensitivity of WT and CPVT-
linked mutant human RyR2 when recombinantly expressed alone or co-expressed with 
CSQ2, JUN or CSQ2 and JUN. Figure 4.5 illustrates the Ca2+ activation curve for WT 
hRyR2 channels expressed alone, which yielded an EC50 of 0.58 ± 0.27µM. As 
demonstrated, the Ca2+ activation data can also be plotted as specific [3H] ryanodine 
bound in pmol/mg of protein, as used in Du et al., 1998 and Li and Chen 2001.  Using [3H]-
ryanodine binding assays, the sensitivities to Ca2+ activation of mouse (EC50 of 
0.28±0.02µM (Jiang et al., 2005) and 0.31±0.02µM (Jiang et al., 2007)) and rabbit (EC50 of 
0.79±0.08µM (Du et al., 1998)) recombinant RyR2 are not dissimilar to those obtained in 
this investigation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mutant hRyR2 Ca2+ activation curves were compared with that obtained for WT hRyR2 
channels. Given that all protein samples used in the Ca2+ activation assays were first 
standardised for hRyR2 expression, at first glance, it was not deemed necessary to 
normalise results to maximal (max) [3H] ryanodine binding, since arguably all max binding 
should be the same. As shown in Figure 4.6, this is the case for the N4104K hRyR2 mutant 
(A), which displays similar max binding to WT hRyR2 channels. However, when A4556T 
hRyR2 channels were assessed (B), [3H] ryanodine binding appeared much higher at 
Figure 4.5: [3H] ryanodine binding Ca2+ activation curve of WT hRyR2 channels: 
The Ca2+ activation profile achieved for WThRyR2 was derived from an n=10 assays, 
where values were obtained from 4-5 separate binding experiments. The curve was 
constructed using a sigmoidal dose-response (variable slope) fit (GraphPad Prism). 
As shown, the dose-response data can be presented using the [3H] ryanodine binding 
counts achieved (in dpm), determined by liquid scintillation counting or the binding 
counts generated can subsequently be used to calculate the specific [3H] ryanodine 
bound in pmol/mg of protein.  
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every Ca2+ concentration tested and thus max binding differed significantly from the WT. 
Due to the variable nature of the data, it was therefore decided that in order to rigorously 
compare the EC50 between datasets, the Ca2+ activation curves needed to be fitted with 
constraints (as without it, statistical differences may be difficult to pinpoint), as 
recommended in the GraphPad Prism Statistics Guide (www.graphpad.com). Often used 
to exhibit [3H] ryanodine binding data in the literature (Jiang et al., 2005, Li and Chen, 
2001), the simplest way to do this was to normalise the data. The [3H] ryanodine binding 
dose-response curves generated will thus be presented both as non-normalised (raw) and 
normalised data, as in Figure 4.6.    
 
N4104K hRyR2 channels displayed a significantly sensitised cytoplasmic Ca2+ activation 
profile (seen as a left-shift in the curve) compared to WT hRyR2, which yielded an EC50 of 
0.22 ± 0.27µM (Figure 4.6 (A), normalised, right-graph). Furthermore, the mutant elevated 
channel activation at basal Ca2+ levels (as evident in the non-normalised Ca2+ activation 
curve (Figure 4.6 (A), left graph)). Normalised WT hRyR2 data yielded an EC50 of 1.63µM, 
which is almost identical to the EC50 (1.65± 0.43µM) reported by Mukherjee et al., 2012, at 
the single channel level.  
 
Displaying the [3H] ryanodine binding results both in the normalised and non-normalised 
form was important, since interesting aspects of the data might have otherwise been 
overlooked. In the raw data for example, increased [3H] ryanodine binding was evident at 
all Ca2+ concentrations >1!M with A4556T hRyR2 channels (Figure 4.6 (B), right graph, 
highlighted with asterisks). However, the Ca2+ sensitivity of A4556T hRyR2 channels to 
activation was comparable to WT hRyR2, and yielded a similar EC50 = 0.63 ± 0.08µM 
(normalised data, right graph, (B)). Discussed further in section 4.4.1.1, the fact that 
enhanced [3H] ryanodine binding was evident, yet the sensitivity to Ca2+ activation was 
similar to WT channels, may be due to an experimental error or it could reflect a bona fide 
consequence of channel mutation.  
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Figure 4.6: A comparison of the [
3
H] ryanodine binding Ca
2+
 activation curves of 
WT, A4556T and N4104K hRyR2 channels: Each dataset was fitted as a non-linear 
regression, sigmoidal (four parameter logistic) curve using GraphPad Prism. All 
statistical differences were also detected using this software, evaluated using the sum of 
squares F test (to reliably assess EC50 values), (GraphPad Prism). To normalise (right 
graphs), the data was constrained to 0 (bottom) and 100 (top) before fitting the curve. 
The tables indicate best-fit values, where (A) highlights a comparison of N4104K hRyR2 
and (B) A4556T hRyR2, where nsd = no significant difference and p<0.05 = a significant 
difference to WT hRyR2. The Ca
2+
 activation profiles achieved for N4104K and A4556T 
hRyR2 were derived from an n=6 curves (for each, i.e 12 in total), obtained from 3 
separate [
3
H]-ryanodine binding experiments and using 3-4 different mixed membrane 
preparations expressing the mutant channel of interest. The A4556T mutant (non-
normalised data, left graph (B)) displayed enhanced [
3
H] ryanodine binding at all [Ca
2+
] 
>1!M (* p = <0.05 vs WT hRyR2 response, Student’s t-test (GraphPad Prism)).  
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4.3.2.1. Ca2+ dependence of [3H]-ryanodine binding for WT hRyR2 channels in the 
presence of CSQ2, JUN or CSQ2 and JUN: 
 
Figure 4.7 shows the Ca2+ activation (determined using [3H] ryanodine binding) of 
WThRyR2 channels in the presence of the luminal accessory proteins. Examination of both 
non-normalised (left graphs) and normalised Ca2+ activation data with constraints (right 
graphs) revealed that co-expression of CSQ2, JUN or CSQ2+JUN did not significantly 
affect the cytoplasmic Ca2+ activation of WThRyR2 and yielded similar EC50 values to WT 
channels (WThRyR2+JUN = 0.58 ± 0.15µM (A), WThRyR2+CSQ2 = 0.43 ± 0.08µM (B) 
and WThRyR2+CSQ2+JUN = 0.85 ± 0.21µM (C)). Co-expression of WT channels with 
JUN alone however, did appear to have a slight activatory effect on channel activity, both 
at basal and increasing Ca2+ levels, though this was not determined as statistically 
significant. Interestingly, this effect was not evident when WThRyR2 channels were co-
expressed in the presence of both accessory proteins, suggesting CSQ2 may dampen any 
stimulatory effect observed. 
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Figure 4.7: [3H] ryanodine binding Ca2+ activation curves of WT hRyR2 channels 
expressed alone and in the presence of luminal accessory proteins CSQ2 and JUN: 
Established from 3-4 separate experiments, co-expression of WThRyR2 with (A) JUN (n=6 
assays), (B) CSQ2 (n=7 assays) and (C) CSQ2+JUN (n=7 assays) did not have any 
appreciable effects on the cytosolic Ca2+ activation profile achieved for WT channels 
expressed alone (plotted in (A)-(C)). All curves were fitted and statistically analysed as 
described in Figure 4.6, nsd = no significant differences in EC50 values compared to 
WThRyR2.  
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4.3.2.2. Examination of Ca2+ dependence of [3H]-ryanodine binding for CPVT-linked 
mutant hRyR2 channels in the presence of CSQ2, JUN or CSQ2 and JUN 
 
 
4.3.2.2.1 A4556T hRyR2 channels: 
 
As observed in the non-normalised data (left graphs), the elevated [3H] ryanodine binding 
of mutant A4556T hRyR2 channels in response to cytosolic Ca2+ was not significantly 
altered by luminal accessory co-expression, as demonstrated in Figure 4.8 (A)-(C). Each 
normalised Ca2+ activation curve yielded the following comparable EC50 values: AT 
hRyR2+JUN = EC50 of 0.50 ± 0.12µM (A), AT hRyR2+CSQ2 = EC50 of 1.0 ± 0.4µM (B) and 
AT hRyR2+CSQ2+JUN = EC50 of 1.23 ± 0.37µM (C). Interestingly, although no statistically 
significant difference was detected, the increased basal [3H] ryanodine binding seen at low 
[Ca2+] in the non-normalised curves appeared to be restored to WT levels when the 
mutants were co-expressed in the presence of both CSQ2 and JUN (Figure 4.8, (C), left 
graph).  
 
 
4.3.2.2.2 N4104K hRyR2 channels: 
 
[3H]-ryanodine binding Ca2+ activation curves obtained using mutant N4104K hRyR2 
channels are shown in Figure 4.9. As found previously with WT and A4556T hRyR2 
channels, luminal accessory protein co-expression did not significantly affect the cytosolic 
Ca2+ activation profile of this mutant. Each normalised Ca2+ activation curve yielded the 
following EC50 values, which were comparable to N4104K channels expressed alone: NK 
hRyR2+JUN = EC50 of 0.49 ± 0.4µM (A), NK hRyR2+CSQ2 = EC50 of 0.34 ± 0.1µM (B) and 
NK hRyR2+CSQ2+JUN = EC50 of 0.26 ± 0.02µM (C).  
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Figure 4.8: [3H] ryanodine binding Ca2+ activation curves of A4556T hRyR2 channels in 
the absence and presence of CSQ2 and/or JUN: Co-expression of AT hRyR2 with (A) JUN 
(n=6 assays), (B) CSQ2 (n=6 assays) and (C) CSQ2+JUN (n=6 assays) did not significantly 
alter the response of the mutant channels to increasing cytosolic Ca2+ concentrations, as 
directly compared with the Ca2+ activation curve achieved using AT hRyR2 channels 
expressed alone (A)-(C). Non-normalised (left graphs) and normalised (right graphs) data 
(collected from 3-4 separate binding experiments) was fitted and statistically analysed as 
described in Figure 4.6, nsd = no significant differences in EC50 values compared to AT hRyR2 
expressed alone.  
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Figure 4.9: [
3
H] ryanodine binding Ca
2+
 activation curves of N4104K hRyR2 channels in 
the absence and presence of luminal proteins: The dose-response curve of N4104KhRyR2 
expressed alone is shown in (A)-(C). Derived from 3-4 separate binding experiments (using 3-
4 different mixed membrane preparations for each combination), co-expression of NK hRyR2 
with (A) JUN (n=6 assays), (B) CSQ2 (n=6 assays) and (C) CSQ2+JUN (n=8 assays) did not 
significantly affect the response of the mutant channels to activating Ca
2+
. Non-normalised 
(left graphs) and normalised (right graphs) data was fitted and statistically analysed as 
described in Figure 4.6, nsd= no significant differences in EC50 values compared to NK hRyR2 
expressed alone. 
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4.3.2.3. Are luminal accessory protein interactions disrupted by the optimised [3H] 
ryanodine binding conditions?  
 
Designed to optimise the open probability of RyR2 and prevent aggregation, [3H] 
ryanodine binding experiments were carried out using a binding buffer containing 1M KCl 
(as used in Jiang et al., 2007, Chopra et al., 2009, Euden et al., 2013). As demonstrated in 
Figure 4.10 (taken from Jiang et al., 2004), when undertaking investigations with 
recombinant (mouse) RyR2, sufficient [3H] ryanodine binding of WT channels (open 
circles) was only achieved when higher concentrations of KCl were used. However, since 
no significant differences in the cytosolic Ca2+ activation profile of WT or mutant hRyR2 
were detected when co-expressed in the presence of luminal accessory proteins, it 
seemed logical to establish if the high salt conditions disrupted the binding interactions of 
CSQ2 and JUN with hRyR2 (Ahmed, 2004). Described in Chapter 5, sections 5.2.2 and 
5.3.4, the protein-protein interactions between CSQ2, JUN and hRyR2 were investigated 
by co-immunoprecipitation (Co-IP), using the !MACS" system from Miltenyi Biotec 
(section 2.4.3.6, Figure 2.5). In these experiments, a low salt buffer (containing 150mM 
NaCl) was used to solubilise all mixed membrane samples. To establish if higher salt 
disrupts the interaction of the luminal proteins with hRyR2, a series of Co-IP investigations 
(n=4) were carried out using both the standard solubilisation buffer (section 2.1.9) and the 
same buffer prepared to contain 1M NaCl. Although not the primary goal of this 
investigation, it has been reported at the single channel level that high concentrations of 
luminal Ca2+ dissociates CSQ2 from RyR2 channels (Beard et al., 2005, Qin et al., 2008). 
To test this concept biochemically, 10mM Ca2+ was added to the standard solubilisation 
buffer (150mM NaCl) and also used in Co-IP investigations.  
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 4.10: [3H] ryanodine binding of WT and mutant RyR2 channels with 
increasing concentrations of KCl: The aim of this investigation carried out by 
Jiang et al., 2004 was to demonstrate that RyR2 mutation enhances [3H] 
ryanodine binding at basal (~3nM) Ca2+ levels. However, the graph also 
demonstrates that optimal binding in WT recombinant RyR2 (mouse in this case) 
is achieved at higher concentrations of KCl. (Image modified from Jiang et al., 
2004).   
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A mixed membrane preparation co-expressing WT hRyR2+CSQ2+JUN was used the Co-
IP investigations, following the protocol described in Chapter 2, section 2.4.3.6. The only 
difference to this protocol was that in addition to using the standard buffer containing 
150mM NaCl (no Ca2+) for solubilisation, aliquots of the mixed membranes were also 
solubilised in the standard buffer (150mM NaCl) but with 10mM Ca2+ added and an 
equivalent buffer containing 1M rather than 150mM NaCl (Figure 4.11).   
 
Figure 4.11 (A) shows an example of the Western blot signals obtained from the detection 
of CSQ2 or JUN expression captured in immunoprecipitates (eluted from anti-GFP 
magnetic microbeads (Miltenyi Biotec)). Derived from an n=4 investigations, the results 
varied somewhat with the use of high salt solubilisation buffer. In some experiments CSQ2 
and JUN were unaffected (n=1 of 4 blots assessed), yet in another CSQ2 and/or JUN 
appeared reduced (n=1 both reduced, n=2 JUN only reduced). In the particular blot shown 
in Figure 4.11 (A), the association of JUN with hRyR2 channels appears to be diminished 
when solubilised in high salt buffer (lane 3, at ~26kDa), but the association of CSQ2 was 
unaffected (lane 3, at ~45kDa). In contrast, a reduction in the interaction of CSQ2 and 
JUN with hRyR2 channels was consistently observed when membranes were solubilised 
in the presence of 10mM Ca2+, as demonstrated in Figure 4.11 (A), lane 2 (CSQ2 at 
~45kDa and JUN at ~26kDa, respectively). Densitometric analysis was performed on all 
Co-IP Western signals  (Figure 4.11 (B)), where a reduction in the association of CSQ2 
and JUN with hRyR2 channels was only found to statistically significant when mixed 
membranes were solubilised in the presence of 10mM Ca2+.  
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Figure 4.11: Co-immunoprecipitation investigations to establish if the association of 
CSQ2 and JUN with hRyR2 is altered by high salt and high Ca2+ concentrations: An 
example of captured immunoprecipitates resolved by SDS-PAGE and detected by Western 
blotting is shown in (A), where lanes 1-3 = mixed membranes from cells expressing WT 
hRyR2, CSQ2 and JUN solubilised (at 2mg/ml) in buffer containing: (1) 150mM NaCl in 
contaminant Ca2+, (2) 150mM NaCl with 10mM Ca2+ and (3) 1M NaCl in contaminant Ca2+. 
Lanes 4,5 and 6 = mixed membranes (50!g, unsolubilised) from cells expressing 
WThRyR2, CSQ2 and JUN (4) or CSQ2 (5) or JUN (6) only. Each blot was probed with "-
CSQ2 and "-JUN antibodies to detect CSQ2 and JUN, respectively. Represented as bar 
graphs (B), densitometric analysis of Western blot signals (n=4 blots) was used to 
distinguish any significant alterations in the association of CSQ2 and/or JUN with hRyR2 
when solubilised in high salt conditions or in the presence of 10mM Ca2+ (normalised to the 
signals obtained using standard solubilisation buffer). Statistically significant differences (* 
p<0.05) were calculated using an ANOVA and a Tukey-Kramer post-test.      
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4.3.3. Imaging of spontaneous Ca2+ release events in HEK293 cells expressing WT 
and mutant hRyR2 channels in the absence of luminal accessory proteins:  
 
As illustrated in Figure 4.12, N4104K hRyR2-expressing HEK293 cells displayed markedly 
different SCR-events, compared with those observed in cells expressing WT or A4556T 
hRyR2. Presented as a series of bar graphs in Figure 4.13, the kinetic parameters of 
these events were examined. The N4104K mutant caused a significant reduction in the 
amplitude, duration and inter-SCR duration of SCR events, thereby increasing their 
frequency. In addition, the rate of Ca2+ release and decay was also reduced in N4104K 
hRyR2 expressing cells, which consequently changed the shape of the Ca2+ waves 
(Figure 4.12). Consistent with an enhanced frequency, the ER Ca2+ content (measured by 
the Ca2+ transient amplitude induced by caffeine application (10mM)) was significantly 
reduced (in comparison to cells expressing WT RyR2), which is indicative of Ca2+ leak 
through RyR2 channels (Jiang et al., 2007). In contrast, all SCR parameters in HEK293 
cells expressing A4556T hRyR2 appeared similar to WT (Figure 4.13), where no 
significant differences between the two were detected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Representative traces of spontaneous Ca2+ release events 
from HEK293 cells expressing WT and mutant A4556T and N4104K hRyR2, 
measured by Fluo-3.  
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Figure 4.13: Assessment of the spontaneous Ca2+ release event properties in 
HEK293 cells expressing WT and mutant hRyR2 channels alone: All kinetic 
parameters of SCR-events were examined as described in section 4.2.2. As shown, 
all Ca2+ oscillation properties were significantly altered by mutant N4104K hRyR2 
expression (purple bars), compared with cells expressing WT hRyR2 (grey bars). 
Unlike expression of the N4104K mutation, HEK293 cells expressing the A4556T 
hRyR2 mutant (green bars) displayed similar SCR-event properties to the WT.  The 
data are presented for each parameter as the combined mean± S.E.M, collected 
from between 11-25 transfected cells and 3-4 separate experiments. Statistical 
significance was calculated using one-way ANOVA, Tukey-Kramer test (GraphPad 
Prism), where p<0.05 is denoted by * (vs WT hRyR2).  
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Figure 4.13: Assessment of the spontaneous Ca2+ release event properties in 
HEK293 cells expressing WT and mutant hRyR2 channels alone: All kinetic 
parameters of SCR-events were examined as described in section 4.2.2. As shown, 
all Ca2+ oscillation properties were significantly altered by mutant N4104K hRyR2 
expression (purple bars), compared with cells expressing WT hRyR2 (grey bars). 
Unlike expression of the N4104K mutation, HEK293 cells expressing the A4556T 
hRyR2 mutant (green bars) displayed similar SCR-event properties to the WT.  The 
data is presented for each parameter as the combined mean± S.E.M, collected 
from between 11-25 transfected cells and 3-4 separate experiments. Statistical 
significance was calculated using one-way ANOVA, Tukey-Kramer test (GraphPad 
Prism), where p<0.05 is denoted by * (vs WT hRyR2).  
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4.3.4. Expression of CSQ2, JUN and CSQ2+JUN with WT hRyR2 channels alters the 
properties of spontaneous Ca2+ release events: 
 
Representative traces of SCR events from WT hRyR2-expressing HEK293 cells, in the 
absence and presence of luminal accessory proteins are demonstrated in Figure 4.14. To 
assess the effects that CSQ2, JUN or CSQ2+JUN co-expression has on the Ca2+ handling 
dynamics of WT channels, the properties of the SCR-events were examined (Figure 4.15). 
Although luminal protein co-expression did not alter the SCR event amplitude, expression 
of CSQ2, JUN or CSQ2+JUN with WT hRyR2 channels significantly enhanced their 
duration, whilst decreasing the rate of Ca2+ release and decay. As shown in Figure 4.14, 
compared with cells expressing WT hRyR2 alone, these effects consequently produced 
longer Ca2+ waves and changed the shape of the SCR-events. In addition to an increase in 
event duration, co-expression with CSQ2 (both alone and in combination with JUN) notably 
lengthened the time period in between each SCR event (inter-SCR duration) and 
subsequently decreased their frequency. This effect was not observed when WT channels 
were co-expressed with JUN alone. Compared with expression of WT hRyR2 only, the ER 
Ca2+ load was found to be significantly lower in all cells co-expressing the luminal proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Representative traces of spontaneous Ca2+ 
release events in HEK293 cells expressing WT hRyR2, in 
the absence and presence of luminal accessory proteins 
CSQ2 and/or JUN, measured by Fluo-3.  
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Figure 4.15: Assessment of the effects CSQ2 and/or JUN co-expression has on 
the spontaneous Ca2+ release event properties of WT hRyR2-expressing cells: 
The kinetic parameters of SCR-events were examined as described in section 4.2.2. 
As shown, co-expression of the luminal proteins with WThRyR2 channels significantly 
altered many of the Ca2+ oscillation properties, as discussed in section 4.3.4. Data are 
presented for each parameter as the combined mean± S.E.M, collected from between 
11-25 transfected cells and 3-4 separate experiments. Statistical significance was 
calculated using one-way ANOVA, Tukey-Kramer test (GraphPad Prism), where 
p<0.05 is denoted by * (vs WT hRyR2 expressed alone).  
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Figure 4.15: Assessment of the effects CSQ2 and/or JUN co-expression 
has on the spontaneous Ca2+ release event properties of WT hRyR2-
expressing cells: The kinetic parameters of SCR-events were examined as 
described in section 4.2.2. As shown, co-expression of the luminal proteins with 
WThRyR2 channels significantly altered many of the Ca2+ oscillation properties, 
as discussed in section 4.3.4. Data is presented for each parameter as the 
combined mean± S.E.M, collected from between 11-25 transfected cells and 3-
4 separate experiments. Statistical significance was calculated using one-way 
ANOVA, Tukey-Kramer test (GraphPad Prism), where p<0.05 is denoted by * 
(vs WT hRyR2 expressed alone).  
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4.3.5. Examination of spontaneous Ca2+ release parameters in cells co-expressing 
mutant A4556T hRyR2 channels and the luminal accessory proteins CSQ2 and/or 
JUN:  
 
Although the SCR-events in cells expressing A4556T hRyR2 channels appeared similar to 
WT (Figure 4.13), some changes in the effects of luminal protein co-expression were 
detected. In particular, as presented in Figure 4.17, CSQ2 expressed alone did not appear 
to have an inhibitory effect on channel activity, suggesting that the way in which the 
mutant responds to CSQ2 differs from that of WT channels. However, co-expression with 
both accessory proteins (CSQ2+JUN), appeared to impart similar effects on A4556T as it 
did to WT SCR parameters - generating an increase in the SCR event duration and inter-
SCR duration, whilst reducing their frequency (as illustrated in Figure 4.16). Consistent 
with WT data, co-expression of both luminal proteins with A4556T channels also reduced 
the rate of Ca2+ release and decay. These data could suggest that the direct effect of 
CSQ2 on RyR2 has been affected by mutation, but that the interaction via JUN has not, 
since the effect is the same as that seen on the WT channel.  The effects of CSQ2 and 
JUN co-expression on A4556T hRyR2 Ca2+ load however had the opposite effect to that 
seen with WT hRyR2 co-expression, where ER Ca2+ content was significantly augmented 
in HEK293 expressing A4556T hRyR2+CSQ2+JUN (Figure 4.17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Representative traces of spontaneous Ca2+ release 
events in HEK293 cells expressing A4556T hRyR2 alone and in 
the presence of luminal accessory proteins CSQ2 and JUN, 
measured by Fluo-3. 
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Figure 4.17: Assessment of the effects CSQ2 and/or JUN co-expression 
has on the spontaneous Ca2+ release event properties of A4556T hRyR2-
expressing cells: In particular, co-expression of A4556T hRyR2 channels with 
both accessory proteins (AT+CSQ2+JUN) appeared to significantly alter the 
Ca2+ oscillation parameters, as discussed in section 4.3.5. Data are presented 
for each parameter as the combined mean± S.E.M, collected from between 11-
25 transfected cells and 3-4 separate experiments. Statistical significance was 
calculated using a one-way ANOVA, Tukey-Kramer test (GraphPad Prism), 
where p<0.05 is denoted by *** (vs A4556T hRyR2 expressed alone) and ^^ (vs 
A4556T+CSQ2+JUN.  
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4.3.6. Examination of spontaneous Ca2+ release events in cells co-expressing 
mutant N4104K hRyR2 channels and the luminal accessory proteins CSQ2 and/or 
JUN:  
 
Although the SCR-events in cells expressing N4104K hRyR2 channels appeared entirely 
different to WT hRyR2 (Figure 4.13), the effects of luminal accessory protein co-
expression were quite similar. Co-expression of CSQ2 and/or JUN with N4104K channels 
did not alter the SCR amplitude, but generated significant increases in the duration and 
inter-SCR duration of the events, thus reducing their frequency (as observed in WT hRyR2 
channels), (Figure 4.19).  Representative traces of SCR events from NK hRyR2-
expressing HEK293 cells, in the absence and presence of both luminal accessory 
proteins, are demonstrated in Figure 4.18. Differing from WT channels however, co-
expression of the luminal proteins with N4104K hRyR2 did not have any significant effects 
on the ER Ca2+ levels (Figure 4.19). However, since N4104K hRyR2 channels expressed 
alone also displayed a significantly reduced Ca2+ content, this could be a reflection of the 
store itself rather than an effect of luminal protein co-expression.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: Representative traces of spontaneous Ca2+ release 
events in HEK293 cells expressing N4104K hRyR2 alone and in 
the presence of luminal accessory proteins CSQ2 and JUN, 
measured by Fluo-3. 
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Figure 4.19: Assessment of the effects CSQ2 and/or JUN co-expression has on 
the spontaneous Ca2+ release event properties of N4104K hRyR2-expressing 
cells: Examination of the kinetic SCR-event parameters in cells co-expressing the 
luminal proteins with N4104K hRyR2 channels revealed some significant alterations in 
the Ca2+ oscillation properties, as discussed in section 4.3.6. Data are presented for 
each parameter as the combined mean± S.E.M, collected from between 11-25 
transfected cells and 3-4 separate experiments. Statistical significance was calculated 
using one-way ANOVA, Tukey-Kramer test (GraphPad Prism), where p<0.05 is denoted 
by ** (vs N4104K hRyR2 expressed alone) and ^^ (vs N4104K+CSQ2+JUN).  
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4.4. Discussion: 
 
• Assessment of the cytosolic Ca2+ dependence of WT and mutant hRyR2 channel 
activation showed that CPVT mutants are functionally heterogeneous with A4556T 
having a comparable half-maximal dose of activation (EC50) comparable to that of 
the WT, whilst N4104K channels displayed a markedly sensitised response to 
activating Ca2+.  
 
• Co-expression with the luminal accessory proteins did not significantly alter the Ca2+ 
dependence of [3H] ryanodine binding to WT or mutant hRyR2. Although, as 
discussed in section 4.3.2.3, altered protein-protein interactions caused by the use 
of high ionic strength conditions in these experiments may have masked any luminal 
protein effects. 
 
• Effects on luminal Ca2+ regulation were appraised by measuring the properties of 
spontaneous Ca2+ release (SCR) events. HEK293 cells transfected with N4104K 
displayed significantly enhanced SCR parameters, which were indicative of Ca2+ 
leak through hRyR2. In contrast, A4556T channels displayed similar SCR events to 
WT hRyR2. Luminal protein co-expression revealed an inhibitory effect of CSQ2 on 
WT and N4104K hRyR2 activity, both in the presence of JUN and when expressed 
alone. A4556T hRyR2 differed in their response to CSQ2 co-expression, with no 
evidence of channel inhibition.  
 
 
4.4.1. Wild type and mutant hRyR2 channels expressed in the absence of luminal 
accessory proteins display differences in Ca2+ sensitivity:  
 
Quantitative [3H] ryanodine binding was used to directly measure the cytosolic Ca2+ 
dependence of WT and mutant hRyR2 channels expressed alone (Figures 4.5 and 4.6), 
before assessing the effects of luminal protein co-expression. As discussed in section 
4.3.2, the Ca2+ activation curves were presented in two ways: as raw (non-normalised) 
data and normalised data (fitted with constraints). Due to the variable nature of the data (in 
particular the A4556T hRyR2 mutant), without normalisation statistical differences 
between the EC50 of each dataset could not be accurately measured. As evidenced in this 
work, a steep dependence of RyR2 open probability or [3H] ryanodine binding on cytosolic 
Ca2+ is not without precedent (see Jiang et al., 2003, 2004 and 2005). Studies on single 
hRyR2 channels in our own lab have also found this to be the case, with a 10-fold 
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increase in channel open probability occurring between 100 nM-1!M Ca2+ (Mukherjee et 
al., 2012). Since [3H] ryanodine binding is activated to a greater extent at micromolar 
concentrations of Ca2+ (Pessah et al., 1987), inclusion of additional Ca2+ concentrations up 
to and above this range (between 250nM-1!M and above) could have smoothed out the 
Ca2+ activation curve to resemble a more sigmoidal relationship. When fitting the four-
parameter logistic model, the Hill slope was a measure of the curves’ steepness 
(GraphPad.com). This however, was not considered in the results, since we cannot be 
sure exactly what the Hill slope signifies in the context of this work. The Hill equation is 
commonly used to quantify the degree of cooperativity in ligand binding, which in this case 
would be a measure of the cooperativity of [3H] ryanodine binding to hRyR2 with activating 
Ca2+, in the absence/presence of luminal accessory proteins. It is however more likely to 
be a measure of the concerted cooperativity of channel activation. As shown in Figures 
4.6-4.9, this steep transition was much more apparent in experiments carried out using 
A4556T hRyR2, and when channels were co-expressed with CSQ2, the significance of 
which will be considered below (sections 4.4.1.1 and 4.4.2.1). Single cell Ca2+ imaging 
was carried out to assess the properties of spontaneous Ca2+ release events in HEK293 
cells expressing WT and mutant hRyR2. Using this technique, the sensitivity of WT or 
mutant channels to luminal Ca2+ could be examined, and any changes in the response 
following luminal accessory protein co-expression ascertained.   
 
4.4.1.1. Investigations of hRyR2 mutation A4556T:  
 
Compared with WT hRyR2, mutant A4556T hRyR2 channels (Figure 4.6 (B) left graph) 
displayed higher [3H] ryanodine binding at every Ca2+ concentration tested, which was 
statistically significant at all concentrations >1!M (Student’s t-test vs. WT hRyR2), and 
may have contributed to the sharp transition (steepness of the slope) seen with increasing 
[Ca2+]. Since binding of [3H] ryanodine reflects the open state of hRyR2 channels, it is 
possible the mutant directly affected the sensitivity of channel opening. However, the 
A4556T Ca2+ activation curve yielded a comparable EC50 to WT channels (0.63± 0.08µM 
vs. 1.63± 0.27µM normalised WThRyR2 data), (Figure 4.6 (B) right graph), suggesting that 
their Ca2+ dependence were similar. It is possible the A4556T mutant may have been 
affecting the association/dissociation rate of [3H] ryanodine itself, since the binding data 
exhibited great variability (as indicated by the larger error bars seen in the graphs). As 
demonstrated in Figure 4.4, it is unlikely that standardisation was affected by the mutation, 
since similar hRyR2 expression levels to WT were evident in mixed membranes 
expressing A4556T (assessed by densitometric analysis of Western blot signals). The 
A4556T mutation however is positioned in or near the pore-forming region of the RyR2 
channel, within which the residues deemed critical for ryanodine binding are situated, such 
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as a glutamine residue at position 4863 (Wang et al., 2003). Mutation of this amino acid 
(Q4863A) was found at the single channel level to considerably reduce the affinity of 
ryanodine for RyR2 channels (Ranatunga et al., 2005), meaning that no [3H] ryanodine 
binding was detected (Wang et al., 2003). It is possible that the A4556T mutant may have 
altered the structure of the ryanodine-binding site, such that the affinity for ryanodine was 
enhanced. The only way to prove this however would be to investigate A4556T hRyR2 
channels at the single channel level, using a reversible ryanoid (as discussed further in 
Chapter 6).  
 
In single-cell Ca2+ imaging investigations, HEK293 cells expressing WT and A4556T 
hRyR2 channels alone displayed remarkably similar SCR-events (Figure 4.12 and 4.13) 
and no statistically significant differences were found. Therefore, taking into account both 
the [3H] ryanodine binding and Ca2+ imaging together, no differences in the sensitivity of 
RyR2 channels to Ca2+ were apparent with A4556T mutation. Although listed in the human 
gene mutation database (HGMD) as a disease-causing variant (Tester et al., 2007), these 
results suggest that A4556T hRyR2 may not be causative of arrhythmia; especially since 
altered Ca2+ sensitivity in CPVT mutants is a well-documented observation (Jiang et al., 
2005, Wehrens et al., 2007, Meli et al., 2011, Loaiza et al., 2013). In agreement with this 
proposal, Jabbari et al (2013) recently concluded that the A4556T mutation is benign 
following the use of numerous prediction tools (including SIFT (Sorting Intolerant From 
Tolerant) and PolyPhen-2 (Polymorphism Phenotyping) to predict its deleterious outcome. 
Additionally, Papadakis et al (2013) reported of a 17 year old male harbouring the A4556T 
mutant, who was found in post mortem to have died due to a structural abnormality 
(marked right ventricular dilatation), unrelated to RyR2 mutation. Thus it is possible that 
A4556T could be a single nucleotide polymorphism, which can be identified in patients, 
but not usually causative of disease.  
 
4.4.1.2. Investigations of hRyR2 mutation N4104K:  
 
In contrast, the N4104K mutation was found to be markedly different to A4556T and WT 
hRyR2 channels in both experimental systems. As shown in Figure 4.6 (A), compared with 
WT channels, the CPVT-linked mutant displayed enhanced [3H] ryanodine binding at basal 
(or sub-activating) Ca2+ levels (non-normalised data, left graph), an observation also 
reported by Jiang et al., 2004. Normalisation of the binding data demonstrated that 
N4104K channels exhibit a sensitised Ca2+ activation profile, seen as a left-shift in the 
dose-response curve (Figure 4.6, (A), right graph); and yielded an EC50 that was 
statistically different from WT channels (0.22 vs. 1.63!M (normalised data)). This result 
differed from that of Jiang et al (2004) who reported that although enhanced basal levels 
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of [3H] ryanodine binding was evident, N4104K did not alter the Ca2+ dependence of [3H]-
ryanodine binding. As illustrated in Figure 4.10 however, the CPVT-linked mutants 
assessed in their study only exhibited elevated [3H] ryanodine binding at contaminant Ca2+ 
levels, when high (>800mM) concentrations of KCl were used. However, all Ca2+ 
activation experiments were undertaken in low (100mM KCl) salt conditions (Jiang et al., 
2004). Thus, it is likely that under such low salt concentrations significant differences in 
the Ca2+ dependence of mutant RyR2 channels compared with WT would not have been 
distinguished. However, the N4104K hRyR2 Ca2+ activation curve in this study appeared 
left-shifted, as found in this investigation (Jiang et al., 2004).  
 
As illustrated in Figures 4.12 and 4.18, the SCR events in cells expressing N4104K-
hRyR2 appeared much smaller and faster than those observed in HEK293 expressing WT 
(or AT) hRyR2. The kinetics of the SCR events differed significantly to WT, represented by 
a series of bar graphs in Figure 4.13. Expression of this mutant lowered the amplitude, 
duration and inter-SCR duration of the Ca2+ transients, which consequently increased their 
frequency (Figure 4.13). Furthermore, the rate of Ca2+ release and decay were also 
decreased. As established by measuring the Ca2+ transient amplitude following high-dose 
caffeine application, (which empties the ER store) the ER Ca2+ load in N4104K-hRyR2 
expressing cells was also significantly lowered and is indicative of Ca2+ leak through 
mutant RyR2 channels (Jiang et al., 2004, 2005, 2007). These findings are in line with the 
published data from Jiang et al (2004), where the N4104K mutant enhanced the 
propensity for SOICR. It was noted that N4104K hRyR2 channels in particular displayed 
greater signal variability ((noise), as shown in Figures 4.12 and 4.18), which has been 
suggested by George et al (2006) to represent conformational instability of the Ca2+ 
release channel.  
 
4.4.2.  Assessment of the effects that CSQ2 and/or JUN co-expression has on WT 
hRyR2 channel activity:  
 
When assessing the response of hRyR2 channels to CSQ2 co-expression, the 
stoichiometry of the luminal protein at the various [Ca2+] used in each experiment should 
be considered. Discussed previously in section 1.6.1, the oligomeric state of CSQ2 is 
thought to be [Ca2+]-dependent, with CSQ2 monomers predicted to self-associate to form 
dimers, tetramers and eventually polymers at higher luminal Ca2+ concentrations (>1 mM), 
where the protein becomes compacted and the Ca2+ binding capacity is enhanced (Park et 
al., 2003, 2004, Kim et al., 2007, Qin et al., 2008, Lee et al., 2012). In a study by Wei et al 
(2009b) however, even at 1 mM Ca2+ under physiological ionic strength, CSQ2 failed to 
form polymers (as assessed by chemical cross-linking), leading to suggestions by the 
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author that the cardiac isoform might not polymerise at all. This however does require 
further investigation.  
 
At low luminal [Ca2+] (<1mM), it is well documented that CSQ2 exists primarily as a 
monomer (Györke and Carnes, 2008, Murphy et al., 2011) or dimer (Park et al., 2003), 
which interacts with other luminal accessory proteins such as triadin and junctin to 
regulate RyR2 activity (Qin et al., 2008, Altschafl et al., 2011). Thus, monomeric CSQ2 (in 
association with JUN/TRD1) is thought to be responsible for regulating Ca2+ release, whilst 
CSQ2 polymers (if formed) store Ca2+ near the site of release (Qin et al., 2008). Although 
hypothesised in the literature, there is currently no published data demonstrating the ability 
of CSQ2 to regulate and bind RyR2 channels directly (in the absence of additional 
accessory proteins). Using a Ca2+ concentration range of 0-500!M for [3H] ryanodine 
binding experiments and in the presence of contaminant (~1-5 µM) Ca2+ in Co-IP 
investigations, CSQ2 was predicted to exist in monomeric/dimeric form, thereby retaining 
the ability to regulate/bind hRyR2 channels. As discussed further in Chapter 5, section 
5.3.4, reduction of CSQ2 binding to RyR2 was only observed at very high (i.e. 10mM) Ca2+ 
concentrations (Figure 4.11). The lack of effect of JUN and CSQ2 on the Ca2+ 
dependence of [3H] ryanodine binding in WT/mutant hRyR2 channels was therefore most 
likely due to the use of high ionic strength (1M KCl) conditions, rather than the use of an 
unsuitable [Ca2+] range altering CSQ2 conformation. In single-cell Ca2+ imaging 
investigations, transfected, Fluo-3 loaded cells were maintained in an extracellular Ca2+ 
concentration of 1.3mM. Within the ER, the dynamic changes in free luminal [Ca2+] during 
SCR could not be reliably measured, however, it was anticipated that CSQ2 remained as 
a monomer/dimer at a free luminal [Ca2+] <1mM, with the ability to interact and regulate 
RyR2 activity. Following analysis, this assumption was confirmed with the observation that 
CSQ2 imparted an inhibitory effect on SCR event parameters compared with hRyR2 
channels expressed alone (as discussed below in section 4.4.2.2 and sections 4.3.4-
4.3.6).   
 
4.4.2.1.  Ca2+ activation as measured by [3H] ryanodine binding:  
 
The Ca2+ dependence of [3H] ryanodine binding for WT hRyR2 channels did not appear to 
be altered by luminal accessory protein co-expression. As demonstrated in Figure 4.7, the 
Ca2+ activation curves generated using both the raw (left graphs) and normalised (right 
graphs) data appeared similar to those constructed for WT hRyR2 channels expressed 
alone and yielded EC50 values that were statistically comparable (A)-(C). The sharper 
slope evident in [3H] ryanodine binding curves when channels were co-expressed in the 
presence of CSQ2 could reflect a direct effect of the protein altering the cooperativity of 
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channel activation (i.e, affecting the population of hRyR2 channels opening). The effect of 
CSQ2 expression on [3H]-ryanodine binding has been explored previously, with both 
stimulatory (Kawasaki and Kasai, 1994) and inhibitory effects (Beard et al., 2002) being 
reported. Since no significant alterations in the Ca2+ dependence of hRyR2 channels (in 
terms of EC50) with CSQ2 co-expression were found in this investigation, it would be 
beneficial to examine the Ca2+-activation profile of hRyR2+CSQ2 and/or JUN further at the 
single channel level. JUN co-expressed alone with WT channels did seem to have a slight 
stimulatory effect on channel activity (Figure 4.7 (A), left graph), seen as a left-shift in the 
curve. However, the EC50 was not significantly different to WT hRyR2. Interestingly, an 
activatory role of JUN on RyR2 channel activity at lower Ca2+ concentrations has been 
reported in the literature (Altschafl et al., 2011 (Table 1.1)).  As tested by co-
immunoprecipitation (Figure 4.11), high salt conditions used in [3H] ryanodine binding 
assays were found to reduce the association of CSQ2 and JUN with hRyR2 channels. 
Although the difference was not calculated as statistically significant, it is possible that this 
reduction was enough to alter their functional effects. Imaging at a cellular level however, 
proved much more effective in detecting the effects of luminal protein co-expression.  
 
 4.4.2.2.  Single-cell Ca2+ imaging investigations:  
 
Co-expression of the luminal proteins with WT channels in HEK293 stable cell lines 
(section 4.2.2) were found to significantly alter the SCR parameters in Ca2+ imaging 
investigations (Figures 4.14 and 4.15). Although no effects on the SCR amplitude were 
exhibited, co-expression of all accessory protein combinations (CSQ2, JUN and 
CSQ2+JUN) with WT hRyR2 enhanced the duration of SCR events, whilst lowering the 
rate of Ca2+ release and decay. CSQ2 co-expression in particular (both alone and with 
JUN) seemed to have a profound inhibitory effect on WT hRyR2 function, where in addition 
to an increase in the duration of SCR, the time period in between each Ca2+ wave (the 
inter-SCR duration) was also significantly lengthened and the frequency of events reduced 
(Figure 4.15). This finding is consistent with the work of Györke et al (2004) where an 
inhibitory effect of CSQ2 on purified RyR2 channels at the single channel level was 
reported. However, channel inhibition was said to only occur in the presence of JUN and 
TRD1 (Györke et al., 2004). Studies of cardiac-specific CSQ2 overexpression in transgenic 
mice have also implicated an inhibitory role of the accessory protein, where impaired Ca2+ 
release was evident upon sarcolemmal depolarisation (Jones et al., 1998, Sato et al., 1998 
(Table 1.1)) and Ca2+ spark frequencies were drastically reduced (Jones et al., 1998). It 
was anticipated that the releasable Ca2+ store would be increased by WT hRyR2+CSQ2 
co-expression, as observed in CSQ2 overexpression studies (Jones et al., 1998, Sato et 
al., 1998). However, as shown in Figure 4.15, the ER Ca2+ content appeared to be 
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significantly lower in all cells expressing luminal proteins. However, a greater store 
capacity is evidenced by the fact that the SCR events in these cells exhibit a reproducibly 
longer duration. In regards to JUN co-expression, a decrease in the SR Ca2+ load has been 
previously observed in myocytes isolated from JUN-overexpressing mice, together with 
depressed relaxation kinetics of the Ca2+ transient (including a prolonged rate of Ca2+ 
decay as found in this investigation (Figure 4.15)), (Kirchhefer et al., 2006). These effects 
were attributed to JUN directly modifying RyR2 Ca2+ release to regulate the SR Ca2+ 
content (Kirchhefer et al., 2006). Furthermore, in human heart failure it has been 
suggested that diminished JUN expression may be a compensatory mechanism intended 
to raise Ca2+ levels within the SR (Yuan et al., 2007).   
 
 
4.4.3. Do mutant hRyR2s respond differently to luminal accessory protein co-
expression? 
 
When evaluating the response of mutant hRyR2 channels to luminal protein co-expression 
and comparing this data to the WT, it was important keep in mind the differences observed 
between the channels when expressed alone (4.4.1).  
 
4.4.3.1.  [3H] ryanodine binding investigations:  
 
Luminal accessory protein co-expression did not modify the enhanced [3H] ryanodine 
binding exhibited by A4556T hRyR2 channels expressed alone (Figure 4.8, non-
normalised data, left graphs) and the EC50 of each Ca2+ activation curve were comparable 
(Figure 4.8, right graphs). Similarly, the Ca2+ activation profile of mutant N4104K hRyR2 
channels, measured by [3H]-ryanodine binding, was unchanged by luminal accessory 
protein co-expression, as found in all other investigations. As discussed in section 4.4.2.1, 
the [3H] ryanodine-binding assay was not sensitive enough to pinpoint subtle differences 
imparted by CSQ2 and/or JUN co-expression (or could reflect altered protein-protein 
interactions caused by the use of high salt conditions, Figure 4.11).  
 
 4.4.3.2.  Measurement of SCR parameters by single-cell Ca2+ imaging:  
 
At the cellular level, differences in the response of mutant channels to CSQ2 and JUN 
association (compared to A4556T and WT hRyR2 alone) were detected as presented in 
Figure 4.17. In particular, the notable inhibitory effects of CSQ2 on the SCR parameters in 
cells expressing WT hRyR2 were not evident when co-expressed with A4556T channels, 
suggesting the mutant responded differently to CSQ2 association. Alternatively, this 
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difference could reflect disrupted association of CSQ2 with A4556T channels, which will 
be examined in Chapter 5. Interestingly, co-expression of A4556T channels with both 
accessory proteins (CSQ2+JUN) seemed to alter the SCR properties in a similar manner 
to WT channels, enhancing the duration of events, inter-SCR duration and causing a 
subsequent reduction in SCR event frequency, rate of Ca2+ release and decay (Figure 
4.17). Collectively, this suggests that the effects of CSQ2 on RyR2 were restored in the 
presence of JUN. Interestingly, in A4556T hRyR2 [3H] ryanodine binding experiments it 
was also noticed that CSQ2 and JUN co-expression restored the increased basal [3H] 
ryanodine binding seen at low [Ca2+] to WT levels (Figure 4.8, (C), left graph), although 
this was not a statistically significant effect. On the contrary, the ER Ca2+ load in 
A4556T+CSQ2+JUN expressing HEK293 cells appeared to be enhanced by luminal 
protein co-expression, which was the exact opposite to the effects observed in WT 
channels (Figures 4.15 and 4.17). Although it was first thought that the A4556T hRyR2 
mutation could be benign (discussed in section 4.4.1.1), the discrepancies in the response 
of the mutant (vs. WT) to luminal protein co-expression (observed in Ca2+ imaging studies) 
could reflect an effect on RyR2 activity after all, albeit because it cannot be regulated in 
the same way by luminal accessory proteins (notably CSQ2), rather than by a direct effect 
on channel gating. As discussed previously, HEK293 cells expressing N4104K hRyR2 
alone displayed an entirely different SCR profile to those expressing WT hRyR2 (Figures 
4.12 and 4.13), which therefore needed to be considered when assessing the response to 
luminal protein co-expression. With this in mind, the observed alterations in the SCR-event 
properties imparted by CSQ2 and/or JUN co-expression were surprisingly similar to those 
found in WT investigations. As demonstrated in Figure 4.19, expression of the luminal 
proteins (all combinations) with N4104K generated a significant increase in the SCR 
duration and a reduction in SCR-event frequency. The inhibitory effects of CSQ2 
(expressed alone and with JUN) exhibited in WT channels were also evident when 
expressed in combination with N4104K. In addition to the alterations aforementioned, co-
expression of CSQ2 with N4104K hRyR2 caused a prolongation of the inter-SCR duration. 
Unlike WT channels, the ER Ca2+ content in cells expressing N4104K was not significantly 
affected by luminal protein co-expression (Figure 4.19). This difference however could be 
a refection of the Ca2+ store itself, which appeared to be significantly lower in N4104K 
expressing HEK293 cells without luminal protein co-expression (Figure 4.13). 
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4.4.4. Concluding Remarks: 
 
Examining the spontaneous Ca2+ release kinetic properties in HEK293 cells appeared to 
be a much more efficient technique than [3H] ryanodine binding to detect small but notable 
changes in the response of hRyR2 channels to activating Ca2+, generated by luminal 
accessory protein co-expression. However, unlike [3H] ryanodine binding, direct Ca2+ 
activation could not be measured in these experiments. As highlighted in section 3.4.2, a 
limitation of using transient expression for [3H] ryanodine binding investigations was the 
possibility that mixed populations of WT/mutant hRyR2+luminal protein complexes could 
exist. Immunofluorescent staining however, demonstrated that most cells expressing 
hRyR2 were likely to also have CSQ2 and/or JUN co-expression, since much higher 
transfection efficiencies of the luminal proteins in comparison were achieved. Given our 
limited knowledge of the exact RyR2-JUN-CSQ2 stoichiometry in vivo (Terentyev et al., 
2006, Lee et al., 2012), it is difficult to establish precisely how such mixed populations 
could have affected the [3H] ryanodine binding data.  In particular, since the technique 
failed to generate any significant differences when WT hRyR2 channels were co-
expressed in the presence of CSQ2 and/or JUN. It is possible that without the 
physiologically relevant stoichiometry, the degree of hRyR2 channel regulation (whether it 
be stimulatory or inhibitory) would be reduced or even completely abolished.  
 
It is typically assumed that JUN binds at a stoichiometry of one JUN per RyR2 monomer 
(or 4 JUN per RyR2 tetramer), and subsequently binds CSQ2, anchoring it close to the 
site of Ca2+ release (Zhang et al., 1997, Terentyev et al., 2006). Further to simply acting as 
an anchoring protein, JUN has been suggested to also ‘sense’ changes in luminal [Ca2+] 
(Altschafl et al., 2011), (Table 1.2). Altschafl et al (2011) proposed that JUN might bind at 
two distinct sites within RyR2, the binding of which is governed according to the luminal 
[Ca2+] within the SR. In vivo, at low luminal Ca2+ (<1 mM), JUN was hypothesised to bind 
to only one RyR2 site, whilst its other binding site is occupied by CSQ2, preventing its 
binding to RyR2 (Altschafl et al., 2011). At low luminal Ca2+ (and in the absence of CSQ2), 
a stimulatory role of JUN on RyR2 gating was reported, an effect that is likely masked in 
the presence of CSQ2 (Altschafl et al., 2011). A small stimulatory effect was evident in [3H] 
ryanodine binding investigations of hRyR2 channels co-expressed with JUN only, as 
discussed in section 4.3.2.1, Figure 4.7. CSQ2+JUN and/or TRD1 (added together at the 
single channel level) were reported by Györke et al (2004) to have an inhibitory effect on 
hRyR2 channel activity. However, the single-cell Ca2+ imaging data carried out in this work 
(discussed further in section 4.3.4) revealed inhibitory effects of CSQ2 on hRyR2 activity 
both when expressed alone and in the presence of JUN, suggesting the precise 
stoichiometry in vivo needs to be examined in greater detail. As outlined in section 1.3, 
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cryo-EM analysis and discovery of CSQ2, JUN and TRD1 binding sites on RyR2 
channels, would facilitate this identification.  
 
In Ca2+ imaging studies, N4104K hRyR2 channels were considerably different to those 
observed in both WT and A4556T hRyR2-expressing cells. Thus, further highlighting how 
functional heterogeneity can exist between CPVT mutants (Thomas et al., 2004). The 
major differences in the response of WT and mutant hRyR2 channels to luminal protein 
co-expression were observed when the channels were expressed with each protein 
individually (CSQ2 or JUN).  However, mutant hRyR2 responded similarly to WT channels 
when co-expressed in the presence of both accessory proteins (hRyR2+CSQ2+JUN). All 
Ca2+ imaging data collected are summarised in the Appendix, Figure 7. Where apparent 
trends in the Ca2+ imaging data were evident, yet no statistically significant differences 
were detected, it is possible that an insufficient number of experiments were conducted. 
To test this idea, using Figure 4.17 (cells expressing A4556T hRyR2 in the 
absence/presence of luminal proteins) and assessment of the inter-SCR duration as an 
example, a post-hoc power analysis was performed on the data using G*Power 3 software 
(www.gpower.hhu.de). The power of the study was calculated according to the mean 
values and standard deviations obtained within each data set (A4556T hRyR2 only vs 
A4556ThRyR2+JUN and/or CSQ2). In those data where significant differences were 
identified, the study was considered to be highly powered (A4556T hRyR2 vs 
A4556T+JUN and vs A4556T+CSQ2+JUN) at  >99%; whilst data derived from cells 
expressing A4556T+CSQ2 (where no significance difference in inter-SCR duration to 
A4556T only was distinguished) was powered to 80%; which is still an accepted level of 
power for detecting differences between the specified data (Beck, 2013). It is therefore 
likely that the number of samples used for analysis were adequate to detect real 
differences. On the other hand, using the same data as an input for a priori sample size 
estimation (where the mean and standard deviation of each group are predicted before 
commencement of the study), it was estimated that a further 10 experiments in total (i.e, 5 
more per group (A4556T hRyR2 only and A4556T+CSQ2 compared) would be required to 
achieve a power of >95%. It is thus possible that undertaking these additional experiments 
may have revealed a statistical difference. In future experiments, finding the sample size 
necessary to achieve a high-powered investigation by use of a power calculation, could 
aid identification of statistically significant differences between datasets.  
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Chapter 5 
 
Protein-protein interactions of wild 
type and mutant (A4556T and 
N4104K) hRyR2 with luminal 
accessory proteins CSQ2 and JUN 
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5.1 Introduction: 
 
5.1.1. Interactions of calsequestrin, junctin and the cardiac ryanodine receptor:  
 
Under normal circumstances, intracellular Ca2+ handling within the myocardium relies on 
an intricate interplay between the Ca2+ release channel, RyR2, and its associated 
accessory proteins, which localise to the junctional SR membrane and form a multimeric 
signalling complex that orchestrates Ca2+ release (Guo et al., 1996, Bers, 2004). As 
discussed further in previous chapters (section 4.1.1), CSQ2 and JUN are thought to form 
part of a luminal Ca2+ sensor, together with the luminal domains of RyR2 and TRD1 
(Zhang et al., 2014; TRD1 discussed in section 1.6.3). However, the exact protein-protein 
interactions underlying assembly of this quaternary complex remain undefined. In 
particular, although CSQ2 is one of the better characterised RyR2 accessory proteins 
(Slupsky et al., 1987, Kim et al., 2007, Knollmann et al., 2009), direct evidence of whether 
CSQ2 interacts directly with hRyR2 channels or indirectly through its anchoring to JUN 
and/or TRD remains to be properly established (Terentyev et al., 2006, Dulhunty et al., 
2012, Chen et al., 2014). This chapter will first describe our current knowledge of the 
protein-protein interactions that take place between CSQ2, JUN and RyR2 in the jSR 
lumen, prior to interaction studies with mutant and WT hRyR2 carried out in this 
investigation.   
 
5.1.2. Evidence of a direct binding interaction between cardiac JUN and CSQ2:  
            
            Using an 125I-calsequestrin filter overlay assay, Mitchell et al (1988) first identified JUN as 
the predominant CSQ2-binding protein present in jSR membranes of dog cardiac muscle, 
leading to the idea that this transmembrane protein was the major physiological anchor of 
CSQ2, holding it within close proximity to RyR2 channels (Mitchell et al., 1988, Beard et 
al., 2004). However, following further investigations, it is now generally accepted that both 
TRD1 and JUN are likely to mediate the interaction between CSQ2 and RyR2 (Zhang et 
al., 1997, Györke et al., 2004), as highlighted in Chapter 1, Tables 1.2-1.3. With emphasis 
on the role of JUN, Zhang et al (1997) used several different techniques to examine the 
binding interactions of the protein with other jSR components important for Ca2+ release, 
including cardiac CSQ2 and RyR2 (Zhang et al., 1997). Evidence that JUN binds directly 
to CSQ2 was demonstrated by immunoprecipitation (IP), where endogenous JUN and 
CSQ2 were immunoprecipitated from detergent-solubilised dog cardiac jSR vesicles by 
incubation with #-CSQ2 (JUN detection) and #-JUN (CSQ2 detection) antibodies, 
respectively. Increasing [Ca2+] disrupted the binding interaction between CSQ2 and JUN, 
with half-maximal inhibition evident between 0.6-0.8 mM CaCl2 (Zhang et al., 1997). The 
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CSQ2-binding domain of JUN was localised to the luminal region of the molecule, 
determined by CSQ2-affinity chromatography with Glutathione S-transferase (GST)-fusion 
proteins corresponding to the cytoplasmic/luminal domains of JUN conjugated to affinity 
beads (Zhang et al., 1997). In contrast to IP experiments, the binding interaction between 
the two proteins remained significant at mM Ca2+ concentrations. Analysis of the JUN 
fusion protein, identified the highly charged “KEKE motif” (section 1.6.3) at the intraluminal 
region (amino acid residues 46-210) of the protein as the site that interacts with the 
aspartyl-rich region of CSQ2, and proposed that these electrostatic interactions stabilise 
protein binding (Zhang et al., 1997, Shin et al., 2000, Pritchard and Kranias, 2009). A later 
investigation by Kobayashi and co-workers however, revealed that JUN does not appear 
to have a discrete CSQ2 binding domain, since deletions in several KEKE motifs along the 
C-terminal tail of the protein significantly reduced CSQ2 binding (Kobayashi et al 2000). 
Furthermore, the aspartyl-rich region of CSQ2 has been suggested as a major Ca2+ 
binding motif, where elevations in [Ca2+] could induce a conformational change in the 
protein structure and diminish its interaction with JUN and/or TRD1 or the proteins may 
compete for the Ca2+ binding sites (Shin et al., 2000). To further examine the role of JUN 
in anchoring CSQ2 within close contact to RyR2 channels (Zhang et al., 1997, Guo et al., 
1996), the structural effects of JUN overexpression have been investigated (Zhang et al., 
2001, Tijskens et al., 2003). Cardiomyocytes isolated from transgenic mice, 
overexpressing cardiac JUN exhibited changes in cellular morphology, such as a 
narrowing of the junctional SR cisternae and compaction of its content (Zhang et al., 
2001), whilst the opposite was seen in an earlier study of CSQ2 overexpression, where 
SR cisternae were greatly enlarged and their content displayed a dispersed appearance 
(Jones et al., 1998). Complementing these findings, Tijskens et al described that although 
JUN was not necessary for targeting of CSQ2 to the terminal cisternae, enhanced 
expression of the protein produced a strong-ordering effect and tighter clustering of CSQ2 
at jSR sites, condensing the Ca2+ binding protein at the jSR membrane within close 
proximity to RyR2 channels (Tijskens et al., 2003). These findings support the view that 
JUN, either directly or indirectly (via an effect on jSR structure) has an effect on the 
functional coupling between CSQ2 and RyR2.  
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5.1.3. Evidence of cardiac JUN association with RyR2: 
 
Zhang et al (1997) also observed a direct binding interaction between cardiac JUN and 
RyR2, demonstrated by IP investigations and [3H] ryanodine binding. Dog JUN was first 
immunoprecipitated from detergent-solubilised jSR vesicles using a JUN monoclonal 
antibody (mouse 5D8) covalently coupled to protein A agarose beads. Once obtained, the 
resultant immunoprecipitate was subsequently incubated with a RyR2 specific antibody 
that detected a substantial amount of RyR2 protein adsorbed to the JUN-bound beads 
(Zhang et al., 1997). Similar to CSQ2, the RyR2 interacting domain of JUN was located to 
the luminal region, identified by [3H] ryanodine binding (established by measuring the 
percentage of purified RyR2 channels precipitated from fusion protein affinity-beads), 
(Zhang et al., 1997). To confirm direct binding between the two proteins without influence 
from other jSR components, a GST fusion protein corresponding to the luminal domain of 
JUN was shown to interact with purified RyR2 channels in a Ca2+-independent manner. 
Following predictions that a single binding site at intraluminal loop II of the RyR1 protein is 
responsible for binding the KEKE-motif of TRD (Goonasekera et al., 2007), Altschafl et al 
in 2011, examined if the KEKE-motif of JUN also binds specifically to the intraluminal loop 
II of RyR2 (Altschafl et al., 2011). Using recombinant JUN and RyR2 polypeptides 
designed to different intraluminal binding regions of the two proteins, the group 
demonstrated biochemically (via a blot overlay assay) that at least two distinct regions of 
JUN are capable of interacting with RyR2 channels, one of which contained the 
aforementioned KEKE-motif (Altschafl et al in 2011). It was suggested that the N-proximal 
intraluminal domain of JUN interacts with intraluminal loop I of RyR2 (residues 4520-
4553), whilst the KEKE-motif of JUN interacts with RyR2 at intraluminal loop II (residues 
4789-4846), (Altschafl et al., 2011). The existence of multiple protein-protein interactions 
between the two proteins strengthened the observations reported by the group that JUN 
plays a dual role in regulating RyR2 activity (as highlighted in Table 1.2.), (Altschafl et al in 
2011) and does not merely act as a linker between CSQ2 and the Ca2+ release channel. 
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5.1.4. Does CSQ2 associate directly with RyR2 channels?  
 
CSQ2 is generally considered to interact with the RyR2 Ca2+ release channel via its 
association with JUN and/or TRD1 (Györke et al., 2004, Beard et al., 2009). However, 
several groups have also proposed that CSQ2 may bind to RyR2 channels themselves 
(Szegedi et al., 1999, Wei et al., 2009b, Murray and Ohlendieck, 1998), but direct 
evidence of such an interaction and its significance to myocardial function has not been 
determined (Murray and Ohlendieck, 1998, Terentyev et al., 2006, Chen et al., 2014). 
Currently, only investigations of protein-protein interactions between the skeletal isoforms 
of the two proteins have been reported. For example, Herzog et al (2000) used surface 
plasmon resonance (SPR) to prove a high affinity molecular interaction between CSQ1 
and RyR1. In addition, Murray and Ohlendieck (1998) observed a complex formation 
between CSQ1 and RyR1 in fast- and slow-twitch muscle rabbit skeletal muscle. 
Furthermore, lipid bilayer experiments have demonstrated that purified RyR1 (absent of 
TRD1, JUN and CSQ2 associations) are activated by exogenous CSQ1 added back to the 
reconstituted channel, providing further evidence that more than one mechanism of CSQ1 
association with RyR channels may exist (Beard et al., 2009). Other unresolved questions 
include whether CSQ2 can bind directly to RyR2 in the presence of JUN and/or TRD, or if 
the anchoring proteins prevent direct binding of CSQ2 to the Ca2+ release channel. It has 
been hypothesised that the Ca2+ binding protein binds directly to RyR2 in both the 
presence and absence of JUN and/or TRD1, the response of the channel may be altered 
from activation to inhibition when bound to the anchoring proteins (Györke et al., 2004, 
Beard et al., 2004, Wei et al., 2009a).  
 
5.1.5. Defective protein-protein interactions contribute to the pathophysiology of 
CPVT 
 
As discussed previously in Chapter 1 sections 1.7-1.8.4, mutations in RyR2 and CSQ2 are 
linked to CPVT, where alterations in the two proteins generate significant Ca2+ handling 
defects that can lead to SCD (Laitinen et al., 2003, Jiang et al., 2004; Song et al., 2007; 
Venetucci et al., 2008). Abnormal expression of JUN is also associated with CPVT 
(Kirchhof et al., 2007). Taking into consideration the numerous accessory proteins that 
have been proposed to interact with the hRyR2 Ca2+ release channel, it is unsurprising 
that defective protein-protein interactions are suggested as a contributing mechanism of 
CPVT (Wehrens et al., 2003, Thomas et al., 2007). For example, a CPVT-linked mutation, 
R2474S, was found by Xu et al (2010) to disrupt regulation of RyR2 interdomain 
interactions; and as a consequence reduced the binding affinity of the accessory protein 
calmodulin (section 1.5.3). Furthermore, a regulatory protein shown by some groups to 
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stabilise the closed state of RyR2 channels, FKBP12.6 (section 1.5.1), has been 
suggested to dissociate from the channels during heart failure (Marx et al., 2000, Blayney 
et al., 2010). Furthermore, the underlying mechanism responsible for the deleterious 
effects of a CPVT2-linked CSQ2 mutation, R33Q, was ascribed to a disruption in the 
protein-protein interactions between CSQ2 and the RyR2 Ca2+ release complex; rather 
than a defective Ca2+ binding capacity which had been reported for other CSQ2 mutants 
(Terentyev et al., 2006, Rizzi et al., 2008, Venetucci and Eisner, 2008). Valle et al (2014) 
recently described how a knock-in mouse model of CSQ2-R33Q displayed not only a 
significant reduction in CSQ2-R33Q expression in early development, but also down-
regulation of JUN and TRD1, and morphological changes of the jSR, all of which may 
culminate to promote diastolic Ca2+ release from the SR (Valle et al., 2014, Knollmann et 
al., 2006). Given the proposed roles of CSQ2 and JUN in regulating the response of 
hRyR2 channels to luminal Ca2+ (Györke et al., 2004, Fan et al., 2008, Altschafl et al., 
2011) and since mutations in CSQ2 appear to alter its structure such that it can no longer 
associate with the channel (either directly or via its association with JUN and/or TRD1), it 
is plausible that CPVT-linked RyR2 mutations (in particular those located at the luminal 
domain of the channel (e.g., A4556T) could affect the interaction of these accessory 
proteins; a concept that will be investigated in this chapter. 
 
5.1.6. Chapter Aims  
 
This chapter examines the protein-protein interaction between WT/mutant hRyR2 and the 
jSR luminal accessory proteins, CSQ2 and JUN. The transfection efficiencies of co-
expressed CSQ2/JUN, and their intracellular trafficking, will be assessed using 
immunofluorescent detection. In addition, fluorescent labelling will be used to measure the 
degree of co-localisation between the luminal accessory proteins and WT/mutant hRyR2, 
where any differences in mutant protein interaction will be indicated. To specifically 
establish if defective interaction of the luminal proteins with mutant hRyR2 may be a 
contributing factor in the pathophysiology of CPVT, co-immunoprecipitation (Co-IP) 
experiments will also be carried out. Using this technique, the ability of CSQ2 and JUN to 
directly bind to hRyR2 channels (in the absence of other interacting proteins) will be 
assessed, before determining whether mutant hRyR2 channels associate differently with 
CSQ2 and/or JUN in situ. 
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5.2 Methods: 
 
5.2.1. Immunofluorescent detection of hRyR2 and co-localisation with luminal     
accessory proteins CSQ2 and JUN:  
 
HEK293 cells co-expressing hRyR2 and either CSQ or JUN (or both in combination) were 
fixed in 4% paraformaldehyde and probed with #-CSQ2 or #-JUN primary and Alexa® Fluor 
594 labelled secondary antibodies, as specified in Chapter 2, section 2.4.3.6. WT and 
mutant hRyR2 expression were detected by their eGFP epitope tag. The transfection 
efficiencies of CSQ2 and JUN within a transfected HEK293 cell population were calculated 
by imaging the cells using a Zeiss fluorescence microscope. To visualise the co-
localisation of WT/mutant hRyR2 with CSQ2 or JUN, the cells were imaged using an SP5 
confocal microscope (Leica) with an oil immersion, x63 objective. Alexa® -594 fluorescence 
was excited at 590nm with a helium-neon laser and was detected over a 617nm±33 range, 
whilst eGFP fluorescence was excited with an argon laser (peak excitation = 488nm) and 
detection of emission at 520nm±28. As described by George et al (2003a), high resolution 
overlay images of the co-incident eGFP and Alexa® Fluor pixels were captured using Leica 
Microsystems LAS-AF software, such that the “percentage overlap” of co-incident pixels 
(corresponding to eGFP-hRyR2 and CSQ2/JUN expression, respectively) could be 
calculated. Adobe Photoshop was used to quantify the percentage of eGFP (green) pixels 
that were directly co-incident with Alexa®-594 (red) pixels, which appeared as yellow pixels 
when directly overlaid (or “merged”) with each other  (George et al., 2003a).  
 
5.2.2. Co-Immunoprecipitation of CSQ2 and JUN by WT and mutant hRyR2: 
 
Mixed membrane preparations were generated from transfected HEK293 cells (section 
2.4.3.1) expressing WT or mutant hRyR2, in combination with either JUN or CSQ2 alone, 
or co-expression of both accessory proteins (JUN+CSQ2). As demonstrated in Figure 5.1 
(A-C), all samples were first standardised for hRyR2 expression by Western blotting (A) 
and densitometric analysis (B), such that comparable amounts of WT and mutant hRyR2 
protein were used in all Co-IP experiments (C). Using the !MACS" system from Miltenyi 
Biotec (Figure 2.5), detergent-solubilised ER membranes (2 mg/ml) were incubated with 
50!l anti-GFP magnetic microbeads to covalently couple the eGFP-tagged hRyR2 protein 
and the immunoprecipitated material captured using !MACS" columns. Details of the Co-
IP protocol are described in Chapter 2, section 2.4.3.6, together with those for SDS-PAGE 
and Western blotting (sections 2.4.3.3-2.4.3.4) which were used to visualise co-
immunoprecipitates eluted from the !MACS" columns. These were subsequently 
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analysed by densitometry. This protocol was also used to examine the direct association of 
CSQ2 with JUN, where detergent-solubilised microsomal membranes were captured using 
!MAC" Protein A microbeads (Miltenyi Biotec) labelled by incubation with "-CSQ2  
antibody and the resultant immunoprecipitate probed via Western blot analysis for JUN 
detection.  
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Figure 5.1: All mutant hRyR2 samples were standardised to WT hRyR2 expression before 
use in Co-IP investigations:  
 
(A) Illustrates an example of a Western blot of hRyR2 expression in mixed membranes co-
expressing WT/mutant hRyR2 and CSQ2 only (NK= N4104KhRyR2, AT=A4556ThRyR2).  
 
(B) Represented as a bar graph, to normalise for hRyR2 expression densitometric analysis was 
carried out on the Western blot signals obtained in (A).  
 
(C) Following densitometry and before use, mutant hRyR2 test samples were standardised 
against WT for hRyR2 expression, such that equivalent amounts of each were used in the Co-IP 
experiment.  
 
(D) Detection of any non-specific CSQ2/JUN binding to the !MACS" columns was established 
in preliminary Co-IPs. Shown here is an example of JUN detection by Western blot, where in 
solubilised (2mg/ml) mixed membranes expressing JUN only, no JUN expression was evident 
following elution from anti-GFP microbeads. In contrast, JUN was detected in immunopreciptates 
co-expressing the luminal protein with WT/mutant hRyR2. JUN detection in unsolubilised 
material expressing JUN only (JUN Unsol) is also demonstrated.  
 
The preparatory stages described in (A)-(D) were carried out for all test samples before use in 
Co-IP experiments.  
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5.3 Results: 
 
5.3.1. Determination of CSQ2 and JUN transfection efficiencies by 
immunofluorescent labelling:  
 
Alexa® Fluor-594 labelling enabled the transfection efficiencies of untagged CSQ2 and 
JUN constructs to be calculated. In each field of view analysed, the accessory proteins 
and eGFP-hRyR2 were expressed to a high level, and predominantly within the same cells 
of a population (assessed by the % of cells which appeared both green and red, indicative 
of hRyR2 and CSQ2/JUN expression, respectively). Co-expression of WT or mutant 
hRyR2 with the accessory proteins yielded similar transfection efficiencies as illustrated in 
Figure 5.2 (n=4 populations counted for each expressed protein). When the transfection 
efficiencies of CSQ2 and hRyR2 were assessed, the percentage of cells which appeared 
both green and red were as follows: WT: 98±1%, A4556T: 97±2% and N4104K: 97±1%. 
Assessment of JUN and hRyR2 transfection efficiencies yielded similar results (WT: 
98±2%, A4556T: 96±1% and N4104K: 98±1%), suggesting a high degree of luminal 
protein co-expression. An example of JUN and CSQ2 staining in transfected HEK293 
populations co-expressing WT hRyR2+CSQ2+JUN is shown in Figure 5.3. To detect any 
non-specific staining, two controls were used: (1) transfected HEK293 cells treated with 
the Alexa® Fluor-594 secondary antibodies only and (2) untransfected HEK293 cells 
treated with both CSQ2/JUN primary and Alexa® Fluor-594 secondary antibodies (Figure 
5.3). When imaging the cells by confocal microscopy, the negative controls were used to 
adjust the photomultiplier tube (PMT) voltage gain (red), such that the cells were imaged 
at a level where no non-specific staining could be identified.  
 
!"
#"
$!"
$#"
%!"
%#"
&!"
&#"
'!"
'#"
()" *'##+)" ,'$!'-"
!"
$!"
%!"
&!"
'!"
#!"
+!"
.!"
/!"
0!"
()" *'##+)" ,'$!'-"
!"
$!"
%!"
&!"
'!"
#!"
+!"
.!"
/!"
0!"
()" *'##+)" ,'$!'-"
!"
#$
%&
'(
)*
$+
,-
(.'
$(
/+0
1
2+
34/45+'67"'%%.*$+
!"
#"
$!"
$#"
%!"
%#"
&!"
&#"
'!"
'#"
()" *'##+)" ,'$!'-"
!"
$!"
%!"
&!"
'!"
#!"
+!"
.!"
/!"
0!"
()" *'##+)" ,'$!'-"
!"
$!"
%!"
&!"
'!"
#!"
+!"
.!"
/!"
0!"
()" *'##+)" ,'$!'-"
89:5+'67"'%%.*$+
!"
#"
$!"
$#"
%!"
%#"
&!"
&#"
'!"
'#"
()" *'##+)" ,'$!'-"
!"
$!"
%!"
&!"
'!"
#!"
+!"
.!"
/!"
0!"
()" *'##+)" ,'$!'-"
!"
$!"
%!"
&!"
'!"
#!"
+!"
.!"
/!"
0!"
()" *'##+)" ,'$!'-"
;<=+'67"'%%.*$+
!"
#$
%&
'(
)*
$+
,-
(.'
$(
/+0
1
2+
!"
#$
%&
'(
)*
$+
,-
(.'
$(
/+0
1
2+
!%#$ !"#$
!&#$
Figure 5.2: Comparable transfection efficiencies of HEK293 cell populations 
(n=4) expressing WT/mutant hRyR2, CSQ2 and JUN  
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Figure 5.3: Imaging of CSQ2 and JUN co-expression with eGFP-hRyR2 in HEK293 
cell populations. Typical fields of view of cells imaged at 10x magnification are shown, 
taken using a Zeiss fluorescent microscope. Top left panels represent brightfield images 
of the transfected cells transiently expressing WT hRyR2, JUN and CSQ2. Top right 
panels display images of (A) CSQ2 detection and (B) JUN detection, following labelling 
of the accessory proteins with a red fluorescent secondary antibody. Images of eGFP 
detection are shown in the bottom left panels. Bottom right panels show immunostaining 
controls. (A) untransfected HEK293 cells were treated with the same primary and 
secondary antibodies to ensure no non-specific (background) binding was detected 
(cells shown were treated with anti-CSQ2 and Alexa®-594 anti-rabbit) and (B) 
transfected cells were treated with secondary antibodies (cells shown were treated with 
Alexa®-594 anti-mouse). As illustrated, only very low background fluorescence was 
evident. 
 
(A) 
(B) 
        150 µm 
        150 µm 
        150 µm 
        150 µm 
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5.3.2. Evidence of greater CSQ2 condensation with JUN co-expression: 
 
To ensure that any observed functional consequences of luminal protein or mutant RyR2 
co-expression was not caused by protein mis-trafficking, immunofluorescence analysis was 
first used to confirm that all co-expressed recombinant proteins were correctly localised 
within HEK293 cells (Chapter 3, Figure 3.9), where the ER is thought to be analogous to 
the junctional SR of cardiac muscle (Milstein et al., 2009; Knollmann et al., 2010). 
Illustrated in Figure 3.9, hRyR2, JUN and CSQ2 signals could be detected throughout the 
ER of the transfected HEK293 cells, both surrounding the nucleus and extending towards 
the central part of the cell. Cardiac CSQ2 has previously been shown to localise primarily 
to proximal ER compartments in non-muscle cells (Rossi and Sorrentino 2002, Houle et al., 
2006), whilst using electrospray ionisation mass spectrometry it has been demonstrated 
that in HEK293 cells, CSQ2 displays a glycan structure characteristic of an endoplasmic 
reticulum-localised glycoprotein (O’Brian et al., 2002).  
 
Consistent with these observations, most CSQ2 staining was identified in proximal ER 
regions (i.e., through the body of the cell but not immediately adjacent to the nucleus), 
however interestingly, more intense staining in the peri-nuclear membrane (i.e., adjacent to 
the nucleus) was visualised when CSQ2 was expressed in the presence of JUN. The 
brighter fluorescence signals corresponding to CSQ2 in this region are demonstrated in 
Figure 5.4: (A) WThRyR2+CSQ2+JUN, (B) N4104KhRyR2+CSQ2+JUN and (C) 
A4556ThRyR2+CSQ2+JUN. In HEK293 imaged with hRyR2+CSQ2+JUN co-expression, 
CSQ2 staining appeared brighter in 68% of cells with WThRyR2 expression, 75% of 
N4104KhRyR2 and 71% of A4456ThRyR2. In contrast, in cells expressing hRyR2+CSQ2 
only, brighter staining in the peri-nuclear membrane was only evident in 20% of cells with 
WThRyR2 expression, 30% of N4104KhRyR2 and 25% of A4456ThRyR2.  
 
Since CSQ2 does not contain any known ER targeting sequences such as the C-terminal 
KDEL tetrapeptide found in other resident ER proteins (such as calreticulin (Sönnichsen et 
al., 1994)), investigations into the molecular mechanism(s) responsible for retaining the 
Ca2+ binding protein in the junctional SR is a popular subject of current research 
(Knollmann et al., 2010; McFarland et al., 2010; Guo et al., 2012). As highlighted in Figure 
5.4, co-expression of JUN with CSQ2 seemed to cause a tighter condensing of the luminal 
protein within the ER, and thus indicates JUN binding could be an important factor involved 
in CSQ2 ER/SR retention. Consistent with this suggestion, in cardiomyocytes isolated from 
transgenic mice with overexpression of both CSQ2 and JUN, CSQ2 was found to be 
packed within close proximity to the SR membrane, whilst when expressed alone the 
protein displayed a more diffuse disposition (Tijskens et al., 2003). In this investigation, the 
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authors concluded that although JUN was not necessary for CSQ2 targeting to the terminal 
cisternae, JUN plays a significant role in retaining CSQ2 within the jSR lumen of cardiac 
muscle and that the typical SR “phenotype” is governed by expression of both luminal 
proteins (Tijskens et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Evidence of CSQ2 condensation at the peri-nuclear region in 
imaged HEK293 cells: When co-expressed in the presence of JUN, CSQ2 staining 
appeared brighter within the peri-nuclear region of HEK293 cells (highlighted with a 
dashed box in (A)). As discussed in section 5.3.2, this brighter staining was evident 
in a much larger percentage of cells co-expressing CSQ2+JUN, compared with 
those expressing CSQ2 only; thus suggesting JUN could be condensing CSQ2 
within this region. Cells expressing WThRyR2 (A), N4104K hRyR2 (B) and A4556T 
hRyR2 (C) in the presence of the luminal accessory proteins are shown.  
 
!"#$
!""#$
!"""#$
%
&$
'(
)(
*+
,-
.
*+
/0
%
$
!"#$%&!'!()*+% ,-!./%012%&!'!()*+%
$$1
2$
'(
)(
*+
,-
.
*+
/0
%
$
32
$'
()
(*
+,
-.
*+
/0
%
$(C) 
(B) 
(A) 
10 µm 
10 µm 
10 µm 
 162 
5.3.3. Immunofluorescence co-localisation studies to examine the interaction of WT 
and mutant hRyR2 with CSQ2 and JUN: 
 
Fluorescence labelling of hRyR2, JUN and CSQ2 (using an epitope tag or antibody 
labelling) enabled the degree of co-localisation between the recombinant proteins to be 
assessed. The extent of Alexa®-594 antibody (CSQ2/JUN) and eGFP (hRyR2) co-
localisation was quantified as the percentage of green pixels (eGFP) that were directly co-
incident with Alexa®-594 pixels (red) within a chosen image, which when merged (co-
incident) were presented as yellow pixels, as demonstrated in Figure 5.5 and 5.6 (right 
panels, (i) in A and B). Data (mean ± S.E.M) were obtained from the analysis of 8-12 
images in each instance and statistical differences detected using a Student’s t-test 
(GraphPad Prism).  No statistical differences were identified using ANOVA with a Tukey-
Kramer post-test. As suggested in the GraphPad Prism handbook (graphpad.com) this 
may have been due to the conservative nature of this post-test, which can result in subtle, 
but significant differences in the data being undetected. The findings are represented in 
Figures 5.5 and 5.6 as a series of bar graphs A and B, (ii).   
 
Figure 5.5 illustrates hRyR2 and CSQ2 detection, where overlay images of individual cells 
co-expressing WT/mutant hRyR2 with CSQ2 alone (A), (i) or in the presence of JUN (B), (i) 
are shown. N4104K hRyR2 appeared to co-localise with CSQ2 to a similar extent as WT 
hRyR2 channels (ii), in cells expressing CSQ2 alone (A): N4104K = 84% co-incident pixels 
± 3.0 vs. WT hRyR2 = 93.6% co-incident pixels ± 2.6, and with JUN co-expression (B): 
N4104K = 85% co-incident pixels ± 6.75 vs. WThRyR2 = 93% co-incident pixels ± 1.46. In 
cells expressing A4556T hRyR2 however, a significant reduction in the co-localisation of 
CSQ2 was evident, both when expressed alone with the Ca2+ release channel (A), (ii), 
(81% co-incident pixels ± 2.8) and in combination with JUN (B), (ii),  (80% co-incident 
pixels ± 3.0). Figure 5.6 demonstrates the detection of hRyR2 and JUN. Overlay images of 
individual cells co-expressing WT/mutant hRyR2 with JUN alone and in the presence of 
CSQ2 are shown in A, (i) and B, (i), respectively. When JUN was co-expressed alone with 
hRyR2 channels, no differences in its co-localisation with hRyR2 mutants were identified 
and a high degree of eGFP and Alexa® 594 co-localisation was evident in all cells imaged: 
WThRyR2+JUN only = 90%± 2.15, A4456T+JUN =86%± 4.0 and N4104K+JUN = 85%± 
6.75 co-incident pixels. In contrast, in the presence of both luminal proteins (CSQ2+JUN), 
JUN co-localisation appeared to be significantly reduced when co-expressed with A4556T 
hRyR2 channels B, (ii): A4556T = 79% co-incident pixels ± 6.0 vs. WT hRyR2 = 98% co-
incident pixels ± 0.89). As with CSQ2, no difference in the co-localisation of JUN with 
N4104K hRyR2 channels was evident (90% co-incident pixels ± 5.04, (B), (ii)).  
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To summarise, using immunofluorescence analysis, the A4556T hRyR2 mutation 
appeared to significantly reduce binding of CSQ2 in both the presence/absence of cardiac 
JUN. In addition, a decrease in JUN binding to this mutant was also evident, but was only 
calculated as significantly different in cells with CSQ2 co-expression (hRyR2+CSQ2+JUN). 
As discussed in the next section (5.3.4), following these observations, co-
immunoprecipitation experiments were carried out to closer examine the association of 
CSQ2 and JUN with WT/mutant hRyR2. 
 
 
Figure 5.5: Evidence of reduced CSQ2 binding to the A4556T hRyR2 mutation by 
immunofluorescent co-localisation: The top panels illustrate high-resolution images 
of transfected cells with detection of: eGFP-hRyR2 expression identified as green pixels 
(left images), CSQ2/JUN detection identified as red pixels (middle images) and a merge 
of the two (right images), which appear as yellow pixels and used to assess the degree 
of co-localisation. Immunofluorescent detection of CSQ2 in cells transfected with (A) 
hRyR2+CSQ2 only and (B) hRyR2+CSQ2+JUN are shown. The resultant pixel counting 
data (presented as the mean % co-incident pixels ± S.E.M) is represented in (A) and 
(B), (ii) as bar graphs, where 8-12 images in each instance were counted and any 
significant differences detected using a Student’s t-test (GraphPad Prism), where * = 
p<0.05 (compared with WT hRyR2+CSQ2 (A) (ii) or CSQ2+JUN (B) (ii), respectively). 
Co-localisation of CSQ2 appeared significantly reduced when co-expressed with 
A4556T mutant channels.  
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Figure 5.6: Evidence of reduced JUN binding to the A4556T hRyR2 mutation by 
immunofluorescent co-localisation: Top panels illustrate high-resolution images of 
transfected cells with detection of: eGFP-hRyR2 expression identified as green pixels (left 
images), CSQ2/JUN detection identified as red pixels (middle images) and a merge of the two 
(right images), which appeared as yellow pixels and was used to assess the degree of co-
localisation. Immunofluorescent detection of JUN in cells transfected with (A) hRyR2+JUN 
only and (B) hRyR2+CSQ2+JUN are demonstrated. The resultant pixel counting data 
(presented as the mean % co-incident pixels ± S.E.M) is represented in the bottom panels (A) 
and (B), (ii) as bar graphs, where 8-12 images in each instance were counted and any 
significant differences detected using a Student’s t-test (* = p<0.05). Compared with 
WThRyR2, co-localisation of JUN appeared significantly reduced with the A4556T mutant, but 
only when co-expressed in the presence of CSQ2 (B), (ii).   
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5.3.4. Assessment of protein-protein interactions between hRyR2 and the luminal 
accessory proteins using co-immunoprecipitation:  
 
A series of Co-IP experiments were carried out to further examine the association of WT 
and mutant hRyR2 with CSQ2 and JUN (individually and in combination (CSQ2+JUN)). 
The aim of using this technique was not only to assess the ability of each luminal 
accessory protein to directly interact with hRyR2, but also to study the effect hRyR2 
mutation may have on the ability of CSQ2 and/or JUN to bind with the Ca2+ release 
channel. In addition, although previously published by Zhang et al (1997) Co-IP was used 
to demonstrate a direct protein-protein interaction between recombinant CSQ2 and JUN in 
this investigation for completeness.   
 
Proteins captured by !MACS" columns (Figure 2.5), were eluted from anti-GFP 
microbeads (coupled to eGFP-hRyR2) and resolved by SDS-PAGE. Bound proteins were 
subsequently detected by Western blot analysis. Figure 5.7 illustrates two examples of 
Western blot detection, with protein bands corresponding to co-immunoprecipitated CSQ2 
and JUN shown in A (i) and (ii), respectively. In order to normalise the signal from the 
eluate (solubilised material) for expression of the luminal protein of interest, unsolubilised 
mixed membranes (50!g) were loaded and resolved alongside the corresponding 
experimental samples (as shown in Figure 5.7, A (i) and (ii)). Densitometric analysis was 
used to assess the signals obtained from the immunoprecipitates, where an n=5 blots were 
analysed for each mixed membrane sample tested, i.e., WT/mutant hRyR2 co-expressing 
CSQ2 and/or JUN.  
 
Interestingly, Co-IP investigations demonstrated that human cardiac muscle CSQ2 could 
directly interact with hRyR2 channels in the absence (Figure 5.7 (A), (i)) of other binding 
proteins, namely cardiac JUN in this project. To our knowledge, this is the first biochemical 
evidence to show a direct interaction of the Ca2+ binding protein with hRyR2. In the 
presence of JUN, CSQ2 was also found to be immunoprecipitated from hRyR2 channels. 
Likewise, a direct interaction of JUN with hRyR2 channels was seen in the presence 
(Figure 5.7 (A), (ii)) and absence of CSQ2 co-expression. Represented in Figure 5.7 (B), 
(i)-(iv) as a series of bar graphs, densitometric analysis of Western blot signals revealed 
that A4556T and N4104K hRyR2 channels appear to associate with CSQ2 and JUN to the 
same extent as WT, suggesting that these particular mutants do not alter the protein-
protein interactions between the luminal accessory proteins and hRyR2.   
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Although the focus in this investigation was to examine the binding of the luminal proteins 
to hRyR2 channels, further Co-IP investigations were completed to establish if CSQ2 and 
JUN interact directly with each other (as proposed by Zhang et al., 1997). Still using the 
!MACS" system, detergent-solubilised hRyR2+CSQ2+JUN mixed membranes (previously 
standardised for hRyR2 expression, as demonstrated in Figure 5.1) were instead 
incubated with !MACS" Protein A microbeads labelled with "-CSQ2 antibody (section 
2.4.3.6). As illustrated in Figure 5.8, to detect the presence of JUN in the 
immunoprecipitates, the collected eluates were resolved by SDS-PAGE and detection 
achieved by Western blot analysis. Since the primary aim of this investigation was to 
examine the interaction of CSQ2 and JUN with hRyR2 channels, densitometric analysis 
was not carried out the Western blot signals that examined the direct association between 
CSQ2 and JUN. However, JUN was successfully immunoprecipitated from solubilised 
hRyR2+CSQ2+JUN-expressing membranes by "-CSQ2 labelled microbeads (Figure 5.8), 
indicating a direct binding interaction between the luminal accessory proteins.  
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Figure 5.7: Co-immunoprecipitation demonstrates that mutation does not alter the 
interaction of CSQ2 or JUN with hRyR2: Examples of Western blot signals obtained 
from the detection of CSQ2 or JUN expression in captured immunoprecipitates are shown 
in (A) i and ii, respectively. Detection of CSQ2 in solubilised mixed membranes 
expressing hRyR2+CSQ2 only demonstrate that the luminal protein can bind directly to 
hRyR2 channels in the absence of other interacting proteins ((A),i). Unsolubilised material 
was resolved and detected alongside the experimental samples, such that the signals 
obtained in the eluate could be normalised for CSQ2/JUN expression by densitometry. 
Mutant hRyR2 channels were found to associate with CSQ2 and JUN to the same extent 
as WThRyR2 channels, as represented here as a series of bar graphs (B), i-iv. An n=5 
blots were analysed for each Co-IP study of CSQ2 or JUN immunoprecipitation when 
expressed alone or in combination (CSQ2+JUN) with hRyR2 and no statistically 
significant difference in WT/mutant RyR2 binding of luminal proteins was evident 
(assessed using one-way ANOVA and Tukey-Kramer post test (GraphPad Prism).  
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Figure 5.8: Direct protein-protein interactions between CSQ2 and JUN 
demonstrated by co-immunoprecipitation: JUN was successfully detected in 
solubilised hRyR2+CSQ2+JUN immunoprecipitates captured by protein A 
microbeads coupled with a "-CSQ2 antibody. As in previous Co-IP investigations, 
corresponding unsolubilised material was resolved alongside the experimental 
samples. JUN (+) highlights JUN detection in an unsolubilised mixed membrane 
sample expressing JUN only, included as a positive control. The appearance of an 
additional band underneath the cardiac JUN signal in some lanes during Western 
blotting has been reported in previous studies and has been attributed to the 
presence of an internal methionine at amino acid residue 30 (Lim et al., 2000). Upon 
assessing all Western signals generated that corresponded to JUN expression, only 
a single band was evident in 54% of blots, whilst in the other 46% a second band 
was evident (but appeared substantially fainter).   
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5.4 Discussion: 
   
• Immunofluorescent staining was used to identify cells co-expressing CSQ2/JUN and 
WT/mutant hRyR2 where accessory proteins routinely achieved higher transfection 
efficiencies than those seen for hRyR2. Assessment of co-incident pixels found that 
WT and N4104K hRyR2 associate with the luminal proteins to a similar extent, whilst 
A4556T hRyR2 display a significantly reduced association with CSQ2 and JUN.  
 
• Assessment of protein-protein interactions using co-immunoprecipitation and 
subsequent Western blotting demonstrated for the first time, the ability of CSQ2 to 
bind directly to hRyR2 channels, in the absence of JUN. Furthermore, direct binding 
of JUN alone and in the presence of CSQ2 to hRyR2 channels was established. 
Densitometric analysis of Western signals evidenced similar binding of CSQ2 and 
JUN to both WT and mutant hRyR2. The diminished association of CSQ2 and JUN 
with A4556T hRyR2 channels could not be replicated using this technique. 
 
 
5.4.1. Immunofluorescence staining confirms successful co-expression of CSQ2 
and JUN with hRyR2 in HEK293 cells: 
 
Following imaging of immunofluorescently labelled CSQ2 and JUN (Figure 5.3), it was 
established that high transfection efficiencies of CSQ2 and JUN were achieved by co-
expression with both WT and mutant hRyR2 channels, and that the efficiencies obtained 
were comparable (Figure 5.2).  As illustrated in Figure 5.3 and discussed in section 5.3.1, 
the luminal proteins and eGFPhRyR2 were predominantly expressed within the same cells 
of a population. This was vital to reliably assess the functional response of WT and mutant 
hRyR2 to luminal protein co-expression and indicated the ability of the proteins to 
associate in situ.   
 
Further to the immunofluorescence investigations described in Chapter 3 (section 3.3.5 
and Figure 3.9) to confirm correct trafficking of all co-expressed proteins to the ER of 
HEK293 cells, it was also recognised that JUN might play an important role in CSQ2 
retention. As demonstrated in Figure 5.4, as well as a reticular pattern of CSQ2 staining in 
proximal ER regions (also observed by Houle et al., 2006), much brighter fluorescence 
signals were observed in the peri-nuclear regions of cells when CSQ2 was co-expressed 
in the presence of JUN (i.e., cells transfected with hRyR2+CSQ2+JUN). Precisely how 
CSQ2, (being a small protein without a membrane spanning domain) is retained in the 
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junctional SR, has been the subject of a number of investigations. Milstein et al (2009) 
suggested that CSQ2 polymerisation is responsible for its retention in the jSR, since this is 
the first cellular compartment with ionic conditions favourable for CSQ2 polymerisation in 
cardiomyocytes; but did not discuss the potential involvement of the luminal accessory 
proteins (Milstein et al., 2009). It was however suggested by Knollmann et al (2010), that 
JUN (and TRD1) might help anchor a mesh of linear CSQ2 polymers to the mouth of the 
RyR2 Ca2+ release channels. The involvement of JUN in CSQ2 retention is supported by 
co-immunoprecipitation investigations in this project (Figures 5.7 and 5.8) and as 
demonstrated by Zhang et al (1997), where JUN is immunoprecipitated with both CSQ2 
and RyR2 channels.  
 
 
5.4.2. Examination of the protein-protein interactions between WT or mutant hRyR2 
with CSQ2 and/or JUN using immunofluorescent co-localisation and co-
immunoprecipitation: 
 
The possibility that hRyR2 mutation may alter protein-protein interactions between CSQ2, 
JUN and the Ca2+ release channel were investigated in this chapter. Since the N4104K 
mutant resides on the cytosolic side of the hRyR2 channel, whilst A4556T is located on 
the luminal side, another aim was to establish if the location of the mutation could be a 
determinant of altered binding.  
 
In addition to its use in the assessment of CSQ2 and JUN intracellular trafficking within 
HEK293 cells and establishing transfection efficiencies, immunofluorescence analysis was 
also used to measure the extent of co-localisation between the luminal accessory proteins 
and WT/mutant hRyR2 (Figures 5.5 and 5.6). As described in section 5.2.1, the direct 
overlay of eGFP- (hRyR2 detection) and Alexa® 594 (CSQ2 or JUN detection) images 
enabled the degree of co-localisation between the two signals to be calculated (George et 
al., 2003a). As represented as bar graphs in Figure 5.5 (A and B (ii)), co-incident pixel 
counting demonstrated that the co-localisation of CSQ2 with A4556T hRyR2 channels was 
significantly reduced, both when expressed alone and in the presence of JUN. This 
reduced binding could provide a possible explanation for the lack of CSQ2 inhibition 
evident in A4556T+CSQ2 only-expressing HEK293 cells in Ca2+ imaging investigations 
(Figure 4.17). However, inhibition of channel activity was apparent in HEK293 co-
expressing A4556T+CSQ2+JUN (Figure 4.17). Furthermore, in cells transfected with 
hRyR2+JUN or +CSQ2+JUN, JUN co-localisation also appeared significantly decreased 
when co-expressed with the A4556T mutant. However, this was only evident when the 
protein was co-expressed in the presence of CSQ2 (Figure 5.6, B (ii)).  
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It is interesting that the A4556T mutation is located on the luminal side of the Ca2+ release 
channel and positioned very close to a proposed JUN binding site on the M5-M6 linker of 
RyR2 at residues 4520-4553 (Altschafl et al., 2011, Dulhunty et al., 2012). Given the 
observed decrease in co-localisation of both CSQ2 and JUN with the A4556T hRyR2 
channel, it could be suggested that the mutant disrupts this JUN-RyR2 binding site, which 
could also be the site at which JUN anchors CSQ2 within close proximity to RyR2 
channels. Although a decrease in JUN co-localisation with the A4556T mutant was also 
evident in Figure 5.6, B (i), (when expressed alone), the reduction was not calculated as 
significantly different from WT and N4104K hRyR2 channels. JUN has however been 
shown to associate at more than one site on RyR2 channels, for example luminal residues 
78-210 also bind to a region that encompasses the pore loop at residues 4789-4846 
(Altschafl et al., 2011). 
 
Co-immunoprecipitation was used to assess the ability of CSQ2 and JUN to bind to each 
other and directly to hRyR2, in combination and individually. This technique was also used 
to further examine if the association of the luminal proteins with hRyR2 is altered by 
mutation. Co-IP investigations revealed that human cardiac muscle CSQ2 could directly 
interact with hRyR2 channels both in the absence (shown in Figure 5.7, A, (i)) and 
presence of cardiac JUN. This appears to be the first biochemical evidence to demonstrate 
a direct interaction of the Ca2+ binding protein with hRyR2 channels. Similarly, a direct 
interaction of JUN with hRyR2 channels was also observed in the presence (Figure 5.7 (A), 
(ii)) and absence of CSQ2 co-expression, consistent with previous research studies 
(section 5.1.3). Demonstrated previously by Zhang et al (1997), Co-IP was also used to 
observe a direct protein-protein interaction between recombinant CSQ2 and JUN in our 
experimental system, as illustrated in Figure 5.8.  
 
In contrast to the immunofluorescent co-localisation findings discussed previously, 
densitometric analysis of Western blot signals obtained in Co-IP experiments 
demonstrated that A4556T- and N4104K hRyR2 channels associate with CSQ2 and JUN 
to the same extent as WT hRyR2, represented in Figure 5.7, B, (i)-(iv) as a series of bar 
graphs. This may suggest that mutants do not disrupt the protein-protein interactions 
between hRyR2, CSQ2 and JUN. However, the discrepancies between the results could 
also reflect limitations of the technique. The samples for example were standardised twice, 
once for hRyR2 expression (Figure 5.1) and then for CSQ2/JUN expression, following 
densitometric analysis of Western signals. Standardisation of hRyR2 was required to 
ensure equivalent protein binding to the anti-GFP microbeads, whilst the Western signals 
corresponding to the luminal proteins needed to be normalised to account for differences 
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in the expression levels of CSQ2/JUN amongst different mixed membrane preparations. It 
is thus possible that subtle changes could be missed. The results were however also 
prepared without luminal protein normalisation (data not shown) and still no statistical 
differences were calculated. The accuracy of densitometric analysis may have been 
improved by generating a standard curve from serial dilutions of each membrane 
preparation across an SDS-PAGE gel and subsequent Western blotting, or use of a 
loading control (such as actin, ~42 kDa) alongside experimental samples to correct for any 
errors in loading or transfer efficiencies (Taylor et al., 2013). Loading excessive amounts 
of the membrane preparation such that the Western signals were near saturation when 
analysed could have also hindered the detection of true changes in protein-protein 
interaction, as suggested by Mollica et al., 2009. Due to the somewhat variable nature of 
transient transfections (see Figure 3, Appendix), loading 50!g of each mixed membrane 
preparation was deemed the most sufficient amount for adequate signal detection.  
 
Given the functional heterogeneity of CPVT-linked RyR2 mutations identified in previous 
investigations (Thomas et al., 2004, 2010) and between N4104K and A4556T hRyR2 in 
this project (see Chapter 4), the possibility that RyR2 mutants can disrupt protein-protein 
interactions of the channel complex can not be ruled out as a contributing factor in the 
pathogenesis of cardiac disease.  
 
 
 
 
 
 
 
 
 
 173 
 
 
 
 
 
 
Chapter 6 
 
General Discussion 
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6.1. Closing Discussion and Future Work: 
 
The principal aim of this investigation was to establish if CPVT-linked mutant hRyR2 
channels interact or respond differently to luminal accessory protein regulation by CSQ2, 
JUN and TRD1, proteins predicted to form a quaternary complex with RyR2 and to act as 
a luminal Ca2+ sensor for channel activity (Györke et al., 2004, Zhang et al., 2014). It is 
well documented that defective cytosolic and/or luminal Ca2+ sensing by RyR2 channels 
contributes to the aberrant Ca2+ release seen in CPVT (reviewed in Thomas et al., 2010). 
In addition, some CPVT-linked CSQ2 mutations result in a nonsense transcript effectively 
causing a knockout of the protein, which results in loss of SR Ca2+ buffering and Ca2+ 
binding capacity or association with RyR2 channels, which culminates in accelerated 
restitution of Ca2+ release  (Terentyev et al., 2006, Rizzi et al., 2008). Evidently, defective 
luminal regulation of hRyR2 is implicated in arrhythmogenesis and this is the first study to 
examine how mutant hRyR2 channels respond to luminal accessory protein co-
expression.  
 
Two CPVT-linked hRyR2 mutations were examined: N4104K and A4556T, which reside 
on the cytosolic and luminal side of the channel, respectively. Since CSQ2, JUN and/or 
TRD1 are predicted to associate within the SR lumen, the location of the hRyR2 mutation 
could have been an important factor in detecting any differences in their interaction or 
response (i.e. luminal accessory protein association/effects may only be disrupted by 
mutations located on the luminal portion of the channel). Biochemical and functional 
assessment of luminal accessory protein interaction with WT hRyR2 were compared to 
that of the mutants.  WT data were also used to inform on the respective roles of the 
accessory proteins in hRyR2 regulation. 
 
To avoid species variability, often reported in the literature (described in Chapter 3, section 
3.1.1, Qin et al., 2009, Wei et al., 2009b) the aim was to use only human isoforms of both 
RyR2 and the luminal accessory proteins, where a recombinant approach was employed. 
Expression constructs in (pcDNA3.1hygro(+)) for human cardiac muscle CSQ2 and JUN 
were successfully generated, as outlined in Chapter 3, section 3.2.1 and 3.3.1-3.3.3. 
Specific amplification of cardiac TRD1 however proved problematic (Figure 3.2, section 
3.4.1), which was largely due to the fact that at the time this work was carried out, the 
human cardiac muscle TRD1 sequence was unknown. Although a number of different 
primers were used in PCR amplification reactions, in an attempt to amplify TRD1 (section 
3.3.1, Figure 3.1), without knowing the exact human sequence even undertaking a BLAST 
search for sequence homologies with the prospective amplicons isolated (cloned into 
TOPO® vector) proved difficult.  In future work, the human cardiac muscle TRD1 sequence 
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published by Roux-Buisson et al (2012), could be consulted to re-design the PCR primers, 
in particular the reverse 3’ primer, since the TRD1 sequence is reported to display its 
greatest divergence in the C-terminal region of the protein (Kobayashi and Jones, 1999, 
Roux-Buisson et al., 2012). Since TRD1 could not be successfully isolated, this project 
focussed exclusively on the response of WT/mutant hRyR2 channels to CSQ2 and JUN 
co-expression, both as a complex and expressed individually with the Ca2+ release 
channel. A mammalian HEK293 heterologous system was chosen to co-express WT and 
mutant hRyR2 with the luminal accessory proteins. Expression in HEK293 cells eliminated 
the need for purification and allowed the luminal proteins to associate with hRyR2 
channels in situ.  
 
The generation of HEK293 stable cells lines expressing CSQ2 and/or JUN is discussed in 
Chapter 3, sections 3.2.2. The original intent was to use these stable cells, and transfect 
them with eGFP-hRyR2, for use in all functional and protein-protein interaction 
investigations. However, the growth rate of the stable cell lines was much slower than 
anticipated, which consequently reduced the transfection efficiencies of transient eGFP-
hRyR2 expression (using CaPO4 precipitation). Since [3H] ryanodine binding (Chapter 4) 
and co-immunoprecipitation assays (Chapter 5) require high levels of hRyR2 expression, 
the material for use in these experiments was generated by large-scale transient 
transfection of WT/mutant eGFP-hRyR2 with CSQ2 and/or JUN in an equimolar ratio. 
Using this optimised method, high transfection efficiencies of all co-expressed proteins 
were achieved, and as immunofluorescence studies proved that the transfection efficiency 
for JUN/CSQ2 was nearly twice that of hRyR2 (being expressed in ~% of the cells), it was 
judged that cells expressing hRyR2 would likely also be expressing the luminal accessory 
protein of choice as well, enabling complex formation. Accordingly, expression levels 
obtained for all proteins were sufficiently high as assessed by Western Blotting.  
 
Stable cell lines were however essential for use in single-cell Ca2+ imaging, where it was 
necessary that each cell imaged, expressed the luminal accessory protein(s) of interest. 
Cells co-expressing WT or mutant hRyR2 could be identified by their caffeine response 
(Thomas et al., 2004). To obtain sufficient eGFP-hRyR2 transfection efficiencies in these 
cells, Effectene® reagent was used, the rationale for which included that fact that this 
method required less DNA and was therefore less cytotoxic than the CaPO4 precipitation.  
 
The functional assays used to assess the influence of CSQ2 and JUN on the intracellular 
Ca2+ regulation of WT and mutant hRyR2 are described in Chapter 4. The Ca2+ 
dependence of [3H] ryanodine binding for WT and mutant hRyR2 channels in the absence 
and presence of CSQ2 and/or JUN was examined. When assessed alone (i.e., in the 
 176 
absence of accessory proteins), notable differences in the Ca2+ activation profile of the 
hRyR2 mutants, compared to WT channels, were found. Although the half-maximal [Ca2+] 
for activation of A4556T hRyR2 channels was not significantly different from that of the 
WT, the binding of [3H] ryanodine was significantly higher at every Ca2+ concentration 
>1!M. This may have been due to a standardisation problem, due to vastly different 
expression levels, or it could reflect a genuine effect of the mutant on the 
association/dissociation of [3H] ryanodine. If this was to be investigated further, the mutant 
could be explored at the single channel level with a reversible ryanoid (such as Ryanodol, 
used by Sigalas et al., 2009) so as to verify this assumption by the measurements of 
ryanoid association and dissociation rates (as in Tanna et al., 1998, Sigalas et al., 2009). 
The primary aim of the [3H] ryanodine assay however, was to explore the sensitivity of 
Ca2+ activation, which for this mutant was no different to WT. In contrast, N4104K hRyR2 
channels displayed a significantly sensitised Ca2+ activation profile, indicating that these 
mutations are functionally heterogeneous. Demonstration of this concept is an important 
contribution to the field, since as discussed in Chapter 1 (sections 1.8-1.8.3) the 
mechanism behind CPVT-linked hRyR2 dysfunction is often attributed in the literature to a 
single unifying factor, such as an altered interaction of FKBP12.6 with hRyR2 (section 
1.8.1). It is however likely that the form of channel dysfunction is mutation-specific, 
possibly determined by its location in the polypeptide. The different modes of channel 
dysfunction found in this work between CPVT-linked mutants N4104K and A4556T are 
summarised as a schematic in Figure 6.1, and directly compared with WT hRyR2 (A-C).  
 
To ascertain any functional effects conferred by luminal accessory protein co-expression, 
the aforementioned [3H] ryanodine binding experiments were repeated in the presence of 
CSQ2 and/or JUN.  However, no significant changes in the response of WT or mutant 
hRyR2 channels to Ca2+ activation were evident. Since differences were identified in 
single-cell Ca2+ imaging studies, it was concluded that the [3H] ryanodine binding 
technique may not have been sensitive enough to detect subtle changes in the Ca2+ 
response imparted by CSQ2 and/or JUN (section 4.4.2). Alternatively, it is possible that 
the use of high salt conditions (used to optimise RyR2 Po (Chopra et al., 2009, Euden et 
al., 2013)) could have disrupted protein-protein interactions between RyR2 channels and 
the luminal proteins, such that any functional effects were diminished. Indeed, it was 
demonstrated using co-immunoprecipitation studies that luminal protein association was 
diminished, albeit not significantly, under high salt conditions and this may have been 
enough to cause a functional effect. In future work, these experiments could be repeated 
using lower salt conditions, but it is unlikely using recombinant RyR2 that sufficient [3H] 
ryanodine binding counts would be achieved. 
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Ca2+ imaging investigations proved more suitable in examining regulation of mutant 
hRyR2 by CSQ2 and/or JUN (Chapter 4). First, the properties of the SCR parameters 
(section 4.3.3) in HEK293 cells expressing WT and mutant hRyR2 channels alone were 
assessed.  Figures 4.12 and 4.13 illustrate the similarity between the SCR properties of 
WT and A4556T channels, where no parameters were found to be statistically different. 
On the contrary, SCR events in cells expressing N4104K hRyR2 channels appeared 
completely different (Figures 4.12 and 4.13), where amplitude and duration were 
significantly reduced (compared to WT channels); whilst the SCR events appeared much 
faster (measured as an increase in SCR frequency). These differences needed to be 
considered when assessing any changes introduced by luminal protein co-expression. 
The alterations in the SCR parameters in stable HEK293 cells expressing CSQ2 and JUN 
alone or in combination with WT hRyR2 channels are described in detail in section 4.3.4, 
Figures 4.14 and 4.15. In the presence of the luminal proteins, properties such as the SCR 
event duration and inter-event duration were significantly enhanced, thereby reducing the 
frequency of events. Co-expression with CSQ2 in particular, both alone and in the 
presence of JUN, seemed to have a notable inhibitory effect on hRyR2 SCR activity 
(Figure 1.6 (A and B). This inhibition has been reported by others using different 
experimental systems (Jones et al., 1998, Beard et al., 2005, Györke et al., 2004). Despite 
the altered properties of SCR events evident in cells expressing N4104K channels alone, 
both A4556T and N4104K channels responded in a similar manner as WThRyR2 to CSQ2 
and JUN co-expression (4.16-4.19). Surprisingly however, the inhibitory effects of CSQ2 
co-expressed alone with hRyR2 channels (seen with WT and N4104K) were diminished in 
cells expressing A4556T channels (Figure 1.6 (C)). This is a novel finding of a previously 
uncharacterised, luminallly located hRyR2 mutation and will be of interest in further 
investigations.  
 
In future work, the findings of the Ca2+ imaging studies could be verified by assessing WT 
or mutant hRyR2 channels in the presence of CSQ2 and/or JUN at the single channel 
level. Both cytosolic and luminal Ca2+ activation could be assessed using this technique, 
where conditions either side of the hRyR2 channel (reconstituted into a lipid bilayer) can 
be manipulated. This however would require extensive optimisation, starting with the 
decision of whether each protein should be purified and added back to the hRyR2 channel 
(as carried out by Györke et al., 2004) or the recording of heavy ER preparations (mixed 
membranes) should be optimised. If mixed membranes were to be used, different 
permeant ions (such as K+, Cs+, Ba2+and Ca2+) would need to be tested, in order to 
establish a sufficient signal to noise ratio where the activity of RyR2 channels could be 
clearly identified amongst other ion channels (such as Cl- and K+) that would also 
incorporate into the lipid membrane. In addition, a strategy to identify changes imparted by 
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the luminal proteins would need to be devised. Purification of the luminal proteins is 
another option, which again would require the development of a reliable purification 
strategy. Györke et al (2004) used two different expression systems to purify dog CSQ2, 
JUN and TRD1, suggesting that sufficient levels of expression may have been 
problematic. Recombinant dog calsequestrin was cloned into the bacterial expression 
vector pET5a (as used in Kobayashi et al, 2000), whilst JUN (Zhang et al, 1997) and 
TRD1 (Kobayashi and Jones, 1999) were both isolated and purified by infecting Sf21 
insect cells with baculovirus encoding the recombinant proteins (Gyorke et al, 2004). 
Furthermore, in order to confidently determine the functional effects of the CSQ2 and/or 
JUN-hRyR2 interaction and establish if mutants respond differently, a reliable method to 
detect re-association/dissociation of the luminal proteins would need to be devised. 
Gaburjakova et al (2013) suggested that this issue is likely to be the reason why 
conflicting findings have been reported upon investigating the functional role of CSQ2 at 
the single channel level.    
 
Chapter 5 describes the examination of WT and mutant hRyR2 interactions with the 
luminal accessory proteins. Demonstrated by immunofluorescent co-localisation and 
subsequent co-incident pixel counting (described in section 4.3.3), the interaction of CSQ2 
with the previously uncharacterised A4556T channels was significantly reduced when 
expressed both alone and in the presence of JUN (Figure 5.5 and illustrated in Figure 1.6 
(C)). Furthermore, a decrease in JUN binding with A4556T channels was also identified, 
but only when co-expressed in the presence of CSQ2 (Figure 5.6 and 6.1 (C)). No 
differences in the association of CSQ2 or JUN with N4104K channels (compared with WT 
hRyR2) were detected. This altered interaction of A4556T channels with CSQ2 could 
explain why in Ca2+ imaging investigations, the inhibitory effects of the luminal protein on 
channel activity was reduced in cells co-expressing CSQ2 only (Figure 4.17). If this were 
the case however, I would have also expected to see the same effect in HEK293 cells 
expressing A4556T, CSQ2 and JUN.   
 
The ability of CSQ2 and JUN to bind both individually and in combination to WT/mutant 
hRyR2 channels was also explored using co-immunoprecipitation (section 5.3.4). In 
contrast to immunofluorescent co-localisation studies, both A4556T and N4104K hRyR2 
channels were found to bind to CSQ2 and JUN to the same extent as WT channels 
(Figure 5.7). It is possible that since Western blot signals used for densitometric analysis 
were standardised twice, first for hRyR2 expression and then for luminal accessory protein 
expression (which differed between mixed membrane samples, section 5.4.2), subtle 
differences in the interaction between these proteins could have been missed. As 
illustrated in Figure 1.6 (A), Co-IP experiments biochemically demonstrated for the first 
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time the ability of human cardiac CSQ2 to bind directly to hRyR2 channels in the absence 
of any additional accessory proteins (i.e, JUN). Since the literature suggests that CSQ2 is 
only anchored within close proximity to hRyR2 via its association with JUN and/or TRD1 
(as shown in Figure 1.2), this finding is a major contribution to the field.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Schematic summarising the major findings of this work:  
(A) Illustrates the ability CSQ2 to bind directly to WT hRyR2 alone and via its 
association with JUN. CSQ2 co-expression appeared to have an inhibitory effect on 
hRyR2 channel activity (indicated with a red cross). (B) N4104K channels responded 
similarly to luminal protein co-expression, where an inhibitory effect on channel gating 
was observed in the presence of CSQ2 (expressed alone and with JUN). This mutant 
however displayed enhanced sensitivity to activating Ca2+ evident in both [3H] 
ryanodine binding assays and Ca2+ imaging investigations; resulting in elevated SCR 
activity and a significantly reduced ER Ca2+ load, indicative of Ca2+ leak through the 
channel. (C) In Ca2+ imaging studies, no notable inhibitory effects of CSQ2 (when 
expressed alone) on A4556T hRyR2 activity were evident. Thus, this mutant did not 
respond in the same manner as WT and N4104K hRyR2 to CSQ2 co-expression. 
Demonstrated by co-immunofluorescent co-localisation and subsequent co-incident 
pixel counting, lack of an inhibitory effect may have been due to significantly reduced 
protein-protein associations between CSQ2 and A4556T hRyR2. Furthermore, JUN 
binding (when expressed in the presence of CSQ) was also significantly diminished in 
A4556T hRyR2 channels.   
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In future work, it would be beneficial to investigate the interaction of mutant (and WT) 
hRyR2 with CSQ2 and/or JUN using a more sensitive technique, such as Surface 
Plasmon Resonance. Briefly, recombinant GST-fusion proteins corresponding to CSQ2 
and JUN could be created and immobilised to the surface of a sensor chip (Blayney et al., 
2010). To measure the affinity and binding kinetics between the proteins, WT or mutant 
hRyR2 could then be used as an analyte, and passed in solution over the chip surface, to 
which the luminal accessory proteins are bound (Hutsell et al., 2010, Blayney et al., 2010). 
Furthermore, the co-immunoprecipitation studies used in this investigation could be 
repeated, but instead using the stable HEK293 cells expressing CSQ2 and/or JUN. This 
would eliminate the need for further standardisation to account for luminal protein 
expression. However, since these investigations require high-levels of hRyR2, the protocol 
for transient transfection of hRyR2 in stable HEK293 cells would first need to be further 
optimised. In summary, these studies find that CPVT-linked hRyR2 mutant channels are 
functionally heterogeneous and that dysfunction of some mutants is unlikely to be caused 
by a lack of response to luminal accessory protein (e.g. N4104K). However, CSQ2 was 
found to bind directly to the WT channel, having a similar inhibitory effect as seen in the 
presence of JUN (its anchoring protein – Zhang et al., 1997). This study suggests that the 
A4556T mutation results in reduced CSQ2 binding to the channel resulting in altered 
regulation, however this was not found using all detection methods and requires 
verification by more sophisticated methods.  
 
As discussed in Chapter 1, section 1.7, ß-blockers represent the first line in CPVT 
treatment.  However, this treatment is often insufficient with many patients still suffering 
potentially fatal symptoms (Mackrill, 2010, Liu et al., 2011). The work carried out in this 
project provides evidence of the functional heterogeneity that exists between CPVT-linked 
mutations and demonstrates that therapeutic interventions may need to be tailored 
towards the specific pathogenic properties of a given RyR2 mutant, with consideration 
towards their location and severity.  
 
N4104K RyR2 channels showed sensitised Ca2+ activation and aberrant Ca2+ release both 
in the absence and presence of luminal accessory proteins. Previous reports have 
suggested that gain-of-function mutations, such as N4104K, alter the ability of RyR2 
channels to close during diastole, resulting in enhanced SCR release (described as Ca2+ 
leak, Jiang et al., 2004, 2005) and a decreased SR Ca2+ store (as demonstrated in Figure 
4.13). Suppression of this enhanced SCR release (or SOICR) by decreasing RyR2 luminal 
Ca2+ sensitivity has been proposed as a promising antiarrhythmic treatment for patients 
harboring such mutations (Hunt et al., 2007, Zhou et al., 2011, Chen et al., 2014). 
However, the extent to which SOICR is eliminated needs to be controlled, since complete 
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inhibition also triggers arrhythmogenesis (Chen et al., 2014). A major challenge in drug 
development is to identify compounds with the ability to reduce diastolic Ca2+ leak without 
affecting RyR2 channel gating during systole (Mackrill, 2010, McCauley and Wehrens, 
2011, Fischer et al., 2013). Hunt et al 2007 demonstrated that a 1,4-benzothiazepine 
derivative K201 (or JTV519) significantly reduced the occurrence of SOICR in HEK293 
cells expressing WT hRyR2 (in Ca2+ imaging studies) and inhibited [3H] ryanodine binding 
to both WT and N4104K RyR2 channels, diminishing the enhanced basal activity seen 
with CPVT-linked mutants (as demonstrated in this work, Figure 4.6). SOICR inhibition 
and subsequent stabilisation of the closed state (deduced from the fact that [3H] ryanodine 
binding is reduced and the activation threshold increased with K201 treatment) occurred 
the absence of FKBP12.6, despite previous reports suggesting that the effectiveness of 
the drug stems from its ability to enhance FKBP12.6-RyR2 binding (Wehrens et al, 2004). 
Altered Ca2+ sensitivity however was only evident with the use of higher (!M) K201 
concentrations, and thus seems unsuitable for use in patient clinical trials (Hunt et al., 
2007). Another drug found to successfully suppress SOICR occurrence is carvedilol, 
which interestingly is one of the most effective ß-blockers used in preventing arrhythmia in 
HF patients (Zhou et al., 2011). Independent of its ability to inhibit ß-adrenergic 
stimulation, Zhou et al (2011) demonstrated that of the 14 known ß-blockers tested, only 
carvedilol displayed a direct effect on RyR2 gating, reducing RyR2 channel Po at the 
single channel level. The concentrations of carvedilol required to effectively inhibit SOICR 
however, were much higher than those required as a ß-blocker, raising concern of 
adverse reactions when used in vivo (Zhou et al, 2011). To overcome this effect, the group 
demonstrated the use of carvedilol analogs (such as VK-II-86, tested in mice harbouring a 
CPVT-linked mutant and HEK293 cells), which retained their ability to suppress SOICR 
activity whilst having much lower actions as ß-blockers (Zhou et al, 2011). These analogs 
combined with an alternative ß-blocker (such as metoprolol) could improve protection 
against arrhythmia in CPVT patients with a mutation that displays a gain-of-function 
phenotype (Zhou et al., 2011).  A4556T hRyR2 channels displayed similar SCR event 
properties to WT hRyR2 in the absence of accessory protein expression (Figure 4.13); 
however, the inhibitory effect of CSQ2 co-expression was diminished in cells expressing 
A4556T hRyR2. As discussed previously (section 5.4.2), this effect may have been 
caused by a disruption in the protein-protein associations between CSQ2 and A4556T 
hRyR2 (Figure 5.5). To date, only a few drugs have been proposed to enhance the 
interaction of RyR2 with its accessory proteins, such as the aforementioned K201, which 
has been proposed to stabilise the binding of FKBP12.6 (Wehrens et al, 2004, Mackrill, 
2010), though this is in dispute (Hunt et al., 2007). The development of therapeutic agents 
to modify the binding interaction between RyR2 and CSQ2 may facilitate the treatment of 
CPVT mutants such as A4556T.   
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Figure 1: Visualisation of PCR/gel extraction products by agarose gel 
electrophoresis: Original images that were cropped for presentation purposes in 
Chapter 3, Figure 3.2 are shown. (A) Demonstrates the PCR products generated in 
attempts to isolate TRD1. As indicated with an asterisk (lane 2), these products are 
shown in (Figure 3.2, B, (ii)) which were obtained following PCR amplification using a 
reverse primer designed to target the pACT2 vector (see section 3.3.1). Lane 1 
corresponds to the same PCR recovered products shown in Figure 3.2 B, (iii), however 
the same recovery loaded on a different gel is shown in the chapter. (B) Illustrates the 
gel extraction recovery products of CSQ2 and JUN shown in Figure 3.2 (D) as 
highlighted with asterisks. Lanes 1 (CSQ2) and 2 (JUN) shown are the same as lanes 3 
and 4, respectively. However, these were not shown in Figure 3.2, due to the loading 
error in lane 2.  
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Figure 2: Comparable hRyR2 transfection efficiencies in HEK293 cell populations: Illustrated 
are representative fluorescent images (and corresponding phase images) of HEK293 cell 
populations transfected with (A) hRyR2 only, (B) hRyR2+JUN, (C) hRyR2+CSQ2 and (D) 
hRyR2+CSQ2+JUN. Comparable transfection efficiencies were obtained in cells transfected with 
WT or mutant hRyR2, and the efficiencies were unaffected by co-expression with the accessory 
proteins.  
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Figure 3: Additional Western blots of hRyR2 expression: Illustrated are representative 
Western blot signals obtained following SDS-PAGE of mixed membrane samples expressing (A) 
WT hRyR2, (B) A4556T (AT) hRyR2 and (C) N4104K (NK) hRyR2 alone and in the presence of 
CSQ2 and/or JUN. WT (+) refers to a positive WT hRyR2 only control loaded alongside test 
samples. (D) hRyR2 signals (WT shown) were detected at 565 kDa (fainter signals below this 
band are breakdown products of the protein), above the highest reference band of the pre-
stained Kaleidoscope™ marker (Bio-Rad) at 250 kDa. 
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Figure 4: Additional Western blots of CSQ2 and JUN expression: Illustrated are 
representative western blot signals obtained following SDS-PAGE of mixed membrane 
samples expressing (A) hRyR2+CSQ2 (i) and hRyR2+CSQ2+JUN (ii) – CSQ2 detection 
shown and (B) hRyR2+JUN (i) and hRyR2+CSQ2+JUN (ii) – JUN detection shown. CSQ2 
and JUN only refers to mixed membrane samples generated from HEK293 cells transfected 
with CSQ2 and JUN only, respectively.  
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Figure 5: Untransfected HEK293 loaded with Fluo-3 did not display spontaneous 
Ca2+ release events or respond to caffeine addition: As discussed in Chapter 4, 
section 4.2.2, cells successfully transfected with hRyR2 could be identified by their 
caffeine response and in Ca2+ imaging investigations these cells displayed SCR activity. 
In control experiments, untransfected HEK293 cells were loaded with Fluo-3 and 
imaged by confocal microscopy. As shown, untransfected HEK293 (5 cells selected 
here, also called regions of interest (ROI)) did not display SCR events or respond to 
10mM caffeine application.  
 
 
 
 
 188 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 6: Column scatter plots of all Ca
2+
 imaging data: Described in Chapter 4, sections 
4.3.3-4.3.6, all properties of the SCR events evident in cells expressing WT or mutant hRyR2 in 
the presence/absence of luminal accessory proteins CSQ2 and JUN were assessed. Shown here 
are column scatter plots of all the collected data, constructed using GraphPad Prism. Outliers 
were detected and removed using the GraphPad Prism Grubbs’ test (graphpad.com).  
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Figure 6: Column scatter p ots of all Ca2+ maging data: Describ d in Chapter 4, sections 
4.3.3-4.3.6, all pro erties of the SCR v nts evident in cells expressing WT or mutant hRyR2 in 
th  presence/absence of lumi al accessory proteins CSQ2 and JUN were assessed. Shown here 
are column scatter plots of all the collected data, constructed using GraphPad Prism. Outliers 
were detected and removed using the GraphPad Prism Grubbs’ test (graphpad.com).  
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*** = vs A4556T hRyR2 
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Figure 7: Bar graphs of all Ca2+ imaging data: All experimental data generated from 
assessment of the SCR event parameters in cells expressing WT or mutant hRyR2 in the 
presence/absence of luminal accessory proteins CSQ2 and JUN (Chapter 4, sections 4.3.3-4.3.6) 
are summarised here. Calculated using one-way ANOVA and a Tukey-Kramer post-test 
(GraphPad Prism), parameters that were statistically different from WT/A4556T/N4104K only are 
indicated.  
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